Regulation of Pulmonary Vascular Tone in Health and  Disease: Special emphasis on exercise and pulmonary hypertension after myocardial infarction by Houweling, B. (Birgit)
Regulation of Pulmonary Vascular Tone in 
Health and Disease
Special emphasis on exercise and pulmonary 
hypertension after myocardial infarction
Birgit Houweling
Regulation of Pulmonary Vascular Tone in Health and Disease
Special emphasis on exercise and pulmonary hypertension after 
myocardial infarction
© 2007 Birgit Houweling
Thesis Erasmus University Medical Center, Rotterdam
The Netherlands
ISBN 978-9020919-7
Printed by Ipskamp, Enschede
Regulation of Pulmonary Vascular Tone in 
Health and Disease
Special emphasis on exercise and pulmonary hypertension 
after myocardial infarction
Regulatie van de pulmonale vaattonus in 
gezondheid en ziekte 
Met de nadruk op inspanning en pulmonale hypertensie 
na een hartinfarct
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magniﬁ cus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 6 juni 2007 om 09.45 uur
door
Birgit Houweling
geboren te Rotterdam
Promotiecommissie
Promotor:  Prof.dr. D.J.G.M. Duncker
Overige leden:  Prof.dr.  J.M.J. Lamers
        Prof.dr.  A.H.J. Danser
   Dr. A.H. van den Meiracker 
Copromotor: Dr. D. Merkus
The studies in this thesis have been conducted at the Laboratory for 
Experimental Cardiology, Erasmus MC Faculty, The Netherlands
Financial support by the Netherlands Heart Foundation for the 
publication of this thesis is gratefully acknowledged. 
The study described in this thesis was supported by a grant of the 
Netherlands Heart Foundation (NHF-2000T038)

Contents
Chapter 1 
General introduction and outline of thesis
Chapter 2
Interaction between prostanoids and nitric oxide in regulation 
of systemic, pulmonary and coronary vascular tone in exercising 
swine
Daphne Merkus, Birgit Houweling, Alisina Zarbanoui and Dirk J Duncker. 
AJP-Heart Circ Physiol 286:1114-1123, 2004
Chapter 3
Contribution of endothelin and its receptors to the regulation 
of vascular tone during exercise is different in the systemic, 
coronary and pulmonary circulation
Daphne Merkus, Birgit Houweling, Amran Mirza, Frans Boomsma, Anton H. 
van den Meiracker and Dirk J Duncker. Cardiovasc Res 59: 745-754, 2003
Chapter 4
Nitric oxide blunts the endothelin-mediated pulmonary 
vasoconstriction in exercising swine
Birgit Houweling, Daphne Merkus, Marjolein M D Dekker and Dirk J Duncker.  
J. Physiol 568: 629-638, 2005
Chapter 5
Role of endothelin receptor activation in secondary pulmonary 
hypertension in awake swine after myocardial infarction
Birgit Houweling, Daphne Merkus, Oana Sorop, Frans Boomsma and Dirk J 
Duncker. J. Physiol 574: 615-626, 2006
Chapter 6
Alterations in endothelial control of the pulmonary circulation 
in exercising swine with secondary pulmonary hypertension 
after myocardial infarction
Daphne Merkus, Birgit Houweling, Vincent J de Beer, Zaida Everon and 
Dirk J Duncker. J. Physiol 2007,  in press
9
41
67
89
109
131
Chapter 7
Pulmonary hemodynamic effects of the Phosphodiesterase-5 
inhibitor EMD360527 in awake swine at rest and during treadmill 
exercise
Birgit Houweling, Daphne Merkus, Johan Quispel, Pieter D Verdouw and 
Dirk J Duncker.
Chapter 8
Pulmonary vasodilator effect of phosphodiesterase 5 inhibition 
is enhanced in swine with pulmonary hypertension after a 
recent myocardial infarction
Chapter 9  
General discussion and summary
Nederlandse samenvatting
Dankwoord
List of publications
Curriculum Vitae
161
181
195
209
220
222
225

Chapter 1
General introduction and outline of thesis

11
Chapter 1: General introduction
Background
In the last decades, ischemic heart disease has become the most prominent 
cause of heart failure in the western world and is estimated to become world’s 
leading cause of death in the future [3, 4]. Ischemic heart disease occurs after 
an occlusion of a coronary artery, which deprives the heart muscle behind the 
occlusion from oxygen. Without reperfusion, this part of the heart muscle will die 
(myocardial infarction) and loose its ability to contract. Treatment and survival of 
myocardial infarction has increased due to better treatment options, but secondary 
problems will occur as a result of the decreased performance of the heart. One of 
the problems that might occur is pulmonary hypertension, a high blood pressure 
in the pulmonary circulation. As a result of the increased ﬁ lling pressures in the 
left ventricle, pressure in the left atrium and the pulmonary venous system rises 
and augments the workload for the right ventricle. Since the incidence of ischemic 
heart failure is growing, incidence of pulmonary hypertension after myocardial 
infarction also is increasing. Treatment options (as will be described later in this 
introduction) for pulmonary hypertension are increasing, but there is still a lot 
unknown about the normal regulation of pulmonary vascular tone and how it is 
regulated in pulmonary hypertension after myocardial infarction. 
During exercise, regulation of the pulmonary vasculature might be different 
from the normal regulation of the pulmonary vasculature in order to accommodate 
the increase in cardiac output. An important determinant of the pulmonary 
vascular bed is pulmonary vascular resistance (PVR). PVR is determined by the 
pressure-fall over the pulmonary vascular bed (pulmonary artery pressure minus 
left atrial pressure) divided by the cardiac output. During exercise, pulmonary 
artery pressure increases concomitant to increases in cardiac output in order to 
maintain the low PVR. Since patients with pulmonary hypertension already have an 
increased pulmonary artery pressure, exercise is difﬁ cult and sometimes impossible. 
Therefore it is also important to understand the regulation of pulmonary vascular 
tone during exercise, in the normal and the hypertensive pulmonary circulation. 
Thus the focus of this thesis is to study the regulation of pulmonary vascular 
tone under normal physiological conditions as well as alterations in regulation 
of pulmonary vascular tone after myocardial infarction. Regulation of pulmonary 
vasomotor tone will be studied at resting conditions as well as during exercise.
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Circulatory system
The human body is supplied of blood by a double circulatory system, which 
means that there is a separate pulmonary and systemic circulation. In short, 
deoxygenated blood (containing little or no oxygen) collects in two major veins: 
the superior vena cava and the inferior vena cava. The superior and inferior vena 
cava empty into the right atrium. The blood is then pumped through the tricuspid 
atrioventricular valve into the right ventricle. From the right ventricle, blood is 
pumped through the pulmonary semi-lunar valve into the pulmonary trunk. The 
deoxygenated blood leaves the heart by the pulmonary arteries and travels through 
the lungs (where it is oxygenated) and into the pulmonary veins. The oxygenated 
blood then enters the left atrium. The blood then travels through the bicuspid 
valve, also called mitral valve, into the left ventricle. The left ventricle is thicker 
and more muscular than the right ventricle because it pumps blood throughout the 
body against higher pressure. From the left ventricle, blood is pumped through 
the semi-lunar valve into the aorta. Once the blood goes through the systemic 
circulation, deoxygenated blood will again collect inside the vena cava and the 
process will continue.
Figure 1: Alveoli with pulmonary and 
bronchial circulation. Pulmonary circulation: 
deoxygenated blood leaves the heart via the 
right ventricle and ﬂ ows through the pulmonary 
artery to capillaries, which surround the alveoli 
where oxygen is taken up. Oxygenated blood is 
directed to the left ventricle by the pulmonary 
vein. Bronchial circulation: oxygenated blood 
from the systemic circulation is directed to the 
bronchiole by a bronchial artery. Deoxygenated 
blood ﬂ ows into the pulmonary vein by shunts. 
Adapted with permission from [6].
Pulmonary 
artery
Pulmonary 
vein
Bronchial 
artery
Bronchiole
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Pulmonary circulation- anatomy 
The main function of the lungs is to oxygenate blood by exchanging oxygen 
and carbon dioxide. Deoxygenated blood is carried to the lungs by the pulmonary 
arterial bed whereas oxygen is supplied by the bronchi. The pulmonary artery 
arises from the right ventricle, bifurcates, and carries relatively deoxygenated 
blood to each lung. The two main branches of the pulmonary artery follow the 
two mainstem bronchi into the lungs and bifurcate along with the bronchi and 
bronchioles. A single pulmonary arteriole supplies all the capillaries of a terminal 
respiratory unit (Fig. 1) [6]. Pulmonary venules collect the oxygenated blood from 
the capillary network, which then enters the left atrium via the pulmonary veins. 
The capillaries surrounding the alveoli are part of the pulmonary circulation, 
whereas lung tissue itself is oxygenated by the bronchial circulation, which is part 
of the systemic circulation.
Systemic versus pulmonary circulation
The pulmonary circulatory system handles the same cardiac output as the 
systemic circulation, but there are some distinct differences. The pulmonary 
circulation is a low pressure system with a low resistance in opposite to the systemic 
circulation which has a high pressure and resistance. The mean aortic pressure is 
approximately 90 mmHg in contrast with the approximately 15 mmHg of the mean 
pulmonary arterial pressure.
Conversely the pulmonary vascular bed has a total resistance that can be ten 
times lower than that of the systemic circulation. The systemic circulation needs 
a higher pressure because it has to be able to pump blood to the top of the brain 
while standing, whereas the pulmonary circulation only needs to pump blood to 
the top of the lungs. The pulmonary circulation must be a low-pressure system 
to avoid the consequences of starling forces, which would otherwise ﬂ ood the 
lung with edema ﬂ uid [6]. The differences in arterial pressures between the two 
circulations are due to the enormous number of small muscular pulmonary arteries; 
the large pulmonary capillary bed; and the normally dilated state (low vascular 
tone) of the pulmonary resistance vessels [1]. Most of the pressure drop in the 
systemic circulation occurs in the arterioles, while in the pulmonary circulation 
the arterioles make a much smaller contribution and almost the entire pressure 
drop occurs rather uniformly between the pulmonary artery and the end of the 
capillaries. [1, 6] (Fig. 2). 
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Blood vessels are composed of different layers, the inner layer which forms the 
lumen of the vessel consists of endothelial cells and the layer surrounding these 
endothelial cells consists of smooth muscle cells. Both endothelial and smooth 
muscle cells play an important role in regulation of vascular tone. The layer on 
the outside of the blood vessel is mainly composed of collagen. Pulmonary blood 
vessels are generally shorter and wider than their counterparts on the systemic 
side. The walls of pulmonary vessels are also thin. The thinness and paucity of 
smooth muscle give the pulmonary vessels a high compliance that allows pulmonary 
vessels to dilate in response to modest increases in pulmonary arterial pressure [6]. 
In addition, endothelial cells that form the inner layer of the vasculature, differ 
between the systemic and pulmonary vascular bed. For example, endothelial cells 
that line in the pulmonary artery of the rat are larger and more rectangular than 
those lining in the aorta [7]. 
Figure 2: Schematic representation of the phasic and mean pressures within the systemic and 
pulmonary circulation in a normal resting human. Units are mmHg. Adapted with permission from 
[1]
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Pulmonary circulation- regulation of vascular tone
Passive regulation.
In the pulmonary circulation, both passive and active regulation of vascular tone 
occurs. There are two passive mechanisms at work in the pulmonary vasculature 
being recruitment and distension of the small vessels (arterioles, capillaries and 
venules) [1, 6]. Under normal conditions, when pulmonary atrial pressure is low, 
some pulmonary vessels are open and conducting blood, others are open but not 
conducting and others are closed. As pressure increases, vessels that previously 
had been open but not conducting now begin to conduct blood, and some vessels 
that were completely closed may now open. This recruitment of new vessels will 
decrease pulmonary vascular resistance and any additional dilation of this vessels 
(distension) will cause a further reduction in overall pulmonary resistance [6]. This 
remarkable ability to lower the resistance even further makes it possible to only 
have a minor increase in mean pulmonary artery pressure during exercise when 
cardiac output sometimes doubles. 
Exercise results in an increase in left atrial pressure that is progressive with 
exercise intensity and accounts for the majority of the increase in pulmonary arterial 
pressure that can be observed [8]. For the lungs to perform their gas-exchange 
function efﬁ ciently, the pulmonary circulation must maintain low pulmonary 
arterial and capillary pressure while accommodating this increased cardiac output. 
In addition, perfusion must be distributed among the ventilated units so that local 
ﬂ ow matches local ventilation. Both pulmonary pressure and vasomotor tone are 
low in the normal lung under resting conditions, so due to gravity, posture may be 
an important determinant of local pulmonary perfusion [9]. 
In humans, in upright posture, the vertical distance from lung base to apex is 
relatively large resulting in very low perfusion pressures of the top of the lungs 
while perfusion pressures are larger in the lower lung segments. This “passive” 
pressure distribution helps to direct the ﬂ ow to the well-ventilated lower lung 
areas. During exercise, ventilation increases, thereby recruiting the upper lung 
segments [10]. Moreover, pulmonary pressure increases which results in improved 
perfusion of these same regions. Thus, the large decrease in pulmonary vascular 
resistance from rest to exercise in the upright position mainly reﬂ ects recruitment 
of vessels that were unperfused at rest [11]. In contrast, in the supine posture, the 
vertical distance is less, such that the whole lung can be perfused rather evenly 
even at low pulmonary arterial pressures as evidenced by a lower pulmonary 
vascular resistance as compared to the upright position. Moreover, transition from 
rest to exercise in the supine position has only little effect on pulmonary vascular 
resistance [11], reﬂ ecting the low levels of pulmonary vascular tone.
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In medium-size quadrupeds such as dogs and pigs the vertical distance from 
the most ventral to the most dorsal part is approximately 15 cm, with the heart 
lying on the sternum at the “bottom” of the lung. Unlike the human lung with 
its large base and small apex, quadruped lungs have small ventral volumes but 
large dorsal volume [12]. Thus, to enable adequate gas-exchange, with most of 
the lung volume being situated well above the heart, pulmonary artery pressure 
in these quadrupeds (approximately 15-16 mmHg, [12] needs to be slightly higher 
than in humans (13-14 mmHg [11, 12]). Since the entire lung is already perfused in 
prone position in quadrupeds, there is very little effect of posture on the regional 
pulmonary blood ﬂ ow [13-16].
During exercise the ﬂ ow through the pulmonary bed increases, as a result of 
increasing cardiac output. In quadrupeds, the ﬂ ows in all lung areas during exercise 
are proportional to their resting ﬂ ows, so that the distribution of ﬂ ow across the 
pulmonary vasculature does not change [12]. Hence, the fall in pulmonary vascular 
resistance with exercise is primarily due to decreased pulmonary vascular tone and 
passive pulmonary arterial distension due to the increase in pulmonary pressure. 
Active regulation 
There are a lot of vasoconstrictor or vasodilator inﬂ uences that cause active 
regulation of the vasculature (Fig. 3). Eventually they all result in vascular 
smooth muscle cell contraction or relaxation. The vascular smooth muscle cells 
are lined in the arterial wall just underneath the endothelial cells. They are 
highly specialized cells whose principal functions are contraction and relaxation 
[17]. They express a variety of contractile proteins, ion channels, and signalling 
molecules that regulate contraction. In the intact body, the process of smooth 
muscle contraction is principally regulated by pharmacomechanic activation (i.e., 
activation by ligands of cell surface receptors) and electromechanic activation (i.e., 
stretch, intraluminal pressure) of the contractile proteins myosin and actin [18]. 
Contraction and relaxation of the smooth muscle cells are caused by an increase 
or decrease of intracellular calcium respectively, or by deactivation and activation 
respectively of the myosin light chain phosphatase. Calcium (Ca2+) and myosin light 
chain phosphatase act synergistically to change vascular tone (Fig. 4). 
The cell membrane is permeable to a number of ions, the most important of 
which are Na+, K+, Ca2+ and Cl-. These ions pass across the membrane through speciﬁ c 
ion channels that can open (become activated) and close (become inactivated). 
Their opening and closing can occur in response to 1) voltage changes (voltage gated 
channels), 2) activation of receptors (receptor gated channels), or speciﬁ c ions or 
ligands. Importantly, there are several different types of K+-channels that play an 
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important role in resting membrane potential and in action potentials. Activation 
of these K+-channels leads to efﬂ ux of K+-ions, a decrease in membranepotential 
(hyperpolarization), decrease in intracellular Ca2+, thereby causing smooth muscle 
relaxation and vasodilation. (Fig. 4) [19, 20].
As described in the paragraphs above, Ca2+ is an important signaling molecule 
in physiology, since it is responsible for the actual constriction of smooth muscle 
cells. Therefore it is highly regulated with dynamic, localized, and temporal 
changes in its intracellular concentration. Within the intracellular Ca2+ stores of 
the sarcoplasmic reticulum and in the extracellular space of smooth muscle cells 
the Ca2+ concentration is high (several millimoles per litre). Since basal cytoplasmic 
Ca2+ is in the range of 120 nmol/l [21-23], a large chemical gradient exists for Ca2+ to 
enter from the extracellular space and the sarcoplasmic reticulum lumen into the 
cytoplasm during smooth muscle cells excitation. The relative contributions of these 
two major Ca2+ sources to the increase in cytoplasmic Ca2+, eliciting contraction of 
smooth muscle cells, remain in debate [24-28] but may vary depending on smooth 
Figure 3: Diameter of arteries is inﬂ uenced by different vasodilators and vasoconstrictors. 
α, alpha adrenoreceptors;  β,  beta adrenoreceptors; NO, nitric oxide; PGI2, prostacyclin; PO2, 
partial O2 tension; PCO2, partial CO2 tension; K
+
ATP , ATP dependent potassium channel; K
+
Ca2+. Calcium 
dependent potassium channel; ET, endothelin; ETA, endothelin A receptor; ETB, endothelin B receptor; 
AT1, angiotensin 1 receptor; PDE, phosphodiesterase; 5-HT, serotonin; TXA2, thromboxane. Adapted 
with permission from [2]
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muscle cells type and excitatory stimulus [29]. 
Ca2+ is removed from cells by two basic mechanisms. The ﬁ rst mechanism 
involves an ATP-dependent Ca2+ pump that actively removes calcium from the 
cell. The second mechanism is the sodium-calcium exchanger. This is a non-ATP-
dependent protein that, under steady-state conditions, extrudes Ca2+ from the 
interior of the cell into the extracellular space via facilitated transport [30].
Many vasoactive substances inﬂ uence vascular resistance by increasing the 
production of the second messengers cAMP and/or cGMP, which can cause an 
increase in intracellular Ca2+. These second messengers are short-lived because 
they are degraded by PDE (Fig. 4) [31]. At least eleven different gene families of 
PDE are currently known to exist in mammalian tissues but the tissue distribution 
of the PDE-isoforms as well as their speciﬁ city for cAMP and cGMP varies [32]. 
Inhibition of PDE in vascular smooth muscle can provide a powerful tool to reduce 
vascular resistance, by prolonging the half-life of cAMP and/or cGMP. The PDE 
isoforms that are predominantly present in vascular smooth muscle are PDE1, 3, 
 
 
↓Ca release
↑Ca uptake
Endoplasmatic 
reticulum: 
PDE 
Vasodilators 
↑ cGMP/ cAMP
↑K channels
Plasma 
membrane: 
Hyperpolarization 
↓VOCC ↓ROCC 
↑Na/Ca exchanger 
↑Ca ATPase 
↓Ca influx ↑Ca efflux 
↑Myosin light chain 
phosphatase 
↓[Ca2+]i ↓Myosin light chain kinase 
↓Myosin light chain 
phosphorylation 
↓TONE 
Figure 4: Mechanism of vasodilation in smooth muscle cells. cGMP, cyclic guanosine monophosphate; 
cAMP, cyclic adenosine monophosphate; PDE, phosphodiesterase; Ca, calcium; K, potassium; VOCC, 
voltage-operated calcium channels; ROCC, receptor-operated calcium channels; [Ca2+]i, intracellular 
free calcium ion concentration. Adapted with permission from [5]
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4, 5, 7 and 9 [33, 34]. PDE1, PDE4 and PDE7 are cAMP-speciﬁ c, while PDE3 has 
a 4-10 times higher afﬁ nity for cAMP than for cGMP. PDE5 and PDE9 are cGMP-
speciﬁ c [32]. However, PDE9 is abundantly expressed throughout the body [32], 
whereas PDE5 expression is 10 times more abundant in the pulmonary vasculature 
as compared to the heart [35, 36].
Endothelial cells. 
The endothelial cells interact with the smooth muscle cells present in the 
vascular wall on one hand and with circulating cells on the other hand. Endothelial 
cells can produce different vasodilators (i.e. nitric oxide (NO), prostacyclin 
(PGI2), endothelium derived hyperpolarisation factor (EDHF)) and vasoconstrictors 
(endothelin (ET)) in response to physiological stimuli such as shear stress. Shear 
stress is a force acting in the direction of the blood ﬂ ow on the surface of endothelial 
cells and increases when ﬂ ow increases.
Prostaglandins. Lung tissue is particularly active in the synthesis, metabolism 
and release of a number of prostaglandins, which may play a role in the regulation 
of pulmonary vascular resistance [37]. The isoenzymes cyclooxygenase (COX)-1 
and -2 catalyze the conversion of arachidonic acid into thromboxane A2 (TXA2) 
and prostaglandins (PGs). Prostaglandins I2 (PGI2) and E1 (PGE1) are active 
pulmonary vasodilators, whereas PGF2α and PGA2 are pulmonary vasoconstrictors. 
PGI2, prostacyclin, is the principal arachidonic acid metabolite released by 
the endothelium and possesses both vasodilatory and antiplatelet effects [38]. 
Physiologically, prostacyclin is a local hormone rather than a circulating one and 
release of prostacyclin by endothelial cells causes relaxation of the underlying 
vascular smooth muscle and prevents platelet aggregation within the bloodstream 
[8]. Prostacyclin exerts its effects through activation of the cyclic adenosine 
monophosphate (cAMP)-dependent pathways. 
Nitric oxide. Nitric oxide (NO) is another vasoactive agent synthesized by the 
endothelium that plays an important role as a vasodilator [39]. It is synthesized 
from L-arginine by NO synthase (NOS), which exists in 3 isoforms: inducible NOS 
(iNOS), an isoform, expressed mainly by macrophages, neuronal NOS (nNOS), an 
isoform expressed by neurons, and an endothelial form [38]. Endothelial NOS (eNOS) 
is dependent on calcium and is widely expressed in the pulmonary endothelium of 
healthy individuals [38]. NO acts through cyclic guanosine monophosphate (cGMP) 
to regulate potassium channels and has a very localized effect. If any NO diffuses 
into circulating blood, it immediately and irreversibly binds to the heme iron in 
hemoglobin. Thus, its action is strictly localized to the vascular bed in which it is 
produced [1]. Endothelial NO synthase is found in the vascular endothelium of the 
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normal pulmonary vasculature, where it is responsible for generating NO to govern 
vascular tone. 
Endothelium derived hyperpolarisation factor. Endothelium derived 
hyperpolarisation factor (EDHF) is a substance synthesized in, and released from, 
the endothelium which hyperpolarizes vascular smooth muscle cells thus reducing 
the open probability of voltage-dependent Ca2+ channels so that intracellular Ca2+ 
is lowered, and relaxation can take place. The name “EDHF” is confusing because 
it implies that a single diffusible substance mediates this type of endothelium-
dependent relaxation. In fact, numerous endothelium-derived factors, including 
NO and prostacyclin themselves, can hyperpolarize the underlying smooth muscle. 
There is still a lot unknown about non-prostanoid–dependent, non-NO–dependent 
endothelium-dependent hyperpolarization factors, but it is generally assumed that 
cytochrome p450 plays a role in the production of EDHF. Cytochrome p450 products 
proposed to be EDHFs are the epoxyeicosatrienoic acids (EETs) Indeed, EETs are 
generated by endothelial cells and mediate part of the endothelium-dependent 
dilator effect of arachidonic acid  [40]. Other substances that are proposed to be 
a EDHF include derivates of the lipoxygenase pathway, hydrogen peroxidase and 
c-type natriuretic peptide [41]
Endothelin. Endothelin is a potent vasoconstrictor peptide that plays an 
important role in the regulation of pulmonary vascular tone. Three isopeptides 
of endothelin have been identiﬁ ed, endothelin-1, endothelin-2 and endothelin-
3, each containing 21 amino acids [42]. These peptides are synthesised from the 
39 amino acid intermediate big ET by ET converting enzyme [43]. ET-1 is the 
predominant isoform of endothelin in the cardiovascular system and it is produced 
from big-ET by endothelin-converting-enzym (ECE)-1, while big-ET is produced 
from preproendothelin by furin-like enzymes [44]. ET-1 is synthesized by a variety 
of different cell types, including endothelial cells, vascular and airway smooth-
muscle cells, leukocytes, macrophages, cardiomyocytes and mesangial cells [45]. 
In endothelial cells it is released toward the vascular smooth muscle cell, consistent 
with a paracrine rule. ET-1 is abundantly expressed in the pulmonary vasculature 
and exerts its major vascular effects through activation of two distinct G-protein-
coupled ETA and ETB receptors [46]. 
ETA receptors are located on the vascular smooth muscle cells were they cause 
vasoconstriction, while ETB receptors are localized on endothelial cells and smooth 
muscle cells [47]. The activation of ETB receptors on endothelial cells causes 
the release of NO and PGI2, thereby causing vasodilation [48]. However, the ETB 
receptors that are located on smooth muscle cells induce vasoconstriction [49, 
50]. ETA receptors are the predominant ET vasoconstrictor receptors in arteries 
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throughout the body. Vasoconstrictor ETB receptors are present in the veins and 
pulmonary vessels in larger numbers than in arteries, although ETA still predominate 
over ETB receptors in these vessels [51]. In the large pulmonary arteries, ET-
induced constriction is mediated by ETA receptors, whereas it is mediated by ETB 
receptors in the smaller pulmonary resistance vessels [52]. In accordance with 
these ﬁ ndings, the density of ETA receptors in the lung decreases with decreasing 
vessel size, whereas the density of ETB receptors, both on the endothelium and the 
smooth muscle increases [53]. 
 The net effect of ET-1 depends mainly on the relative density and activity 
of ETA receptors on smooth muscle cells and of ETB receptors on smooth muscle 
and endothelial cells [54]. Normally there is a balance between production and 
clearance. The latter is mediated by the endothelial ETB receptor such that 
circulating endothelin is at low level [46]. 
Neurohumoral control. 
The pulmonary vasculature expresses both alpha (α) and beta (β) 
adrenoreceptors, which help regulate  vascular tone by producing vasoconstriction 
or vasodilation, respectively [55]. These receptors primarily bind norepinephrine 
that is released from sympathetic adrenergic nerves. Additionally, they bind 
norepinephrine and epinephrine that circulates in the blood. Vascular smooth 
muscle has two primary types of alpha-adrenoceptors: alpha1 (α1) and alpha2 (α2). 
The α1-adrenoceptors are located on the vascular smooth muscle. In contrast, 
α2-adrenoceptors are located on the sympathetic nerve terminals as well as on 
vascular smooth muscle. Smooth muscle α1 and α2-adrenoceptors are linked 
to a G-protein, which activates smooth muscle contraction. Prejunctional α2-
adrenoceptors located on the sympathetic nerve terminals serve as a negative 
feedback mechanism for norepinephrine release. α1-Adrenoreceptors in the 
pulmonary arteries have increased afﬁ nity and responsiveness to their agonists 
when compared with other vessels [56]. The downstream signaling events in α1-
adrenergic stimulation are an increase in calcium levels and activation of protein 
kinase, which mediate vascular contractile and proliferative responses. The 
increased sensitivity of α1-adrenoreceptors to norepinephrine in the pulmonary 
arteries may greatly facilitate local regulation of vascular tone in response to 
acute changes in oxygen concentrations, thereby adjusting regional perfusion. 
Stimulation of α1-adrenoreceptors increases intracellular free calcium levels by 
at least two mechanisms: (1) coupling to speciﬁ c G proteins on the cell membrane 
and (2) blockade of potassium ion channels [57]. There are two β receptorsubtypes, 
β1 and β2 receptors. Vascular smooth muscle  cells have β2-adrenoceptors that are 
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normally activated by norepinephrine released by sympathetic adrenergic nerves 
or by circulating epinephrine. These receptors, are coupled to a Gs-protein, which 
stimulates the formation of cAMP. Increases in intracellular cAMP caused by β2-
agonists inhibit myosin light chain kinase thereby producing less contractile force 
(i.e., promoting relaxation). 
Angiotensin II.  Angiotensin II, the effector peptide of the renin-angiotensin 
system [58] causes vasoconstriction. It is generated in the lung by means of enzymatic 
conversion of angiotensin I [46]. It binds to two speciﬁ c receptor subtypes, AT1 
and AT2, and activates complex intracellular signalling systems. AT1 predominates 
in vascular tissues and contributes to chronic diseases by promoting cell growth, 
inﬂ ammation, and ﬁ brosis, while AT2 is expressed in pathological settings and is 
involved in vasodilation and apoptosis [58]. 
Thromboxane A2. Thromboxane (TXA2) is a product of arachidonic acid 
metabolism and acts as a vasoconstrictor of pulmonary arterial and venous smooth 
muscle. TXA2 act or signal by binding to speciﬁ c receptors, located on the surface 
of their target cell. In humans, thromboxane signals through two distinct but 
closely related thromboxane receptors, referred to as the thromboxane receptor 
α and β. Many cells, particularly macrophages, but also leukocytes, platelets and 
endothelial cells produce and release TXA2. The effect is localized mainly in the 
region where the TXA2 is released, because the half time of TXA2 inactivation in 
blood is only several seconds [1].
Serotonin. Serotonin (5-HT), is an important constituent of platelet-dense 
granules and is released upon activation. Serotonin can be a vasodilator in healthy 
vasculature, but is a vasoconstrictor that promotes smooth muscle cell hypertrophy 
and hyperplasia in damaged vasculature. Normal endothelial cells respond to 
serotonin by enhancing the release of NO, thereby leading to vascular smooth 
muscle relaxation and vasodilation. In the setting of endothelial dysfunction, 
serotonin is unable to stimulate NO release and increases vascular smooth muscle 
tone, thereby leading to vasoconstriction [59].
 Serotonin receptors are classiﬁ ed into 7 types, each type can have subtypes 
A, B and so on. Vasoconstriction occurs when 5-HT binds to 5-HT receptors. 5-
HT can also be transported inside the cells by 5-HT transporters [60]. The 5-HT 
receptors and 5-HT transporters are abundantly expressed in the lung, where they 
are predominantly located in the pulmonary arterial smooth muscle cell [61]. A 
clear distinction between the two classes of molecules, 5-HT transporter and 5-
HT receptors, has so far been indeﬁ nable. Either or both may play a role in the 
pulmonary arterial smooth muscle cell response to 5-HT [60].
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Oxygen tension. 
The effects of changes in PO2 on the pulmonary circulation are the opposite to 
those in the systemic circulation [1, 6]. A decrease in PO2 causes constriction of the 
pulmonary arteries whereas in the systemic circulation a decrease in PO2 accounts 
for relaxation of the resistance vessels. However, in the pulmonary circulation, the 
PO2 in the lumen of the arteries appears not to be the most important factor, but 
rather the PO2 in the air spaces of the alveoli. Indeed, perfusion of the pulmonary 
circulation with a hypoxic solution results in less vasoconstriction than ventilating 
the airways with a low PO2 air mixture [6]. Oxygen diffuses through the thin 
alveolar walls into the smooth muscle cells and a reduced alveolair PO2 results 
in local vasoconstriction (hypoxic vasoconstriction). Hypoxic vasoconstriction is 
a unique physiological response in pulmonary arteries and arterioles so that the 
blood ﬂ ow is shunted away from hypoxic regions toward better ventilated areas of 
the lung, improving the ventilation-perfusion matching within the lung [46]. The 
mechanism behind this hypoxic vasoconstriction remains unknown, but since it 
also occurs in isolated lung tissue and thus does not rely on the nervous system or 
systemic hormones, it is believed to act directly on the pulmonary vascular smooth 
muscle cells [6].
People that live at high altitude have to cope with this hypoxic vasoconstriction 
due to chronic hypoxia. Altitude decreases the inspired partial pressure of oxygen 
because of a decrease in barometric pressure [46]. At sea level, PO2 is on average 
150 mm Hg, while at high altitudes, PO2 decreases to 80 to 100 mm Hg, and at 
extreme altitudes PO2 decreases to 40 to 80 mm Hg. Life at altitude is therefore 
associated with pulmonary hypertension of variable severity [46].
Active regulation during exercise 
The regulation of active pulmonary vasomotor tone during exercise is 
incompletely understood. There are a lot of mechanisms that can play a role. In 
previous studies we found that β-adrenergic blockade by administration of propanolol 
increased PVR at rest and during exercise, while α-adrenergic blockade showed 
the opposite [62]. This was also found in sheep at rest [63]. Since pharmacological 
β -adrenoceptor stimulation produces vasodilation in pulmonary arteries [64], as 
well as other vascular beds [65, 66], that is in part mediated by K+
ATP
 channel 
activation, the exercise-induced pulmonary vasodilation could also be mediated 
via K+
ATP
 channel opening. But blockade of K+
ATP
 channels showed clearly that the 
K+
ATP
 channels are not mandatory for maintaining pulmonary vascular resistance 
in awake swine at rest and during treadmill exercise [67]. Another well known 
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vasoactive substance is adenosine, which has been shown to be a vasodilator in 
the systemic and the coronary vascular bed [68], but its role in the pulmonary 
circulation is controversial. Saadjian et al [69] found a correlation between PVR 
and the adenosine plasma concentration in the pulmonary circulation in men, which 
suggests that adenosine may play a part in the regulation of pulmonary vascular 
tone. However, a study in swine showed no effect on PVR after blocking adenosine 
with 8-phenyltheophylline in rest and during exercise [68]. The role of other 
important vasodilators (NO, prostacyclin, PDE5 inhibition) and vasoconstrictors 
(ET) in the pulmonary circulation of swine at rest and during exercise will be 
determined in this thesis.
Pulmonary hypertension
Pulmonary hypertension is characterized by elevated levels of pulmonary 
arterial pressure and pulmonary vascular resistance. Clinically it is deﬁ ned as a 
mean elevation of pulmonary artery pressure > 20 mm Hg at rest or > 30 mm Hg 
during exercise [70-72]. It is a rare disease with a poor prognosis when untreated 
[73]. 
Several years ago there were two classiﬁ cations for pulmonary hypertension, 
primary pulmonary hypertension which indicated the patients who were diagnosed 
with pulmonary hypertension of an unexplained etiology, and secondary pulmonary 
hypertension, which indicated the patients with pulmonary hypertension as 
a result of an underlying disease. In 1998, during the Second World Symposium 
on Pulmonary Hypertension held in Evian, France, a clinical classiﬁ cation of PH 
was proposed because the term “secondary pulmonary hypertension” was found 
confusing and without value for diagnosis and treatment [74]. Thus, this term was 
left out in the new classiﬁ cation, which consist of ﬁ ve groups, the ﬁ rst group to be 
pulmonary arterial hypertension, which included primary pulmonary hypertension. 
During the third World Symposium on Pulmonary Hypertension in 2003 some changes 
were made to the classiﬁ cation and the most important might be the deletion of 
the name primary pulmonary hypertension. The revised clinical classiﬁ cation of 
pulmonary hypertension is indicated in table 1 [74].
 
The ﬁ rst two pulmonary hypertension classiﬁ cations will shortly be discussed 
in light of the genetic knowledge of the last few years (idiopathic and familial 
pulmonary hypertension) and as an outline for the rest of this thesis (pulmonary 
hypertension with left heart disease)
Idiopathic and familial pulmonary hypertension. Idiopathic and familial 
pulmonary hypertension are relatively rare with an estimated incidence of 1 or 2 
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Table 1: Evian Classification of pulmonary hypertension [74]  
 1. Pulmonary arterial hypertension (PAH)  
 1.1. Idiopathic (IPAH)  
 1.2. Familial (FPAH)  
 1.3. Associated with (APAH):  
  1.3.1. Collagen vascular disease  
  1.3.2. Congenital systemic-to-pulmonary shunts  
  1.3.3. Portal hypertension  
  1.3.4. HIV infection  
  1.3.5. Drugs and toxins  
  
1.3.6. Other  
(thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic 
telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) 
 
 1.4. Associated with significant venous or capillary involvement  
  1.4.1. Pulmonary veno-occlusive disease (PVOD)   
  1.4.2. Pulmonary capillary hemangiomatosis (PCH)   
 1.5. Persistent pulmonary hypertension of the newborn  
 2. Pulmonary hypertension with left heart disease  
 2.1. Left-sided atrial or ventricular heart disease   
 2.2. Left-sided valvular heart disease   
 3. Pulmonary hypertension associated with lung diseases and/or hypoxemia   
 3.1. Chronic obstructive pulmonary disease   
 3.2. Interstitial lung disease   
 3.3. Sleep-disordered breathing   
 3.4. Alveolar hypoventilation disorders   
 3.5. Chronic exposure to high altitude   
 3.6. Developmental abnormalities   
 4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease   
 4.1. Thromboembolic obstruction of proximal pulmonary arteries   
 4.2. Thromboembolic obstruction of distal pulmonary arteries   
 4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign material)   
 5. Miscellaneous   
 Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels 
(adenopathy, tumor, fibrosing mediastinitis) 
  
 
per million in the population. In the last few years more understanding towards 
the genetic basis of pulmonary hypertension has occurred by the suggestion that 
mutations in the gene encoding the bone morphogenetic protein receptor type II 
(BMPR2), localized to chromosome 2q33, underlies approximately 50% of cases of 
familial pulmonary hypertension [75]. Moreover, mutations in BMPR2 have been 
identiﬁ ed in up to 26% of sporadic cases of PPH [76]. Mutations associated with 
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pulmonary hypertension also occur in Alk/endoglin, wich is a TGF receptor  [77]. 
However, the chance of a disease gene carrier developing pulmonary hypertension 
is as low as 20% [74, 78]. It is incompletely understood why this chance is only 20%, 
but different gene mutations or use of drugs might be the trigger for pulmonary 
hypertension in patients with the BMPR2 mutation. Moreover, studies are needed 
to identify other genes, modiﬁ ers, and regulatory genes of PH.
Pulmonary hypertension with left heart disease. With the improved 
treatment and survival of myocardial infarction, the importance of ischemic heart 
disease increased and has become the most prominent cause of heart failure 
in the western world [4]. After myocardial infarction a part of the myocardium 
is dead and has lost its ability to contract. To adequately maintain cardiac 
output, the remaining ‘healthy’ part of the myocardium has to work harder and 
eventually these cells will hypertrophy. When the pumpfunction of the heart is 
still insufﬁ cient, left heart failure will occur. As a result of the decreased ability 
of the heart to empty the left ventricle, pressure in the left ventricle and left 
atrium will increase. The increased left atrial pressure is transmitted backwards 
into the pulmonary circulation wich will lead to reactive increase in PVR and thus 
pulmonary hypertension and eventually right heart failure [79, 80].
Endothelial dysfunction in pulmonary hypertension. 
The precise cause of idiopathic pulmonary hypertension remains unknown, 
but as with most other forms of pulmonary hypertension, including pulmonary 
hypertension secondary to an underlying disease, endothelial dysfunction plays 
an important role. The normal pulmonary vascular endothelial cell maintains 
the vascular smooth muscle cells in a state of relaxation [37], although in 
patients with pulmonary hypertension increased pulmonary vascular reactivity 
and vasoconstriction was found [70]. Indeed, there is growing evidence that the 
deregulation of pulmonary vascular tone in disease states involves alterations in 
the counterbalancing systems of the endothelium (such as NO, PGI2 and ET) [80]. In 
accordance with that, studies in both experimental models and patients suggest that 
NO-dependent pulmonary vasodilation is impaired in heart failure [80, 81]. Clinical 
studies suggest that basal pulmonary artery NO production is relatively deﬁ cient 
in patients with heart failure and secondary pulmonary hypertension, and that the 
loss of NO-dependent vasodilation may contribute to the development of pulmonary 
hypertension [82, 83]. However, there are also reports on increased production of 
NO in early stages of pulmonary hypertension [5]. Hypothetically both the increase 
and decrease of NO can contribute to the pathogenesis of pulmonary hypertension, 
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since increased endothelial cell NO could lead to abnormal angiogenesis and VEGF 
signalling while decreased targeting by NO could contribute to cell proliferation 
and vasoconstriction [81].  
Prostacyclin has very potent pulmonary vasoconstrictor capacities although it 
seems not to contribute to basal vasomotor tone [84, 85]. However, in patients with 
severe pulmonary hypertension a decrease in prostacyclin synthase expression is 
observed [86] and prostacyclin-receptor deﬁ cient mice develop severe pulmonary 
hypertension changes [87] which both indicate a role of prostacyclin in pulmonary 
hypertension. The feedback mechanism in which NO and prostanoids are capable 
of inhibition of the release of ET [88-90] will also be decreased with decreased 
levels of NO and PGI2, resulting in increased levels of ET. Indeed, increased levels 
of circulating ET, as well as increased local production [80, 91, 92]. Moreover, 
there is a correlation between ET plasma levels and the severity of pulmonary 
hypertension in patients with chronic heart failure [93]. Whether this increased ET 
inﬂ uence is the result of the decreased inhibition by NO and PGI2 or the result of 
decreased clearance or receptor sensitivity is still incompletely understood.
Morphology and remodelling
Arteries are composed of a tunica intima, which are the endothelial cells that 
form the inner layer of the vascular wall, a tunica media, the smooth muscle cells 
and a tunica externa or tunica adventitia which consist of loose ﬁ brous connective 
ﬁ brous tissue. Pulmonary arteries in pulmonary hypertension are characterized by 
intimal ﬁ brosis, medial hypertrophy and adventitial proliferation, so thickening of 
the layers of the vessel wall [94]. This thickening can be the result of hypertrophy 
and/ or hyperplasia of the cell types within one layer. This alterations in vascular 
structure are seen in both human and animal models of pulmonary hypertension 
and take place more rapidly than the remodeling of systemic arteries in systemic 
hypertension [95].
Pulmonary vascular remodeling occurs in response to a variety of stimuli, both 
physical (mechanical stretch, shear stress) and chemical (e.g. hypoxia, vasoactive 
substances, growth factors). The physical factors may involve direct activation 
of stretch sensitive ion channels [96] or indirect via growth factors [97]. Some of 
the vasoactive substances that are important in the regulation of vascular tone 
are also important in remodeling. NO and PGI2 both have antimitogenic effects in 
the pulmonary vasculature, meaning they inhibit DNA synthesis and proliferation 
[95]. Prostacyclin also inhibits the proliferation of vascular smooth muscle cells 
and decreases platelet aggregation [98]. Furthermore, both NO and PGI2 can 
inhibit the production of ET. ET stimulates the production of growth factors such 
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as vascular endothelial growth factor (VEGF), basic ﬁ broblast growth factor (FGF) 
and cytokines [54] and strengthens the effects of some growth factors [46]. It has 
proliferative effect on vascular smooth muscle cells [99, 100] and therefore, ET-1 
leads to morphologic abnormalities of small- and medium-sized pulmonary arteries. 
The consequences of vascular remodeling of the pulmonary vasculature are that 
due to the wall thickening, vessel inner diameter decreases, and as a result of that 
pulmonary artery pressure increases. Also the lumen-to-wall ratio is important. 
Constriction of the smooth muscle cells, induced by a vasoconstrictor, will cause a 
greater increase in vascular resistance in vessels with a small lumen-to-wall ratio. A 
thirth important consequence is that due to alterations in the extracellular matrix, 
compliance of the vessels is reduced and therefore the pulmonary circulation will 
have less ability to accomodate increases in cardiac output [95], and pulmonary 
artery pressure will rise more during exercise.
Exercise and pulmonary hypertension
During exercise, pulmonary artery pressure increases concominant to increases 
in cardiac output in order to maintain the low pulmonary vascular resistance. Since 
patients with pulmonary hypertension already have an increased pulmonary artery 
pressure, exercise is difﬁ cult and sometimes impossible. These limitations can be 
explained by ﬁ ndings of Franciosa et al, who found that the right ventricle and 
the pulmonary arterial pressure limit exercise capacity [101] and Holverda et al, 
who found that in patients with pulmonary hypertension an exercise-induced rise 
in pulmonary artery pressure results in further impairment of right ventricular 
function and underﬁ lling of the left ventricle, which leads to a failing stroke 
volume response to exercise [102]. However, to date little is known about the 
regulation of pulmonary vascular tone during exercise and little research is carried 
out to investigate this regulation even though it is important for patients to be 
treated with a vasodilator therapy which maintains its vasodilator inﬂ uence during 
exercise.
One of the endpoints in many patient studies on therapies for pulmonary 
hypertension is the six minute walk to investigate the aimed progress in exercise 
capacity. The change in exercise capacity in patients with pulmonary hypertension 
appears to parallel other clinical indicators of disease severity, such as survival, 
hemodynamics, and time to clinical worsening [103]. The distance walked in these 
6 minutes is measured and compared with the distance the patient can walk with 
vasodilator therapy. An average 6 min walk of a patient with pulmonary hypertension 
is 330 meter, while in healthy subjects this is doubled [104, 105]. In several patient 
studies the progress in the 6 min walk is between 35 and 75 meter, which is not 
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even near ‘normal’ distances [104]. Thus, even though this 6-minute-walk can 
depict the improvement of exercise capacity in different vasodilator therapies, 
there is no evidence that the vasoactive substances studied really contribute 
to the regulation of the hypertensive pulmonary circulation during exercise. In 
addition, in some studies exogenous vasodilators (e.g. NO and prostacyclin) are 
studied instead of the endogenous role of these substances.
Current therapies
Therapies have improved over the last years as knowledge of pulmonary 
hypertension has improved. Since hypoxemia is a pulmonary vasoconstrictor, 
supplemental oxygen can be used in patients to maintain an oxygen saturation of 
greater than 90%. Other currently available therapies include inhalation of NO and/
or administration of Ca2+-channel blockers, exogenous prostacyclin and endothelin-
receptor blockade. However, these therapies have short-duration, limited efﬁ cacy, 
are expensive and/or associated with signiﬁ cant side effects, indicating that there 
is a continued need for novel vasodilator therapies of pulmonary hypertension 
[106, 107]. At this moment a lot of patient studies are being conducted to get 
more information about effect, dosages, increases in quality of life and long-term 
effects. In patients who do not respond to the therapies, atrial septostomy (making 
a hole between atria with a catheter to allow oxygen rich and oxygen poor blood 
to mix) or lung transplantation are the only options left [78].
Animal models of pulmonary hypertension
There are several animal models to investigate different aspects of pulmonary 
hypertension. The most frequently used animals in research in all ﬁ elds are mice. They 
are small and therefore easy to handle and housing does not require a lot of room. 
There are some mouse models of pulmonary hypertension, for example there is a 
BMPR2-deﬁ cient mouse that develops pulmonary hypertension [108]. Also wildtype 
and/ or genetic modiﬁ ed mice exposed to chronic hypoxia develop pulmonary 
hypertension as a result of hypoxic vasoconstriction [109]. Thus, micemodels have 
great potential, although hemodynamic measurements are limited. A slightly larger 
animal, the rat, is also often used in pulmonary hypertension research. Pulmonary 
hypertension can be induced by hypoxia [109], genetics (spontaneously pulmonary 
hypertensive rats (Fawn-hooded rat)) [110], myocardial infarction [111] or by 
monocrotaline, a substance that induces progressive pulmonary hypertension after 
a single subcutaneous injection. Rats exposed to monocrotaline develop acute 
pulmonary vascular inﬂ ammation resulting in vascular remodeling and pulmonary 
hypertension [112]. A large animal model is the sheep. Sheeps and lambs are both 
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often used to perform ligation of the ductus arteriosus, in utero, as a model for 
persistent pulmonary hypertension of the newborn [113]. Sheep are also used to 
study hemodynamics in pulmonary hypertension, which can be more extended 
because of the size of the animal [114]. 
Also swine are commonly used in cardiovascular research because swine and 
humans share important anatomic and physiologic characteristics [115, 116]. For 
example, pulmonary artery pressure of swine is approximately 17 mmHg, while 
a person at sea level has a pulmonary artery pressure of 12-16 mmHg [117]. The 
swine model used to study the pulmonary circulation in this thesis is a chronically 
instrumented swine, which means that hemodynamics of these animals can be 
monitored while they are awake, providing a lot of data on different vasodilators 
and vasoconstrictors that can be administered, free from the effect of anesthesia. 
A subgroup of these animals receives a coronary artery occlusion to induce 
myocardial infarction and pulmonary hypertension. Hemodynamic and neurohumoral 
alterations mimic alterations in humans [118]. These animals are habituated to 
exercise on a treadmill, which provides us with data on the pulmonary circulation 
during exercise [118, 119].
Our model of pulmonary hypertension is a model with mild pulmonary 
hypertension early after MI, without severe endothelial dysfunction. Since detection 
of pulmonary hypertension is improving, more patients are diagnosed before they 
reach the end stage of the disease. It is therefore important that research is being 
conducted on early pulmonary hypertension, to map the changes in regulation of 
pulmonary vascular tone while pulmonary hypertension progresses.  
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Aim and outline of the thesis
The general aim of this thesis is to study the complex regulation of the 
pulmonary circulation, in health and disease (pulmonary hypertension after 
myocardial infarction) in an intact animal model at rest and during exercise.
Knowledge about the regulation of pulmonary vascular tone is necessary to 
treat diseases of this vascular bed. Although it is common knowledge that there 
are vast differences between the systemic and pulmonary vascular bed, e.g. high 
versus low pressure, little is known about the differences in regulation of the 
pulmonary vascular bed in comparison with the systemic vascular bed. Therefore, 
in part one of this thesis (Chapter 2-4) we studied the contribution of different 
endothelial derived vasoactive substances on the regulation of vascular tone of the 
systemic and pulmonary vascular bed under normal physiological circumstances. 
Speciﬁ cally we studied the role of the vasodilators NO and prostacyclin (Chapter 
2) and the role of the potent vasoconstrictor ET (Chapter 3). Since ET can increase 
the production of NO and prostacyclin, which in turn can blunt the release of ET 
[88-90] or modify the responsiveness of its receptors [120] (Fig. 5), we studied 
the integrated role of NO, prostacyclin and ET in the pulmonary and systemic 
circulation at rest and during exercise in Chapter4.
Smooth muscle relaxation, vasodilation 
↑cGMP 
PDE5 
↑cAMP 
 
PGI2 
Prostacyclin pathway 
Endothelial cells   
Endothelin-1 
ETB 
ETA ETB Vascular smooth muscle cells 
Smooth muscle contraction, vasoconstriction 
Endothelin pathway 
 -
 
Nitric oxide 
Nitric oxide pathway 
Preproendothelin →
ECE
L arginine →
eNOS
Arachidonic acid →
COX
?
Figure 5: Three major pathways involved in relaxation and contraction of the smooth-muscle cells 
of the pulmonary artery are shown. PGI2, prostacyclin; ETA, endothelin A receptor; ETB, endothelin 
B receptor; cGMP, cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate; PDE, 
phosphodiesterase.
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Due to increased survival after myocardial infarction, the number of patients 
with pulmonary hypertension secondary to myocardial infarction is increasing. Yet, 
there is still a lot unknown about the regulation of pulmonary vascular tone in 
pulmonary hypertension. Increased levels of circulating ET, as well as increased 
local production [80, 91, 92] are found in patients with pulmonary hypertension 
as well as perturbations in vasodilators as a result of endothelial dysfunction [81]. 
Therefore, in part two of this thesis (Chapter 5-8), we studied the alterations in 
the regulation of pulmonary vascular tone, speciﬁ cally, we studied the role of ET 
(Chapter 5) and the integrated role of NO, prostcyclin and ET (Chapter 6) in swine 
with MI induced pulmonary hypertension. In addition, since PDE5 inhibition (Fig. 
5) is a promising vasodilator therapy for patients with pulmonary hypertension we 
studied the vasodilator effects of a novel PDE5 inhibitor, EMD360527 in normal 
(Chapter 7) and MI swine (Chapter 8). In these chapters we also investigated the 
importance of NO mediated cGMP production by inhibition of NO.
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Abstract
Prostacyclin and nitric oxide (NO) are produced by the endothelium in response 
to physical forces such as shear stress. Consequently, both NO and prostacyclin may 
increase during exercise and contribute to metabolic vasodilation. Conversely, NO 
has been hypothesized to inhibit prostacyclin production. We therefore investigated 
the effect of cyclo-oxygenase (COX)-inhibition on exercise-induced vasodilation of 
the porcine systemic, pulmonary and coronary beds before and after inhibition of 
NO production. Swine were studied at rest and during treadmill exercise at 1-5 
km/h, before and after COX-inhibition with indomethacin (10 mg/kg iv), in the 
absence and presence of NO synthase inhibition with Nω-nitro-L-arginine (NLA, 20 
mg/kg iv). COX-inhibition produced systemic vasoconstriction at rest, that waned 
during exercise. The systemic vasoconstriction by COX-inhibition was enhanced 
after NLA, particularly at rest. In the coronary circulation, COX-inhibition also 
resulted in vasoconstriction at rest and during exercise. However, vasoconstriction 
was not modiﬁ ed by pretreatment with NLA. In contrast, COX-inhibition had no 
effect on the pulmonary circulation, either at rest or during exercise. Moreover, 
a prostanoid inﬂ uence in the pulmonary circulation could not be detected after 
NLA. In conclusion, endogenous prostanoids contribute importantly to systemic 
and coronary tone in awake swine at rest, but are not mandatory for exercise-
induced vasodilation in these beds. Endogenous prostanoids are not mandatory for 
regulation of pulmonary resistance vessel tone. Finally, NO blunts the contribution 
of prostanoids to vascular tone regulation in the systemic but not in the coronary 
and pulmonary bed.
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Introduction
The endothelium plays an important role in the regulation of vascular tone, by 
producing both vasodilators (nitric oxide (NO) and prostacyclin) and vasoconstrictors 
(endothelin). The contribution of these mediators to the regulation of tone varies 
across vascular beds. Thus, in anesthetized swine, basal pulmonary resistance is 
strongly inﬂ uenced by NO and less by prostacyclin whereas the opposite is true 
for the systemic vascular bed [1]. Prostanoids are produced in skeletal muscle in 
response to exercise [2-4] and in response to increased levels of adrenaline [5]. 
Therefore, prostanoids may contribute to metabolic dilation of the coronary [6, 
7] and skeletal muscle vasculature [8, 9], although this is not a ubiquitous ﬁ ndings 
[6, 10-12]. To date no study has investigated the contribution of endogenous 
prostanoids in the regulation of vasomotor tone in various regional vascular beds 
during treadmill exercise. Consequently, the ﬁ rst aim of the present study was 
to determine the contribution of prostanoids to regulation of global and regional 
systemic, as well as pulmonary and coronary, resistance vessel tone in chronically 
instrumented swine undergoing treadmill exercise.
Several studies have suggested that an interaction exists between NO and 
prostanoid production. Thus, not only does NO exert an inhibitory effect on 
prostacyclin production in vitro [13], but also enhanced prostacyclin production 
maintains ﬂ ow-mediated dilation in endothelial NO synthase (eNOS) knockout 
mice [8]. Furthermore, inhibition of cyclo-oxygenase (COX) affected the duration 
of reactive hyperemia in dogs treated with L-NAME, but not control dogs [14]. 
We have previously shown that, whereas endogenous NO exerts a vasodilator 
inﬂ uence on the systemic, pulmonary and coronary vasculature of awake swine, 
the exercise-induced vasodilation was only slightly blunted after inhibition of 
NO production [15]. Hence, other vasodilators, such as prostacyclin, could have 
increased contribution to exercise-induced vasodilation and act to compensate 
when NO synthase activity is blunted. The second aim of the present study was 
therefore to determine whether the contribution of prostacyclin to regulation of 
resistance vessel tone is enhanced after inhibition of eNOS  in exercising swine.
 
Methods
Animals
Studies were performed in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals (NIH pub. no 86-23, revised 
1996), and with approval of the Animal Care Committee of the Erasmus Medical 
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Center. Fifteen 2 to 3-month old Yorkshire X Landrace swine (23± 1 kg at the time 
of surgery) of either sex (4 males, 11 females) entered the study. Daily adaptation 
of animals to laboratory conditions started 1 week before surgery. Studies were 
started 10 days after surgery.
Surgery
Swine were sedated (ketamine, 20 mg/kg im), anesthetized (thiopental, 
10 mg/kg iv), intubated and ventilated with O2 and N2O to which 0.2%-1% (v/v) 
isoﬂ urane was added [15-17]. Anesthesia was maintained with midazolam (2 mg/kg 
followed by 1 mg/kg per hour iv) and fentanyl (10 µg/kg per hour iv). Under sterile 
conditions, the chest was opened via the fourth left intercostal space and a ﬂ uid 
ﬁ lled polyvinylchloride catheter was inserted into the aortic arch for aortic blood 
pressure measurement (Combitrans pressure transducers, Braun) and blood sampling 
for determination of blood gases (Acid-Base Laboratory Model 505, Radiometer), O2 
saturation and hemoglobin concentration (OSM2, Radiometer), and computation of 
O2 content, O2 supply, and O2 consumption [15-17]. An electromagnetic ﬂ ow probe 
(14-15 mm, Skalar) was positioned around the ascending aorta for measurement of 
cardiac output. A microtipped pressure-transducer (P4.5, Konigsberg Instruments) 
was inserted into the LV via the apex. Polyvinylchloride catheters were inserted 
into the LV to calibrate the Konigsberg transducer LV pressure signal [15-17], and 
into the left atrium to measure pressure and inject radioactive microspheres to 
determine regional blood ﬂ ows [15].
Catheters were inserted into the pulmonary artery to measure pressure, 
administer drugs and collect mixed venous samples [15-17]. An angio-catheter was 
inserted into the anterior interventricular vein for blood sampling [15-17], while 
a Transonic ﬂ ow probe (2.5-3.0 mm, Transonic Systems) was placed around the 
left anterior descending coronary artery. Catheters were tunneled to the back and 
animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine im) for 
2 days and antibiotic prophylaxis (25 mg/kg amoxicillin and 5 mg/kg gentamycin 
iv) for 5 days. 
Experimental Protocols
Dosage and stability of the effect induced by indomethacin. To validate that 
the employed dose (10 mg/kg dissolved in 20 ml saline pH 9.0, iv) of indomethacin 
produced complete COX-inhibition, we studied the hemodynamic effects of 1 and 
10 mg/kg in eleven resting swine (27±1 kg). After baseline measurements of heart 
rate, blood pressure and cardiac output had been obtained, animals received a 
dose of 1 mg/kg iv, and ﬁ ve min later hemodynamic measurements were repeated. 
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Then, animals received additional indomethacin to achieve a total dose of 10 
mg/kg iv and ﬁ ve min after completing administration measurements were again 
repeated.
To validate the stability of COX-inhibition by indomethacin, i.e. whether the 
degree of COX-inhibition was maintained during the entire 15-min exercise protocol, 
we studied the stability of the hemodynamic responses to indomethacin (10 mg/
kg iv) in four resting swine over a 20-min period. For this purpose hemodynamic 
baseline measurements were obtained and animals received indomethacin, 
administered over a 10-min period. Five min after completion of administration, 
hemodynamics were measured over a 20-min period.
Role of prostanoids in the regulation of vasomotor tone. Systemic, pulmonary 
and coronary hemodynamic responses to exercise were studied in 13 swine (27±1 
kg). After baseline hemodynamic measurements (lying and standing), blood samples 
(lying), and temperature (standing) were obtained, a treadmill exercise protocol 
was begun (1-5 km/h); hemodynamic data and blood samples were collected 
during the last 30 s of each 3 min exercise stage [15-17]. After completion of 
the exercise protocol, animals were allowed to rest for 90 min. Subsequently, 
indomethacin (10 mg/kg) was administered intravenously over a 10 min period 
and 5 min later the exercise protocol was repeated. We have previously shown 
excellent reproducibility of the hemodynamic responses to consecutive exercise 
bouts [16, 17].
On another day, six swine underwent a control exercise trial and after 90 min 
of rest, animals received the COX inhibitor ibuprofen (60 mg/kg, iv) and underwent 
a second trial.
Regional blood ﬂ ows. On a different day, regional blood ﬂ ows were determined 
in four swine using the radioactive microsphere technique [15]. Radioactive 
microspheres were injected at rest (lying) and during exercise at 5 km/h under 
control conditions as well as 5 min after administration of indomethacin (10 mg/kg 
iv).
Role of prostanoids in the regulation of vasomotor tone in the presence of 
NO synthase inhibition. On a different day seven animals (29±2 kg) underwent a 
control exercise trial and after 90 min of rest, Nω-nitro-L-arginine (NLA, 20 mg/kg 
dissolved in 100 ml saline) was administered intravenously over a 20 min period, 
10 min later followed by the second exercise trial. After another 90 min of rest, 
animals received indomethacin (10 mg/kg iv) and underwent a third exercise 
trial. 
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Data analysis
Digital recording and off-line analysis of hemodynamics and regional blood 
ﬂ ow have been described previously [15-17].  Systemic vascular conductance was 
computed as cardiac output divided by mean aortic blood pressure. Systemic vascular 
resistance was computed as mean aortic blood pressure divided by cardiac output. 
Pulmonary vascular resistance is deﬁ ned as mean pulmonary artery pressure minus 
mean pulmonary backpressure divided by cardiac output. Pulmonary backpressure 
is best reﬂ ected in the pulmonary capillary wedge pressure, but since the increases 
in left atrial pressure that we observe in our laboratory in exercising swine ([15-
17], present study) agree very well with the reported increases in pulmonary 
capillary wedge pressure (from 4 mmHg at rest to 11 mmHg during exercise at 
comparable increases of heart rate [18], we employed mean left atrial pressure 
as backpressure. Blood O2 content (mmol/ml) was computed as (Hb·0.621·O2-
saturation) + (0.00131·PO2). Body O2 consumption (BVO2) was calculated as the 
product of cardiac output and the difference in O2 content between arterial and 
mixed venous blood. Myocardial O2 delivery (MDO2) was computed as the product of 
LAD coronary blood ﬂ ow and arterial blood O2 content. Myocardial O2 consumption 
(MVO2) in the region of myocardium perfused by the left anterior descending 
coronary artery was calculated as the product of coronary blood ﬂ ow and the 
difference in O2 content between arterial and coronary venous blood. Myocardial 
O2 extraction (MEO2) was computed as the ratio of MVO2 and MDO2.
Statistical analysis
Statistical analysis of hemodynamic data within the separate study protocols 
(control and indomethacin, control and ibuprofen, and control, NLA and 
NLA+indomethacin) was performed using two-way (treatment and exercise level) 
analysis of variance (ANOVA) for repeated measures. When a signiﬁ cant effect 
was detected, post-hoc testing for exercise and drug effect was performed using 
Scheffe’s test.
To test for the effects of indomethacin and NLA on the relation between VO2 
and hemodynamic and metabolic variables, analysis of co-variance (ANCOVA) was 
performed in the separate study protocols (control and indomethacin and control, 
NLA and NLA+indomethacin) using treatment as an independent factor and VO2 
as co-variate. Post-hoc testing for drug effect (i.e. control vs NLA and NLA vs 
NLA+indomethacin) was performed using Scheffe’s test.
To test for the interaction of the treatments (indomethacin X NLA), on the 
relation between VO2 and hemodynamic and metabolic variables, ANCOVA was 
performed using indomethacin and NLA as two independent factors and VO2 as co-
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variate. Statistical signiﬁ cance was accepted when P≤ 0.05. Data are presented as 
mean±SEM.
Results
Dosage and stability of the effect induced by indomethacin. The increase in 
mean aortic blood pressure and systemic vascular resistance produced by 1 mg/kg 
indomethacin was identical to the vasoconstrictor and pressure response to 10 
mg/kg, although heart rate decreased somewhat less after 1 mg/kg than after 10 
mg/kg (Table 1). These ﬁ ndings indicate that the dose of 10 mg/kg indomethacin, 
which we employed in the exercise studies, produced a maximal effect. In addition, 
the effect of indomethacin was well maintained over a 20 min period (less than 10 
% change, Table 2).
 
Table 1. Hemodynamic effect of 1 vs 10 mg/kg indomethacin in resting swine 
         Indomethacin iv  Baseline 
1 mg/kg    10 mg/kg 
HR (bpm) 121 ± 5 106 ± 4*    87 ± 5*† 
MAP (mmHg) 93 ± 2 135 ± 5*   132 ± 6* 
CO (l/min) 3.4 ± 0.2 2.8 ± 0.2*   2.6 ± 0.2* 
SVR (mmHg/l/min) 28 ± 2 47 ± 3*      51 ± 7* 
 
 
Table 2. Stability of indomethacin (10 mg/kg iv) induced hemodynamic 
alterations in resting swine 
Time after start of protocol, min  Baseline 
t=0 t=10 t=20 
HR (bpm) 133 ± 4 92 ± 6* 93 ± 7* 93 ± 7* 
MAP (mmHg) 89 ± 2 117 ± 5* 112 ± 5*† 113 ± 5*† 
CO (l/min)   3.5 ± 0.4    2.6 ± 0.3*    2.7 ± 0.3*    2.8 ± 0.3
SVR (mmHg/l/min)  27 ± 4    50 ± 10* 47 ± 9*† 45 ± 9*† 
 
Data are Means ± SE, n=11 swine;. HR: Heart rate; MAP: Mean arterial pressure; CO: Cardiac 
output; SVR: Systemic vascular resistance. * P≤0.05 vs Baseline; † P≤ 0.05 vs Indomethacin 
1mg/kg iv
Data are Means ± SE, n=4 swine; * P≤ 0.05 vs baseline; † P≤ 0.05 vs t=0
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Hemodynamic effects of COX-inhibition in exercising swine
Systemic and pulmonary circulation. Exercise up to 5 km/h resulted in more 
than a doubling of cardiac output which was principally due to the increase in heart 
rate (up to 85% of maximum heart rate), as stroke volume increased by only 15% 
(Table 3). Despite the increase in cardiac output, mean aortic blood pressure was 
maintained, reﬂ ecting marked systemic vasodilation, i.e. a doubling of systemic 
vascular conductance or a 60% decrease in systemic vascular resistance (Fig. 1). 
Administration of indomethacin resulted in a 40% increase in aortic blood 
pressure, due to systemic vasoconstriction (Table 3, Fig. 1). The accompanying 
decrease in cardiac output was mediated by a (probably baroreﬂ ex-mediated) 
decrease in heart rate (Table 3). The indomethacin-induced systemic vasoconstriction 
necessitated an increase in O2-extraction resulting in a decreased mixed venous 
O2-saturation (Fig. 1). The pressor and vasoconstrictor responses to indomethacin 
were progressively blunted during exercise (Table 3, Fig. 1). That the increase in 
systemic vascular resistance was progressively blunted during exercise was not 
merely the mathematical result of a smaller absolute effect of indomethacin at 
lower resistance values, because the relative increase in resistance in response 
to indomethacin was also greater at rest than during exercise (Fig. 2). Although 
the absolute indomethacin-induced decrease in systemic conductance was similar 
at rest and during exercise, the relative decrease in conductance induced by 
indomethacin was also signiﬁ cantly greater at rest than during exercise (Fig. 2). 
Furthermore, the effects of indomethacin on body O2 extraction and mixed venous 
O2 saturation (Fig. 1) also waned during exercise. Thus, the slope of the relation 
between body O2 consumption and O2 extraction decreased from 1.13±0.07 under 
control conditions to 0.76±0.11 in the presence of indomethacin (P<0.05), whereas 
the slope of the relation between body O2-consumption and mixed venous O2-
saturation decreased from –1.06±0.07 under control conditions to –0.73 ±0.10 in 
the presence of indomethacin (P<0.05). 
In six animals, ibuprofen caused systemic vasoconstriction as evidenced by 
signiﬁ cant increases in blood pressure from (91±4 mmHg to 102±4 mmHg, P<0.05) 
and systemic vascular resistance (from 30±4 mmHg/l/min to 35±4 mmHg/l/min, 
P<0.05), albeit to a lesser extent than indomethacin. Similar to indomethacin, the 
effect of ibuprofen waned during exercise (at maximal exercise: blood pressure 
90±4 mmHg without ibuprofen and 94±4 mmHg with ibuprofen, systemic vascular 
resistance 15±2 mmHg/l/min without ibuprofen and 17±2 mmHg with ibuprofen).
Pulmonary artery pressure more than doubled during exercise (Table 3), 
whereas pulmonary vascular resistance decreased by only 25% (Fig. 3). In contrast 
to the systemic vasculature, indomethacin had no effect on pulmonary vascular 
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Data are Means ± SE, n=13 swine; SV: Stroke volume; LVdP/dtmax: Rate of increase in left ventricular 
pressure; PMAP: Mean pulmonary artery pressure; LAP: Left atrial pressure; CBF: Coronary blood ﬂ ow. 
* P≤ 0.05 vs rest (lying); † P≤ 0.05 vs control
Table 3. Hemodynamic parameters before and after administration of indomethacin 
     Rest      Exercise level (km/h)  
  Treatment  Lying  Standing     1     2     3     4     5   
Systemic hemodynamics                                             
CO Control 3.4 ± 0.2 4.3 ± 0.3*   5.3 ± 0.2* 5.8 ± 0.3* 6.3 ± 0.3* 7.1 ± 0.3* 8.1 ± 0.3* 
(l/min) Indomethacin 2.6 ± 0.2† 3.5 ± 0.2*†   4.3 ± 0.2*† 4.8 ± 0.3*† 5.5 ± 0.3*† 6.5 ± 0.4*† 7.4 ± 0.3*† 
                                                
HR Control 121 ± 5 139 ± 6*   167 ± 5* 180 ± 5* 201 ± 6* 229 ± 7* 254 ± 4* 
(bpm) Indomethacin 87 ± 5† 103 ± 4*†   119 ± 4*† 128 ± 3*† 148 ± 5*† 174 ± 6*† 203 ± 6*† 
                                               
SV Control 28 ± 2 32 ± 2*   32 ± 2* 32 ± 2* 32 ± 2* 31 ± 2* 32 ± 1* 
(ml) Indomethacin 30 ± 2 34 ± 2*   36 ± 2*† 37 ± 2*† 37 ± 2*† 37 ± 1*† 37 ± 1*† 
                                               
LVdP/dtmax Control 2550 ± 150 2910 ± 190*   3490 ± 210* 3710 ± 180* 4280 ± 280* 4770 ± 350* 5460 ± 370* 
(mmHg/s) Indomethacin 2410 ± 210 3060 ± 230*   3050 ± 190*† 3170 ± 240*† 3630 ± 260*† 4240 ± 320* 4870 ± 390*† 
                                               
LVdP/dtmin Control -2360 ± 100 -2400 ± 120   -2350 ± 90 -2360 ± 90 -2490 ± 100 -2610 ± 130 -2850 ± 160* 
(mmHg/s) Indomethacin -2930 ± 130† -3000 ± 170†   -2930 ± 150† -2860 ± 160† -2830 ± 150† -2890 ± 140† -2980 ± 140 
                                               
MAP Control 93 ± 2 89 ± 3   85 ± 3* 86 ± 3* 87 ± 3* 89 ± 3 91 ± 3 
(mmHg) Indomethacin 132 ± 6† 124 ± 7*†   111 ± 5*† 109 ± 5*† 108 ± 5*† 103 ± 5*† 102 ± 4*† 
                                               
Pulmonary hemodynamics                                             
PMAP Control 14 ± 1 14 ± 1   17 ± 2* 19 ± 2* 22 ± 2* 27 ± 2* 31 ± 2* 
(mmHg) Indomethacin 20 ± 1† 18 ± 2   18 ± 2 20 ± 2 22 ± 2 25 ± 2* 27 ± 2*† 
                                               
LAP Control 2 ± 1 2 ± 1   0 ± 1 3 ± 1 5 ± 1* 8 ± 1* 10 ± 1* 
(mmHg) Indomethacin 13 ± 1† 8 ± 1*†   6 ± 2*† 8 ± 1*† 8 ± 1*† 9 ± 1* 9 ± 1* 
                                               
Coronary hemodynamics                                             
CBF Control 56 ± 4 73 ± 6*   81 ± 6* 87 ± 7* 99 ± 7* 116 ± 10* 140 ± 11* 
(ml/min) Indomethacin 49 ± 5† 60 ± 5*†   66 ± 5*† 71 ± 6*† 81 ± 8*† 98 ± 11*† 114 ± 11*† 
 
resistance either at rest or during exercise (Fig. 3).
Regional systemic vascular beds. The exercise-induced increase in cardiac 
output was principally diverted towards skeletal muscle, and although brain ﬂ ow 
increased slightly, ﬂ ow to most visceral organs decreased (Fig. 4). Vasoconstriction 
in response to indomethacin occurred in most visceral organs such as kidneys and 
intestine (with exception of the adrenals and spleen), and various regions of the 
brain (Fig. 4). In contrast, skeletal muscle ﬂ ow was not altered by indomethacin 
either at rest or during exercise. 
Coronary Circulation. Exercise resulted in an increase in MVO2 that was 
matched by an equivalent increase in coronary blood ﬂ ow and hence MDO2, so that 
MEO2 and coronary venous PO2 (CVPO2) were maintained constant over the entire 
range of MVO2 (Fig. 5). Indomethacin reduced coronary blood ﬂ ow at any given 
level of MVO2, necessitating an increase in MEO2 (in order to maintain MVO2), which 
resulted in a decrease in CVPO2. The increase in coronary blood ﬂ ow was blunted in 
the presence of indomethacin (P<0.05), suggesting that prostanoids may contribute 
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to metabolic dilation in the coronary vasculature. However, the indomethacin-
induced increase in MEO2 and decrease in CVPO2 were not signiﬁ cantly different 
during exercise compared to resting conditions (Fig. 5), indicating that the relative 
contribution of prostanoids to coronary vascular tone was similar at rest and during 
exercise.
Hemodynamic effects of COX-inhibition in exercising swine with inhibited NO 
synthase activity
Systemic and pulmonary circulation. NO synthase inhibition with NLA produced 
vasoconstriction in the systemic circulation, resulting in an increase in aortic 
blood pressure (Fig. 1, Table 4). Importantly, pretreatment with NLA enhanced the 
indomethacin-induced vasoconstriction in the systemic circulation, as indicated 
by the exaggerated increase in systemic vascular resistance and mixed venous 
O2-saturation (Fig. 1). Although the absolute indomethacin-induced decreases in 
systemic vascular conductance were not augmented (Fig. 1), the relative changes 
in systemic vascular conductance and resistance both showed potentiation of the 
vasoconstrictor effect of indomethacin by NLA, particularly at rest (Fig. 2). Despite 
the marked potentiation of the systemic vasoconstrictor response to indomethacin 
by NLA, the exercise-induced systemic vasodilation was unmitigated.
NLA+Indo vs NLA
Figure 2. Relative changes produced by prostanoid synthesis inhibition with indomethacin (10 mg/kg 
iv) in systemic vascular conductance (SVC, left panel) and systemic vascular resistance (SVR, right 
panel) in the absence and presence of NO synthase inhibition with NLA (20 mg/kg iv). Note that both 
relative changes in conductance and resistance demonstrate that the effects of indomethacin waned 
during exercise. In contrast, NLA alone produced virtually identical increases in systemic vascular 
resistance at rest (57±20%) and during exercise (51±11% at 5 km/h) as well as similar decreases in sys-
temic vascular conductance at rest (-30±7%) and during exercise (-31±5%; data not shown). Also note 
that pretreatment with NLA enhanced the vasoconstrictor effect of indomethacin particularly at rest. 
OL: resting (lying), OS: resting (standing). Dot inside symbol denotes a signiﬁ cant difference (P≤ 0.05) 
from resting (lying) measurement; *P≤ 0.05 effect of indomethacin in the presence of NLA vs effect of 
indomethacin in the absence of NLA (ANOVA).
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NO synthase inhibition produced vasoconstriction in the pulmonary circulation 
(Fig. 3), resulting in an increase in pulmonary artery pressure (Table 4). However, 
subsequent administration of indomethacin had no additional effect on pulmonary 
vascular resistance (Fig. 3).
Coronary circulation. NLA reduced coronary blood ﬂ ow and MDO2 at any given 
level of MVO2, necessating a small increase in MEO2 (to maintain MVO2), which 
resulted in a decrease in CVPO2 (Fig. 5). Although indomethacin resulted in additional 
vasoconstriction as evidenced by a further decrease in CVPO2, pretreatment with 
NLA did not enhance the vasoconstrictor effect of indomethacin, indicating that 
increased prostanoid production does not compensate for the loss of NO in the 
coronary circulation.
Discussion
The major ﬁ ndings of the present study are that in awake swine free from the 
effects of anesthesia and acute surgical trauma: (i) prostanoids are involved in the 
regulation of resistance vessel tone in the systemic and coronary circulation, but 
not in the pulmonary circulation; (ii) the vasodilator inﬂ uence of prostanoids on 
coronary and cerebral resistance vessels is maintained during exercise, whereas 
their inﬂ uence on the total systemic vasculature wanes during exercise; and (iii) 
prostanoids have an increased vasodilator inﬂ uence in the systemic vascular bed 
when NO synthase activity is inhibited.
Figure 3. Effect of inhibition 
of prostanoid synthesis with 
indomethacin (10 mg/kg iv) 
on the relation between 
exercise and pulmonary 
vascular resistance (PVR), 
in the absence (left panel) 
and presence (right panel) 
of NO synthase inhibition 
with NLA (20 mg/kg iv). 
Note that indomethacin had 
no effect on PVR. Dot inside 
symbol denote changes 
(P≤0.05) from resting (lying) 
measurement; *P≤0.05 vs 
control (ANOVA)
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BVO2 (mmol/min) BVO2 (mmol/min)
Figure 4 (page 54 & 55). Effect of inhibition of prostanoid synthesis with indomethacin 
(10 mg/kg iv) on visceral organ, regional brain and skeletal muscle blood ﬂ ows at rest 
(lying) and during exercise at 5 km/h. Dot inside symbol denotes change (P≤0.05) from 
resting (lying) measurement; *P≤0.05 vs control; †P≤0.05 effect of indomethacin waned 
during exercise.
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Methodological considerations
Dosage of indomethacin. The dose of indomethacin that we used (10 mg/kg 
iv) is similar [19, 20] or slightly higher (compared with 3 mg/kg iv [1, 21]) than 
used by others to inhibit COX in swine. This dose should be sufﬁ cient to completely 
block COX for a prolonged period of time in swine as in our study, administration 
of indomethacin in a dose of 1 mg/kg yielded similar alterations in hemodynamic 
variables at rest. To exclude that the decreased effects of indomethacin on the 
systemic and coronary vasculature during exercise were due to diminished blockade 
of COX, we established that hemodynamic variables remained stable during a period 
of 20 min after administration of indomethacin, which encompasses the 15 min 
duration of the exercise trial. Thus, the decreased effect of indomethacin during 
exercise is due to either a decreased contribution of endogenous prostanoids to 
the regulation of vascular tone, or an increased compensation by other vasodilator 
systems during exercise as will be discussed below.
Indomethacin as a COX inhibitor. Some studies have indicated that COX 
inhibitors have other effects besides inhibition of COX. Depending on the 
inhibitor used, transcription factors, MAP kinases, cell cycle proteins and heat 
shock proteins (HSPs) may be affected [22]. We therefore performed additional 
experiments with a different COX inhibitor (ibuprofen). Ibuprofen also caused 
Figure 5. Effect of inhibition 
of prostanoid synthesis with 
indomethacin (10 mg/kg 
iv) on the relation between 
myocardial O2 consumption 
(MVO2) and myocardial 
O2 extraction (MEO2) and 
between MVO2 and coronary 
venous PO2 (CVPO2), in the 
absence (upper panels) and 
presence (lower panels) of 
NO synthase inhibition with 
NLA (20 mg/kg iv). Note 
that NLA did not modify the 
vasoconstrictor effect of 
indomethacin. Exercise did 
not result in changes from 
resting (lying) measurement. 
*P≤0.05 vs control;  ‡P≤0.05 
NLA + indomethacin vs NLA
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Table 4. Hemodynamic parameters before and after administration of NLA and indomethacin 
        Rest         Exercise level (km/h) 
  Treatment  Lying  Standing     1     2     3     4     5   
Systemic hemodynamics                                            
CO Control 3.8 ± 0.4 4.8 ± 0.4*   5.5 ± 0.4* 6.1 ± 0.5* 6.6 ± 0.5* 7.3 ± 0.5* 8.1 ± 0.6* 
(l/min) NLA 3.2 ± 0.3 3.9 ± 0.2*†   4.5 ± 0.3*† 5.0 ± 0.3*† 5.3 ± 0.3*† 6.2 ± 0.3*† 6.9 ± 0.4*† 
  NLA+ Indo 1.9 ± 0.2†‡ 2.6 ± 0.2*†‡ 3.3 ± 0.3*†‡ 3.7 ± 0.3*†‡ 4.2 ± 0.3*†‡ 5.1 ± 0.4*†‡ 6.0 ± 0.4*†‡ 
                                               
HR Control 117 ± 8 137 ± 8*   155 ± 8* 180 ± 8* 200 ± 11* 226 ± 12* 244 ± 9* 
(bpm) NLA 99 ± 4† 117 ± 7*†   129 ± 5*† 141 ± 9*† 155 ± 10*† 188 ± 10*† 220 ± 9*† 
  NLA+ Indo 76 ± 10†‡ 89 ± 7*†‡ 108 ± 10*†‡ 111 ± 9*†‡ 124 ± 9*†‡ 150 ± 10*†‡ 176 ± 11*†‡ 
                                            
SV Control 32 ± 3 35 ± 3   36 ± 3* 34 ± 3 33 ± 2 33 ± 2 33 ± 2 
(ml) NLA 32 ± 3 34 ± 3   35 ± 3* 36 ± 3* 35 ± 3 34 ± 3 31 ± 2 
  NLA+ Indo 27 ± 2†‡ 31 ± 3*†   33 ± 3* 34 ± 3* 35 ± 3* 35 ± 3* 35 ± 3* 
                                            
LVdP/dtmax Control 2960 ± 200 3220 ± 260   3500 ± 180* 4050 ± 270* 4330 ± 270* 4820 ± 420* 5280 ± 430* 
(mmHg/s) NLA 2790 ± 210† 3310 ± 300*   3610 ± 320* 3880 ± 440* 4140 ± 420* 5080 ± 560* 5880 ± 540* 
  NLA+ Indo 2820 ± 370 3360 ± 360   3920 ± 580 3710 ± 290 3920 ± 250* 4500 ± 360* 5340 ± 510*‡ 
                                            
LVdP/dtmin Control -2390 ± 100 -2330 ± 120   -2340 ± 80 -2420 ± 80 -2560 ± 30 -2650 ± 80 -2840 ± 120 
(mmHg/s) NLA -2790 ± 120† -2760 ± 100   -2770 ± 90† -2870 ± 100† -2860 ± 110 -3010 ± 90 -3170 ± 110 
  NLA+ Indo -3040 ± 220† -3290 ± 210†‡ -3240 ± 250† -3300 ± 240† -3390 ± 240‡ -3380 ± 220† -3410 ± 180 
                                            
MAP Control 93 ± 2 87 ± 5   83 ± 3* 86 ± 3 91 ± 2 92 ± 3 94 ± 3 
(mmHg) NLA 120 ± 4† 109 ± 3*†   111 ± 4*† 114 ± 3† 118 ± 4† 119 ± 3† 119 ± 4† 
  NLA+ Indo 159 ± 5†‡ 148 ± 5*†‡ 134 ± 5*†‡ 135 ± 5*†‡ 134 ± 5*†‡ 130 ± 4*† 124 ± 3*† 
                                            
Pulmonary hemodynamics                                          
PMAP Control 15 ± 1 17 ± 1   18 ± 1* 21 ± 1* 27 ± 1* 30 ± 2* 35 ± 2* 
(mmHg) NLA 22 ± 2† 21 ± 3   25 ± 3*† 28 ± 3*† 33 ± 4*† 39 ± 4*† 42 ± 3*† 
  NLA+ Indo 29 ± 2†‡ 26 ± 2†   29 ± 2† 31 ± 2† 35 ± 2*† 39 ± 2*† 41 ± 3*† 
                                            
LAP Control 3 ± 1 3 ± 2   3 ± 2 3 ± 2 9 ± 2* 11 ± 2* 14 ± 2* 
(mmHg) NLA 10 ± 2 4 ± 3   7 ± 2† 7 ± 2† 11 ± 1 12 ± 1 14 ± 2 
  NLA+ Indo 18 ± 4 12 ± 3   14 ± 2 15 ± 2 16 ± 3 17 ± 3 16 ± 2 
                                            
Coronary hemodynamics                                          
CBF Control 60 ± 6 78 ± 7*   84 ± 7* 102 ± 8* 110 ± 8* 133 ± 10* 151 ± 11* 
(ml/min) NLA 60 ± 3 76 ± 5*   84 ± 6* 90 ± 5* 97 ± 6*† 116 ± 8*† 136 ± 10*† 
  NLA+ Indo 43 ± 4‡ 51 ± 4†‡   64 ± 6*†‡ 66 ± 5*†‡ 74 ± 6*†‡ 90 ± 7*†‡ 105 ± 9*†‡ 
 Data are Means ± SE, n=7; * P≤ 0.05 vs rest (lying); † P≤ 0.05 vs control; ‡ P≤ 0.05 vs NLA.  
systemic vasoconstriction, albeit to a lesser extent than indomethacin. Similar to 
indomethacin, the effect of ibuprofen waned during exercise. One of the possible 
differences between ibuprofen and indomethacin is that ibuprofen activates HSP 
formation while indomethacin is devoid of such action [22]. Increased HSP90 
expression may subsequently activate eNOS [23-25], thereby increasing NO 
production and partially counterbalancing the effect of the loss of the vasodilator 
prostanoids. However, the observation that indomethacin and ibuprofen induce 
qualitatively similar effects on systemic hemodynamic parameters, suggests that 
the effects of indomethacin on cardiovascular function in the present study are 
indeed due to inhibition of COX. COX catalyzes the conversion of arachidonic acid 
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into prostaglandin H2, which is subsequently processed by different enzymes into 
various prostanoids. The vasodilator prostacyclin and vasoconstrictor thromboxane 
are the most vasoactive prostanoids, and since COX inhibition resulted in net 
vasoconstriction it is likely that inhibition of prostacyclin was responsible for the 
observed vasoconstriction.
Age of the animals. The animals used in the present study were young adults 
(3 to 4 months), which may have quantitatively inﬂ uenced the contribution and 
interaction between NO and prostanoids. However, the contribution of prostanoids 
in both basal vascular tone as well as vasodilator responses to agonists is 
independent of age [26] or may decrease slightly from newborn to young adult 
swine [20, 27]. In contrast, the role of NO in the regulation of tone in the cerebral 
vasculature does vary with age. However, the largest difference is found between 
newborn and young adult swine, so that while a contribution of NO is absent in 
newborn piglets its importance increases in young adult and adult swine [20, 26, 
27]. In accordance with these reports, we observed in the young adult swine in 
the present study that NO contributed importantly to regulation of vascular tone. 
Taken together, it seems that the swine were of sufﬁ cient maturity so that their 
age did not quantitatively inﬂ uence the results.
Role of prostanoids in regulation of vascular tone
Systemic circulation. Endogenous prostanoids exerted a strong vasodilator 
inﬂ uence on the systemic vasculature at rest as was evidenced by the marked 
increase in blood pressure and the increase in systemic vascular resistance upon 
indomethacin administration. Although prostanoids contribute importantly to the 
regulation of vascular tone at rest, blood pressure and systemic vascular resistance 
gradually returned to control levels during exercise and mixed venous O2-saturation 
approached the values of the control exercise. These ﬁ ndings indicate that either 
there is no role of prostanoids in metabolic regulation or that their role in the 
systemic vascular bed is fully compensated by other vasoactive substances such 
as NO. Little is known about the role of prostanoids in the systemic vasculature 
during exercise. Because prostacyclin is produced in response to increased levels of 
adrenaline [5], prostacyclin production will likely increase during exercise, when 
adrenaline levels increase. Indeed, prostacyclin production increases in the human 
leg during exercise [2-4]. Furthermore, Sun et al [8] showed that prostacyclin is 
involved in ﬂ ow-dependent dilation of isolated murine skeletal muscle arterioles, 
but did not ﬁ nd a contribution of prostacyclin to basal tone in these vessels. These 
ﬁ ndings suggest that prostanoids could indeed have increased importance during 
exercise and thereby contribute to metabolic vasodilation. In apparent support 
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of this concept, Duffy et al [9] reported that prostanoids contribute to exercise-
induced vasodilation in the human forearm. However, in forearm exercise studies, 
ﬂ ow is measured immediately after rather than during exercise, which may have 
inﬂ uenced the results. For example, inhibition of nitric oxide has been shown to 
reduce blood ﬂ ow in the recovery phase following exercise but not during exercise 
[28]. In line with this view, Beaty et al [10] showed in anesthetized dogs that 
inhibition of prostanoid synthesis decreased ﬂ ow to resting skeletal muscle to an 
equal extent as skeletal muscle ﬂ ow during electrical stimulation. The present 
study in awake swine also demonstrates that inhibition of prostanoid production 
does not affect ﬂ ow to various skeletal muscle groups with different ﬁ ber type 
composition [15] either at rest or during exercise up to 85% of maximum heart 
rate.
The present study also shows that the role of prostanoids is strongly dependent 
on the vascular bed. Inhibition of prostanoid production resulted in a decrease 
in ﬂ ow to various regions of the brain of almost 50%, both at rest and during 
exercise. However, indomethacin did not alter the exercise-induced vasodilation, 
suggesting that prostanoids are not essential for metabolic vasodilation in the 
various regions of the brain. Flow to the kidneys and most other visceral organs 
was also decreased by indomethacin in resting swine, indicating that prostanoids 
are important for maintaining basal ﬂ ow to visceral organs. During exercise, 
however, ﬂ ow is redistributed away from the visceral organs towards the exercising 
skeletal muscle. The observation that the effect of indomethacin decreased during 
exercise suggests that this redistribution may in part be caused by withdrawal of 
a prostanoid-mediated vasodilator inﬂ uence in the visceral organs. Conversely, 
the decreased effect of indomethacin on the visceral organs during exercise is 
translated into a decreased effect on total systemic vascular resistance, blood 
pressure and mixed venous O2 saturation, as ﬂ ow to skeletal muscle is not affected 
by indomethacin either at rest or during exercise.
We found in the present study that the effect of inhibition of prostanoid 
production in the systemic circulation was larger after inhibition of NO synthesis 
compared to the control experiments, indicating that prostanoids compensate in 
part for the loss of NO synthesis. There is evidence that NO directly suppresses the 
activity of COX in vitro [13, 29, 30] as well as in vivo. Prostanoids only contribute 
to the regulation of coronary tone in dogs after chronic inhibition of nitric oxide 
synthase [14] as well as in collateral-dependent myocardium [31, 32], whereas 
NO predominates under normal circumstances. Also, prostacyclin is important in 
the regulation of ﬂ ow-induced dilation in eNOS knock-out mice [8]. Functionally, 
it is important to maintain vasodilator capacity through redundant or back-up 
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mechanisms. NO and prostacyclin-production are both activated in response to 
physical stimuli such as shear stress [33, 34], as well as agonists such as acetylcholine 
and bradykinin [34] and share similar regulatory mechanisms such as activation of 
COX and NOS by tyrosine phosphorylation [35] and increased intracellular calcium 
concentrations [36]. Consequently, prostacyclin is a good candidate to act as a 
back-up system in the systemic circulation when NO bioavailability is reduced.
Pulmonary circulation. We found that prostanoids do not play a role in the 
regulation of pulmonary vascular tone at rest in either the presence or absence of 
NO. This is in accordance with a study from Albertini et al [1], who showed that 
endogenous prostanoids do not contribute to pulmonary vascular tone in anesthetized 
swine either in the presence or absence of eNOS inhibition. In accordance with a 
previous study from our laboratory [15] the modest exercise-induced pulmonary 
vasodilation is principally mediated by NO. However, even when NO-production 
was inhibited, there was no role for endogenous prostanoids in the regulation of 
exercise-induced pulmonary vasodilation. Thus, although the porcine pulmonary 
conductance and resistance vessels are sensitive to the vasodilator actions of 
exogenous prostanoids [1, 37, 38], endogenous prostanoids do not appear to exert 
a signiﬁ cant vasodilator inﬂ uence in the pulmonary circulation.
Coronary circulation.  The normal heart is characterized by a high level (80%) 
of MEO2 under basal resting conditions [39, 40]. Consequently, the ability of the 
coronary resistance vessels to dilate in response to increments in myocardial O2 
demand is extremely important to maintain an adequate supply of O2. A sensitive way 
to study alterations in coronary vascular tone in relation to myocardial metabolism 
is the relationship between CVPO2 and MVO2. For example, an increase in coronary 
resistance vessel tone will limit coronary blood ﬂ ow and hence MDO2, forcing the 
myocardium to increase its MEO2 (in order to maintain MVO2), which results in a 
lower CVPO2. The CVPO2 thus represents an index of myocardial tissue oxygenation 
(i.e. the balance between MDO2 and MVO2), which is principally determined by 
coronary resistance vessel tone. 
In the coronary vasculature, we found prostanoids to be involved in the 
regulation of vascular tone both at rest and during exercise, which is in accordance 
with most [6, 7, 41, 42], but not all [12] data from the human coronary circulation. 
Prostanoids have been proposed to contribute to metabolic dilation of the coronary 
resistance vessels in man [7, 42], although this is not a ubiquitous ﬁ nding [6, 12]. 
The present study demonstrates that in swine prostanoids do not appear to have 
increased importance during exercise compared to resting conditions. In contrast 
to humans and swine, prostanoids do not appear to be important in the regulation 
of coronary vascular tone at rest or during exercise in the dog [11]. Although 
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the different observations are difﬁ cult to reconcile, they may be attributable to 
variations in preferential vasodilator systems between species. The contribution 
of prostanoids to the regulation of coronary vascular tone was not altered by 
inhibition of NO synthesis. These ﬁ ndings suggest that prostanoids and NO do not 
act in a compensatory manner when the other pathway is blocked. However, we 
cannot entirely exclude that the near-maximal MEO2 (91-93% of the O2 supplied) 
that occurred after combined blockade of NO and prostanoid synthesis prevented 
detection of an interaction between NO and prostanoids. 
Metabolic vasodilation after inhibition of NO and prostanoids
Although blockade of production of NO and prostanoids results in severe 
vasoconstriction at rest and during exercise, exercise-induced vasodilation was 
principally unperturbed as evidenced by the increase in coronary blood ﬂ ow 
and the decrease in systemic vascular resistance during exercise. There are 
several vasoactive factors that could have contributed to this exercise-induced 
vasodilation, including adenosine and ATP-sensitive K+-channels [43] and β-
adrenergic vasodilation [44, 45]. In addition, endothelium-derived hyperpolarizing 
factor may have contributed as it has been shown to be released in response to 
various agonists [46] as well as pulsatile stress [47], and may thus have increased 
importance at higher heart rates which occur during exercise.
Conclusion
The present study demonstrates that the contribution of prostanoids to 
vasomotor control varies markedly between regional vascular beds. Thus, 
endogenous prostanoids do not play a role in pulmonary resistance vessel control. 
Conversely, prostanoids contribute signiﬁ cantly to vasomotor and blood ﬂ ow control 
in the brain and heart both at rest and during exercise, but are not mandatory for 
the exercise-induced vasodilation in these organs. In contrast, prostanoids do not 
appear to play a role in skeletal blood ﬂ ow regulation either at rest or during 
exercise. In most visceral organs prostanoids exert a marked vasodilator inﬂ uence 
under resting conditions that is withdrawn during exercise. This exercise-induced 
withdrawal of prostanoid-mediated vasodilation may contribute to the exercise-
induced redistribution of blood ﬂ ow from the visceral organs towards the active 
skeletal muscle. Finally, prostanoids compensate for an acute loss of NO in the 
systemic circulation, but not in the coronary and pulmonary circulation.
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Abstract
Exercise-induced vasodilation is thought to be mediated through various 
vasodilator substances, but blunting the inﬂ uence of vasoconstrictors such as ET 
may also play a role. However, the role of ET and its receptors in the regulation of 
systemic, pulmonary and coronary vascular resistance is incompletely understood. 
The aim of this study was to identify the contribution of endothelin (ET)-1  through 
the ETA and ETB receptors to the regulation of tone in the systemic, coronary and 
pulmonary beds at rest and during exercise. Ten chronically instrumented swine 
were studied while running on a treadmill before and after ETA blockade (EMD122946) 
or ETA/ETB  blockade (tezosentan). At rest, EMD122946 resulted in vasodilation in 
the coronary and systemic circulation, evidenced by a decrease in coronary and 
systemic vascular resistance and an increase in coronary and mixed venous O2-
saturation. These effects waned during exercise. The effect of tezosentan on the 
systemic vasculature was similar to that of EMD122946, whereas it was smaller in 
the coronary circulation. EMD122946 had no effect on the pulmonary vasculature, 
whereas tezosentan decreased pulmonary resistance but only during exercise. ET 
exerts a constrictor inﬂ uence on the coronary and systemic circulation through the 
ETA-receptor, which decreases during exercise thereby contributing to metabolic 
vasodilation. ET exerts a tonic vasodilator inﬂ uence on coronary resistance vessels 
through the ETB-receptor. Finally, ET exerts an ETB–mediated constrictor inﬂ uence 
in the pulmonary vasculature during exercise.
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Introduction
 Endothelin (ET)-1  is one of the most potent vasoconstrictor agents known. 
It is produced in endothelial cells by cleavage of its nonvasoactive precursors 
preproendothelin and big ET [1, 2]. The ET receptors are located both on the 
endothelium and on vascular smooth muscle. Binding of ET to ETB receptors on the 
endothelium leads to production of NO and prostacyclin, which induce vasodilation, 
whereas binding of ET to the ETA and ETB receptors on vascular smooth muscle leads 
to vasoconstriction [1-3]. Administration of exogenous ET causes ETB mediated 
vasodilation at low doses but constriction at high doses, indicating that the ETB 
receptor on the endothelium is more sensitive to ET than the receptors on vascular 
smooth muscle [1-3]. Measurements of ET levels in blood yield concentrations 
in the picomolar range, while receptor sensitivities are in the nanomolar range 
[4]. However, reports on the role of endogenous ET have shown that, despite 
its low plasma concentrations and most likely due to its abluminal secretion, ET 
contributes to vascular tone in the systemic [5-10], coronary [6, 11] and possibly 
in the pulmonary circulation [12] under basal physiological conditions. 
 The role of ET in regulating resistance vessel tone during acute exercise is 
incompletely understood. Short term exercise does not result in changes in 
plasma ET-levels [6, 13-15], although small increases have been reported as well 
[16-18]. Nevertheless, local variations in ET-production may still contribute to 
redistribution of ﬂ ow to working muscle. Thus, during one-legged exercise, the 
ET-levels in the venous blood from the working leg did not change, whereas the 
ET-levels in the blood from the non-working leg increased [19]. However, because 
receptor sensitivity to ET can be modulated, for example by exercise training [20] 
and adenosine [21], changes in ET levels may not accurately reﬂ ect its role in 
exercise-induced changes in ﬂ ow. Therefore, the aim of the present study was to 
investigate the role of ET and its receptors in regulation of systemic, pulmonary 
and coronary resistance vessel tone of swine at rest and during exercise, using a 
selective ETA antagonist as well as a mixed ETA/ETB antagonist.
Methods
Animals
The study was performed in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996), and with approval of the Animal Care 
Committee of the Erasmus MC. Yorkshire X Landrace swine (2-3 months old, n=10, 
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22±1 kg at the time of surgery) of either sex entered the study. Daily adaptation of 
animals to laboratory conditions started 1 week before surgery.
Surgery
Swine were sedated (ketamine, 20 mg/kg im), anesthetized (thiopental, 
10 mg/kg iv), intubated and ventilated with O2 and N2O to which 0.2%-1% (v/
v) isoﬂ urane was added [22, 23]. Anesthesia was maintained with midazolam (2 
mg/kg followed by 1 mg/kg per hour iv) and fentanyl (10 µg/kg per hour iv). 
Under sterile conditions, the chest was opened via the fourth left intercostal space 
and a ﬂ uid ﬁ lled polyvinylchloride catheter was inserted into the aortic arch for 
aortic blood pressure measurement (Combitrans pressure transducers, Braun) and 
blood sampling for determination of blood gases (Acid-Base Laboratory Model 505, 
Radiometer), O2-saturation and hemoglobin concentration (OSM2, Radiometer), 
and computation of O2-content, O2-supply, and O2-consumption (VO2) [22, 23]. An 
electromagnetic ﬂ ow probe (14-15 mm, Skalar) was positioned around the ascending 
aorta for measurement of cardiac output. A microtipped pressure-transducer (P4.5, 
Konigsberg Instruments) was inserted into the LV via the apex. Polyvinylchloride 
catheters were inserted into the LV to calibrate the Konigsberg transducer LV 
pressure signal, into the left atrium to measure pressure and into the pulmonary 
artery to measure pressure, administer drugs and collect mixed venous blood 
samples. An angio-catheter was inserted into the anterior interventricular vein 
for blood sampling, while a Transonic ﬂ ow probe (2.5-3.0 mm, Transonic Systems) 
was placed around the left anterior descending coronary artery. Catheters were 
tunneled to the back and animals were allowed to recover, receiving analgesia (0.3 
mg buprenorphine im) for 2 days and antibiotic prophylaxis (25 mg/kg amoxicillin 
and 5 mg/kg gentamycin iv) for 5 days [22, 23].
Experimental Protocols
Efﬁ cacy of ET receptor blockade. In six swine, we tested the efﬁ cacy of the ETA 
antagonist EMD122946 (a gift from Dr P. Schelling, E Merck Darmstadt, Germany) 
and the mixed ETA/ETB antagonist tezosentan (a gift from Dr Clozel, Actelion 
Pharmaceuticals Ltd.) in blocking the arterial pressor response to ET.  EMD122946 
has a pA2 of 9.5 for ETA and a pA2 of 6.0 for ETB receptors, indicating a 3200-fold 
selectivity for ETA compared to ETB receptors [24].  Tezosentan has a pA2 of 9.5 for 
ETA and a pA2 of 7.7 for ETB receptors, indicating only a 63-fold selectivity for ETA 
compared to ETB receptors [6, 25].
While swine were resting quietly, ET-1 (50 ng/kg per ml saline) was infused at 
rates of 25, 50 and 100 ng/kg/min iv (10 min consecutive infusions) and mean aortic 
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blood pressure was measured at the end of each infusion.  On another day, the 
same doses of ET-1 were infused after administration of 3 mg/kg iv of EMD122946, 
dissolved in 40 ml saline (at pH 8), and infused over a 10-min period. On a third 
day, the same doses of ET-1 were infused after administration of 3 mg/kg iv of 
tezosentan, dissolved in 15 ml saline, and infused over a 10-min period, followed 
by 6 mg/kg/h iv infused at a rate of 0.5 ml/min. These three ET-infusion protocols 
were performed in random order.
Exercise study. Systemic, pulmonary and coronary hemodynamic responses to 
exercise were studied 1-2 weeks after surgery. After baseline measurements (lying, 
0L, and standing, 0S) were obtained, a treadmill exercise protocol was started (1-5 
km/h). Hemodynamic data and blood samples were collected during the last 30 s 
of each 3 min exercise stage [22, 23].  After completion of the exercise protocol, 
swine were allowed to rest for 90 min, during which the hemodynamics returned 
to baseline resting values that were similar (less than 5% different) to the baseline 
measurements obtained before the ﬁ rst exercise protocol. Then, either the ETA 
antagonist EMD122946 (3 mg/kg iv, n=8) or the mixed ETA/ETB antagonist tezosentan 
(3 mg/kg + 6 mg/kg/h iv, n= 7) was administered as described above, and 10 min 
later the exercise protocol was repeated. We have previously shown excellent 
reproducibility of the hemodynamic responses to exercise [22,23,26 27].
Determination of plasma levels of ET
In seven swine, arterial and coronary venous blood samples (5 ml) were 
collected at rest (Lying) and at 1, 3 and 5 km/h and kept on ice until the end of the 
exercise trial. Then the blood samples were spun down and plasma was stored at 
-80°C. Plasma levels of ET-like immuno-reactivity were determined using a radio-
immuno assay from Euro-Diagnostica (Malmö, Sweden), which has a cross reactivity 
of 100% toward ET-1, 48% toward ET-2 and 109% toward ET-3. Since production of 
ET-2 and ET-3 appears to be absent in the cardiovascular system of the pig [28], 
the concentrations measured with the radio-immuno assay most likely represents 
ET-1.  Importantly, there was also cross-reactivity of the radio-immuno assay 
with EMD122946 and tezosentan.  To correct for these inﬂ uences, we dissolved 
EMD122946 and tezosentan in naïve porcine plasma in the concentrations estimated 
to be present in vivo (0.04 mg/ml). The ET-level of the plasma before addition of 
the antagonists was 2.4 pM, while it was 4.3 pM in the presence of EMD122946 and 
3.8 pM in the presence of tezosentan. The artiﬁ cial increases in ET levels produced 
by EMD122946 (1.9 pM) and by tezosentan (1.4 pM) were subtracted from the 
ET-values obtained in the in vivo experiments with the respective antagonists to 
estimate true ET-levels.
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Data analysis 
Digital recording and off-line analysis of hemodynamics have been described 
previously [22, 23]. Statistical analysis was performed using two-way (exercise 
and treatment) analysis of variance (ANOVA) for repeated measures, followed by 
Dunnett’s test (exercise effect) and paired t-test (antagonist effect). Analysis of co-
variance (ANCOVA with VO2 as covariate) was used to detect statistically signiﬁ cant 
differences of relations between hemodynamic variables and body or myocardial 
VO2 in control versus ETA or ETA/ETB blockade. Signiﬁ cance was accepted when 
P<0.05. Data are presented as mean±SE.
Results
Efﬁ cacy of blockade
Both ETA and ETA/ETB blockade virtually abolished the ET-1 induced pressor 
response in the systemic circulation (Fig. 1). 
ET levels
Exercise did not inﬂ uence ET levels (Fig. 2). Furthermore, ET concentrations 
in arterial and coronary venous blood were not different. ETA blockade did not 
alter ET levels at rest, although ET levels were slightly lower during exercise. In 
contrast, ETA/ETB blockade resulted in elevated ET levels both at rest and during 
exercise.
ET (ng/kg/min)
0 25 50 100
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Figure 1. Effect of ETA and mixed ETA/ETB blockade on 
mean aortic blood pressure responses to intravenous 
infusion of ET-1. EMD122946: ETA receptor antagonist 
(3 mg/kg). Tezosentan: ETA/ETB receptor antagonist (3 
mg/kg+ 6 mg/kg/h iv). MAP: mean arterial pressure. 
Data are mean±SE; *P<0.05 vs baseline (0 ng/kg/min), 
†P<0.05 vs corresponding control.
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Table 1. Effect of ETA blockade on hemodynamic responses to graded treadmill exercise 
      Rest          Exercise level (km/h)             
  Treatment Lying  Standing    1     2     3     4     5   
                                                
CO Control 3.6 ± 0.2 4.4 ± 0.3*   5.1 ± 0.4* 5.6 ± 0.3* 6.2 ± 0.4* 7.0 ± 0.4* 7.5 ± 0.3* 
 (l/min) EMD122946 3.6 ± 0.3 4.4 ± 0.2*   5.3 ± 0.2* 5.6 ± 0.4* 6.3 ± 0.4* 7.2 ± 0.4* 7.6 ± 0.2* 
                                                
HR Control 128 ± 7 144 ± 8*   167 ± 8* 180 ± 7* 199 ± 10* 229 ± 8* 258 ± 8* 
 (bpm) EMD122946 132 ± 6 150 ± 7*   173 ± 8* 191 ± 9*† 208 ± 8* 245 ± 9*† 260 ± 7* 
                                                
SV Control 29 ± 2 31 ± 2*   31 ± 2* 32 ± 2* 31 ± 2 30 ± 2 29 ± 2 
 (ml) EMD122946 28 ± 2 30 ± 2   32 ± 2* 30 ± 2 30 ± 2 29 ± 2 29 ± 2 
                                                
LVdP/dtmax Control 3170 ± 290 3780 ± 470*   3860 ± 330* 3990 ± 290* 4450 ± 430* 5270 ± 410* 5790 ± 410* 
(mmHg/s) EMD122946 3190 ± 310 3810 ± 330*   3990 ± 380* 4260 ± 350* 4580 ± 410* 5190 ± 420* 5460 ± 470* 
                                                
MAP Control 89 ± 2 84 ± 3*   79 ± 2* 81 ± 2* 82 ± 2* 86 ± 3 89 ± 3 
 (mmHg) EMD122946 82 ± 3† 73 ± 3*†   72 ± 2*† 74 ± 2*† 76 ± 2† 79 ± 2† 80 ± 3† 
                                                
MPAP Control 13 ± 1 13 ± 2   16 ± 2 17 ± 1* 21 ± 2* 24 ± 2* 28 ± 2* 
 (mmHg) EMD122946 15 ± 2 13 ± 1   15 ± 2 17 ± 2 21 ± 2* 25 ± 2* 27 ± 1* 
                                                
MLAP Control 3 ± 1 2 ± 2   3 ± 1 4 ± 1 6 ± 1 7 ± 1 9 ± 2* 
 (mmHg) EMD122946 1 ± 2 1 ± 2   1 ± 1 2 ± 2 5 ± 2 7 ± 2* 8 ± 2* 
                                                
CBF Control 51 ± 5 63 ± 6*   69 ± 6* 75 ± 6* 87 ± 9* 105 ± 10* 123 ± 6* 
 (ml/min) EMD122946 56 ± 5 69 ± 5*   73 ± 6* 83 ± 8*† 96 ± 10* 116 ± 10*† 126 ± 5* 
 Data are mean ± SE; n=8. CO, cardiac output; HR, heart rate; SV, stroke volume; LVdPdtmax, maximum 
rate of rise in left ventricular pressure; MAP, mean arterial pressure; MPAP, mean pulmonary artery 
pressure; MLAP, mean left atrial pressure; CBF, coronary blood ﬂ ow. *P<0.05 vs rest (Lying), † P<0.05 
vs corresponding control measurement 
Figure 2. Arterial and coronary venous endothelin levels at rest and during exercise. Blood samples 
are drawn at rest (0 km/h, lying) and at 1, 3 and 5 km/h. ET: endothelin. EMD122946: ETA receptor 
antagonist (3 mg/kg). Tezosentan: ETA/ETB receptor antagonist (3 mg/kg+ 6 mg/kg/h iv). ART: arterial. 
CV: coronary venous. Data are mean±SE; *P<0.05 vs 0 km/h, †P<0.05 vs corresponding control.
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Systemic circulation 
Exercise produced an increase in cardiac output that was principally mediated 
by the increase in heart rate; LVdP/dtmax almost doubled (Table 1). Mean aortic 
pressure decreased signiﬁ cantly when animals went from lying to standing, but 
remained virtually unchanged thereafter despite the increases in cardiac output, 
reﬂ ecting the decrease in systemic vascular resistance (Fig. 3).
Blockade of ETA or ETA/ETB receptors resulted in a decreased mean aortic pressure 
(Table 1 and 2), which was accompanied by a small, likely baroreceptor reﬂ ex 
mediated, increase in heart rate. Since cardiac output was maintained it follows 
that the decrease in pressure was the result of the decrease in systemic vascular 
resistance, which was similar for ETA and ETA/ETB blockade (Fig. 3). Systemic 
vasodilation was also reﬂ ected in the decreased body O2-extraction and increased 
mixed venous O2-saturation (Fig. 3). These effects of ETA and ETA/ETB blockade 
waned during exercise, indicating that the constrictor inﬂ uence of ET was blunted 
during exercise.
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Figure 3. Effect of ETA (EMD122946, upper panels) and ETA/ETB (Tezosentan, lower panels) receptor 
blockade on the relation between body O2-consumption (BVO2) and systemic vascular resistance (SVR, 
left panels), body O2-extraction (middle panels) and mixed venous O2 saturation (right panels). ET 
receptor blockade resulted in systemic vasodilation at rest, that waned during exercise. Data are 
mean±SE, *P<0.05 vs Control, †P<0.05 effect decreases during exercise
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Coronary circulation
The increase in myocardial O2-consumption during exercise was accommodated 
by an increase in coronary blood ﬂ ow (Table 1), so that myocardial O2-extraction 
was maintained constant at approximately 80% (Fig. 4). ETA blockade resulted in a 
decreased coronary resistance and, as a result of this vasodilator effect, increased 
myocardial O2-supply allowing a decrease in myocardial O2-extraction and leading 
to an increased coronary venous O2-saturation (Fig. 4). The effect of ETA blockade 
waned during exercise.
Combined ETA/ETB blockade also resulted in a decrease in coronary resistance 
thereby increasing myocardial O2-supply and causing a decrease in myocardial 
O2-extraction at rest (Fig. 4). The effect of ETA/ETB blockade disappeared during 
exercise. The effects of ETA/ETB blockade were smaller than those of ETA blockade, 
particularly during exercise.
Pulmonary circulation 
Exercise resulted in a doubling of pulmonary artery pressure and a three-fold 
increase in left atrial pressure. The transpulmonary pressure gradient increased 
almost in parallel with cardiac output so that pulmonary vascular resistance 
decreased by less than 10 % (P=NS).
ff f y p g
      Rest             Exercise level (km/h)                
  Treatment  Lying   Standing     1     2     3     4     5   
                                                
CO Control 3.4 ± 0.2 4.4 ± 0.2*   4.9 ± 0.2* 5.7 ± 0.3* 6.1 ± 0.3* 6.9 ± 0.4* 7.5 ± 0.2* 
 (l/min) Tezosentan 3.8 ± 0.3 4.4 ± 0.3*   5.2 ± 0.3* 5.7 ± 0.3* 6.5 ± 0.4* 7.3 ± 0.5* 7.9 ± 0.3* 
                                                
HR Control 124 ± 5 147 ± 3*   168 ± 6* 185 ± 8* 200 ± 9* 233 ± 12* 263 ± 3* 
 (bpm) Tezosentan 149 ± 5† 165 ± 7*†   182 ± 4*† 195 ± 5* 219 ± 8*† 247 ± 12*† 270 ± 7* 
                                                
SV Control 28 ± 1 30 ± 1   29 ± 1 31 ± 1* 31 ± 1* 30 ± 1 28 ± 1 
 (ml) Tezosentan 26 ± 2 27 ± 1†   28 ± 1* 29 ± 1* 30 ± 1* 29 ± 1 29 ± 1 
                                                
LVdP/dtmax Control 2990 ± 140 3850 ± 260*   4140 ± 270* 4620 ± 390* 4890 ± 440* 5610 ± 480* 6110 ± 330* 
(mmHg/s) Tezosentan 3650 ± 320 4170 ± 380   4240 ± 250* 4590 ± 320* 5250 ± 530 5440 ± 450* 5970 ± 290* 
                                                
MAP Control 100 ± 4 91 ± 4   90 ± 3* 93 ± 3* 90 ± 3* 94 ± 3 95 ± 4 
 (mmHg) Tezosentan 92 ± 3† 82 ± 3†   81 ± 2*† 80 ± 2*† 83 ± 3† 84 ± 2† 87 ± 3† 
                                                
PMAP Control 16 ± 1 14 ± 2   18 ± 1 21 ± 2* 22 ± 2* 27 ± 2* 32 ± 2* 
 (mmHg) Tezosentan 15 ± 2 10 ± 2*   15 ± 1 16 ± 2† 20 ± 2*† 22 ± 2*† 26 ± 2*† 
                                                
LAP Control 5 ± 0 1 ± 3   2 ± 1* 5 ± 1 5 ± 1 7 ± 1 10 ± 3* 
 (mmHg) Tezosentan 3 ± 2† -3 ± 1*   2 ± 0 2 ± 1† 5 ± 1 6 ± 1* 9 ± 1* 
                                                
CBF Control 51 ± 3 66 ± 5*   77 ± 6* 88 ± 7* 93 ± 7* 112 ± 9* 134 ± 5* 
 (ml/min) Tezosentan 59 ± 6 67 ± 3   75 ± 6* 83 ± 7* 100 ± 8* 120 ± 11* 139 ± 3* 
 Data are mean ± SE; n=7.  *P<0.05 vs rest (Lying), † P<0.05 vs corresponding control measurement 
Table 2. Effect of ETA/ETB blockade on hemodynamic responses to graded treadmill exercise
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ETA blockade had no effect on pulmonary artery pressure, left atrial pressure 
or cardiac output (Table 1), so that pulmonary vascular resistance was unchanged 
(Fig. 5). In contrast, ETA/ETB blockade reduced pulmonary artery pressure during 
exercise, whereas left atrial pressure and cardiac output remained unaffected 
(Table 2), reﬂ ecting a decrease in pulmonary vascular resistance (Fig. 5).
Discussion
The major ﬁ ndings in this study are that: (i) endogenous ET contributes 
to vascular tone in the systemic, coronary and pulmonary vasculature; (ii) the 
vasoconstrictor effect of ET on the systemic and coronary vasculature is mediated 
through the ETA receptor, whereas it is mediated through the ETB receptor in the 
pulmonary vasculature; (iii) in contrast, the ETB receptor exerts a vasodilator 
inﬂ uence on the coronary circulation; (iv) although arterial ET levels do not change 
during exercise, its vasoconstrictor inﬂ uence on the systemic and particularly the 
coronary resistance vessels decreases, whereas its vasoconstrictor inﬂ uence on the 
pulmonary resistance vessels increases.
Methodological considerations
Efﬁ cacy and selectivity of ET receptor antagonists. Both EMD122946 and 
tezosentan virtually abolished the ET-1 induced pressor response in resting swine. 
These observations demonstrate that receptor blockade was effective during a 
30 minute period, which encompasses the duration of the exercise protocol and 
that the pressor response to exogenous ET-1 was principally mediated via ETA 
stimulation. 
The selectivity of EMD122946 and tezosentan for the ETA and the ETB receptor 
has been studied in vitro. EMD122946 has a 3200-fold selectivity for ETA compared 
to ETB receptors [24], whereas Tezosentan has only a 63-fold selectivity for ETA 
compared to ETB receptors [6, 25]. In accordance with these in vitro studies, we 
found that ET levels rose after tezosentan, but not after EMD122946. The increase 
in ET levels with tezosentan is due to the blockade of ETB receptors in the lungs, 
which are responsible for clearance of ET [29]. The absence of an increase in ET-
levels with EMD122946, indicates that this compound has no ETB receptor blocking 
properties in the dose employed in the present study in vivo.
Rationale for using  ETA and  ETA/ETB receptor antagonists to assess the 
functional role of ETB receptors. ET is preferentially released on the abluminal 
side of the vasculature. Thus, plasma ET levels may not adequately reﬂ ect the 
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contribution of ET in the regulation of vascular tone. Hence, the most adequate 
way to measure the contribution of ET to the regulation of vascular tone is the use 
of ET receptor antagonists. Since the ETB receptor is responsible for clearance of 
ET in the lungs [29], we chose to use a selective ETA and a mixed ETA/ETB antagonist 
to determine the role of the ETA and ETB receptor, rather than a selective ETB 
antagonist. Selective ETB blockade would increase ET levels, which could then cause 
vasoconstriction through the ETA receptor, thereby confounding interpretation of 
the ﬁ ndings. When ET levels rise in the presence of ETA/ETB blockade, this will 
not affect vascular tone. Thus, the role of the ETB receptor must be derived from 
the difference in response between selective ETA blockade and combined ETA/ETB 
blockade.
Role of ET in the regulation of tone at rest and during exercise
Coronary circulation. The normal heart is characterized by a high level (80%) 
of myocardial O2–extraction under basal resting conditions [30, 31]. Consequently, 
the ability of the coronary resistance vessels to dilate in response to increments 
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Figure 4. Effect of ETA (EMD122946, upper panels) and ETA/ETB (Tezosentan, lower panels) receptor 
blockade on the relation between myocardial O2-consumption (MVO2) and coronary vascular resistance 
(CVR, left panels), myocardial O2-extraction (middle panels) and coronary venous O2-saturation (right 
panels). ET receptor blockade resulted in coronary vasodilation at rest, that waned during exercise. 
Data are mean±SE, *P<0.05 vs Control, †P<0.05 effect of receptor blockade decreases during exercise, 
‡P<0.05 vs EMD122946-induced response.
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in myocardial O2-demand is extremely important to maintain an adequate O2–
supply. A sensitive way to study alterations in coronary vascular tone in relation 
to myocardial metabolism is the relationship between coronary venous O2-content 
and myocardial O2-demand. Thus, an increase in coronary resistance vessel tone 
will limit CBF and hence myocardial O2-supply at a given level of myocardial O2 
consumption, forcing the myocardium to increase its myocardial O2-extraction (in 
order to meet myocardial O2-demand), which results in a lower coronary venous 
O2-content. Conversely, a decrease in resistance vessel tone increases myocardial 
O2-supply at a given level of myocardial O2-consumption resulting in an increased 
coronary venous O2-content. The coronary venous O2-content thus represents an 
index of myocardial tissue oxygenation (i.e. the balance between myocardial O2-
supply and O2-demand) which is determined by the coronary resistance vessel 
tone. Using this approach, several laboratories have indicated roles for myriad 
vasodilator systems such as NO, adenosine, K+ATP channels and β-adrenoceptors in 
metabolic vasodilation [22, 23, 26, 27, 30-33]. 
In the present study, we extended the investigation of metabolic vasodilation 
to the contribution of withdrawal of the endothelin-induced vasoconstriction. 
Using the myocardial O2 balance, we demonstrated ETA-mediated coronary 
constriction and simultaneous ETB-mediated coronary vasodilation in swine. This 
is in accordance with studies that have shown that the constrictor responses of 
coronary conductance and resistance arteries are predominantly ETA-mediated 
[34-37], whereas ETB-mediated vasodilation has been found in the large coronary 
arteries [38, 39] and coronary arterioles [40], although an ETB-mediated constrictive 
component also exists in large coronary arteries [36, 41]. Overall, dose response 
curves to ET in isolated coronary arteries [20] and arterioles [42] indicate that the 
sensitivity for ET increases with decreasing vessel size. 
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In dogs, the effect of ETA/ETB blockade on coronary vascular tone tended to 
decrease during incremental levels of exercise [6]. This led us to hypothesize that 
there is a role for withdrawal of the vasoconstrictor effect of ET in metabolic 
regulation of coronary vascular tone. Indeed we recently showed that the effect 
of ETA blockade on the coronary circulation decreased during exercise and that the 
effects of ET were modiﬁ ed by the cardiomyocytes according to their metabolic 
status [11]. However, in the present study we found that only the ETA-mediated 
vasoconstriction waned during exercise, whereas an ETB-mediated vasodilation 
was tonically present. Although a decrease in local ET release, for example due 
to an increased NO production during exercise [2, 43] could theoretically have 
contributed to metabolic coronary vasodilation, this is unlikely. Thus, neither 
coronary arterial nor coronary venous ET-levels changed during exercise, which 
is in agreement with the study of Takamura et al [6]. Moreover, the vasodilator 
inﬂ uence of the ETB receptor was constant despite a decrease in the vasoconstrictor 
inﬂ uence of the ETA receptor.  There are several other mechanisms that may account 
for exercise-induced modulation of the effects of ET. First, interstitial adenosine 
levels increase during exercise, which can decrease sensitivity of the vasculature 
to ET [21]. Second, NO production increases during exercise, which can directly 
modulate the binding of ET to the ETA receptor [44, 45]. NO has been shown to 
induce depalmitoylation of the β-adrenoceptor thereby affecting its signaling [46] 
and may also result in depalmitoylation of the ETA receptor, thereby decreasing its 
signal transduction [45, 47, 48]. Thus, ETA receptor sensitivity may be decreased 
during exercise through an increase in NO, adenosine or both, thereby facilitating 
metabolic vasodilation.
Systemic circulation. In the systemic circulation, effects of endogenous ET 
were predominantly exerted through the ETA receptor with no net contribution 
of the ETB receptor. In addition, the vasoconstriction caused by exogenously 
administered ET was predominantly ETA-mediated since the increase in aortic 
blood pressure was abolished by both the ETA and the ETA/ETB antagonists. Hence, 
in the systemic vascular bed the effects of both endogenous and exogenous ET 
appear to be mediated exclusively through the ETA receptor. These ﬁ ndings are in 
line with other studies demonstrating that the constrictor response of systemic 
conductance and resistance arteries is principally ETA-mediated [34-36]. Although 
there was no net contribution of endogenous ET through the ETB receptor in our 
study, we cannot exclude that some regional vascular beds exhibit ETB mediated 
constriction whereas others vasodilate, as suggested by studies showing an ETB-
mediated constrictive component in the renal arteries [36, 41] as well as ETB-
mediated vasodilation in the systemic circulation [49].
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In the present study, we found that the contribution of ET to overall systemic 
vascular tone decreased during exercise. From our experiments, it is impossible to 
elucidate the mechanism behind the blunted effect of ET during exercise. The ET 
levels in arterial blood did not change, which is in accordance with data obtained 
in humans [13, 15, 18], dogs [6, 50], and swine [14]. However, in view of the 
preferentially abluminal release of ET, this observation does not exclude alterations 
in the contribution of ET to regulation of resistance vessel tone. Thus, plasma 
concentrations of ET may not adequately reﬂ ect local ET levels. Furthermore, 
ET binds tightly to its receptors and the rate of dissociation is low [1-3], so that 
locally secreted ET binds to its receptors and acts, with minimal accumulation in 
the blood [51]. Further support for a discrepancy between local and arterial ET-
levels is provided by the fact that although the ET-levels in blood were below the 
vasoactive threshold [20, 42], blockade of ET receptors resulted in vasodilation at 
rest, an observation that is corroborated by studies in dogs [6] and humans [8-10]. 
However, spill-over into the blood may occur. For example, Maeda et al reported 
that during one-leg exercise, ET-levels increased in the venous efﬂ uent from the 
non-working leg, while venous ET-levels were unchanged in the exercising leg [19]. 
Hence, ET production may vary locally according to the metabolic status of the 
tissue [18, 52, 53]. Alternatively, local increases in NO and adenosine during exercise 
may have decreased ETA receptor signal transduction, and thereby modulated the 
constriction to ET during exercise [21, 44, 46-48]. Thus, local modulation of ET 
release and/or receptor sensitivity at sites of increased metabolism provides an 
additional way to increase ﬂ ow to areas that need it most, while tone remains intact 
in other areas, thereby ensuring adequate (re)distribution of ﬂ ow commensurate 
with metabolic needs. 
Pulmonary Circulation. ET-induced constriction is mediated by ETA receptors 
in the large pulmonary arteries, whereas it is mediated by ETB receptors in the 
smaller pulmonary resistance vessels [54]. In accordance with these ﬁ ndings, 
the density of ETA receptors in the lung decreases with decreasing vessel size, 
whereas the density of ETB receptors, both on the endothelium and the smooth 
muscle increases [55]. In swine, exogenously administered ET induces transient 
pulmonary hypotension (endothelial ETB receptor), followed by sustained 
pulmonary hypertension (ETB receptor on vascular smooth muscle) [49]. The role 
of endogenous ET in the regulation of pulmonary resistance is less well understood. 
In some studies in the porcine and human circulation, ET receptor blockade had 
no effect [7, 56], while a small vasodilator response was reported in other studies 
[12, 57]. In our study, blockade of neither ETA nor ETB receptors affected pulmonary 
vascular resistance at rest, indicating that endogenous ET does not contribute to 
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resting tone in the pulmonary resistance vessels. During exercise however, an ETB-
mediated vasoconstriction became apparent, which contrasts with the blunted ET-
mediated constriction in the systemic and coronary beds. Since hypoxia-induced 
pulmonary vasoconstriction is in part ET-mediated [56, 57], it could be speculated 
that the decrease in pulmonary arterial PO2 which occurred during exercise may 
have contributed to the ETB mediated vasoconstriction.
Conclusions and implications
In awake swine, free from the effects of anesthesia, endothelin contributes to 
basal resting tone in resistance vessels of the systemic and coronary, but not the 
pulmonary circulation. During treadmill exercise, the ETA-mediated constriction 
of both the systemic and coronary bed wanes, thereby contributing to metabolic 
vasodilation in these beds. A tonic ETB-mediated vasodilator inﬂ uence is present 
in the coronary circulation.  In contrast, an ETB-mediated constriction becomes 
apparent in the pulmonary bed during exercise, which blunts the exercise-induced 
decrease in pulmonary vascular resistance.
The present study provides evidence for a novel concept of metabolic dilation 
in the systemic and coronary circulation during exercise, which involves not only 
increased vasodilator inﬂ uences [22, 23, 26, 27, 30, 31], but also inhibition of 
vasoconstrictor inﬂ uences. Importantly, our study predicts that loss of the capacity 
to inhibit ET mediated vasoconstrictor inﬂ uence (e.g. in situations of endothelial 
dysfunction) may result in impaired vasodilation during increased O2-demand. In 
support of this concept, McEniery et al [58] recently showed that ET receptor 
blockade normalized the impaired exercise-induced vasodilation in the fore-arm 
of hypertensive humans, whereas ET blockade had no effect on exercise responses 
in normotensive subjects.
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Abstract
We have previously shown that vasodilators and vasoconstrictors that are 
produced by the vascular endothelium, including nitric oxide (NO), prostanoids 
and endothelin (ET), contribute to the regulation of systemic and pulmonary 
vascular tone in swine, in particular during treadmill exercise. Since NO and 
prostanoids can modulate the release of ET, and vice versa, we investigated the 
integrated endothelial control of pulmonary vascular resistance in exercising 
swine. Speciﬁ cally, we tested the hypothesis that increased NO and prostanoid 
production during exercise limits the vasoconstrictor inﬂ uence of ET, so that 
loss of these vasodilators results in exaggerated ET-mediated vasoconstriction 
during exercise. Fifteen instrumented swine were exercised on a treadmill at 0-5 
km·h-1 before and during ETA/ETB receptor blockade (tezosentan, 3mg·kg
-1 iv) in 
the presence and absence of inhibition of NO synthase (Nω-nitro-L-arginine, 20 
mg·kg-1 iv) and/or cyclo-oxygenase (indomethacin, 10 mg·kg-1 iv). In the systemic 
circulation, ET receptor blockade decreased vascular resistance at rest, which 
waned gradually with increasing exercise intensity. Prior inhibition of either NO or 
prostanoid production augmented the vasodilator effect of ET receptor blockade, 
and these effects were additive. In contrast, in the pulmonary bed, ET-receptor 
blockade had no effect under resting conditions, but decreased pulmonary vascular 
resistance during exercise. Prior inhibition of NO synthase, enhanced the pulmonary 
vasodilator effect of ET receptor blockade both at rest and during exercise, whereas 
inhibition of prostanoids had no effect, even after prior NO synthase inhibition. 
In conclusion, endogenous endothelin limits pulmonary vasodilation in response 
to treadmill exercise. This vasoconstrictor inﬂ uence is blunted by NO but not by 
prostanoids.
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Introduction
  
The pulmonary vascular bed is a low-resistance system that is capable of 
accommodating large amounts of blood ﬂ ow at low levels of pulmonary artery 
pressure [1]. Consequently, under basal resting conditions the normal arterio-
venous pressure difference across the pulmonary vascular bed is approximately 
10 mmHg, which contrasts sharply with the 90-100 mmHg arterio-venous pressure 
gradient across the systemic bed. Despite the low pulmonary vascular resistance 
under resting conditions, a small further decrease in pulmonary resistance occurs 
during exercise, albeit signiﬁ cantly less (10-30%) than the 60-80% decrease in 
systemic vascular resistance [1]. The exercise-induced decrease in pulmonary 
vascular resistance involves both passive pulmonary vasodilation, including 
vascular recruitment and passive distension due to the exercise-induced increase in 
pulmonary artery pressure, as well as an active reduction in pulmonary vasomotor 
tone [1]. The mechanism of vasomotor tone regulation in pulmonary resistance 
vessels during exercise is still incompletely understood, but differs from that in 
the systemic vascular bed. For example, while endogenous adenosine and K+ATP 
channel activity have been shown to exert a vasodilator inﬂ uence in the systemic 
bed during treadmill exercise, they are not mandatory for the regulation of tone 
in pulmonary resistance vessels [2, 3].
The vascular endothelium releases a variety of vasoactive substances, including 
nitric oxide (NO), prostanoids and endothelin (ET), that contribute to vasomotor 
control. However, the endothelial lining is not a homogeneous compartment as it is 
characterized by signiﬁ cant structural and functional heterogeneity. For example, 
the endothelium in the pulmonary bed differs markedly in ultrastructure and 
function from the systemic endothelium [4, 5]. In support of this concept, recent 
studies in swine indicate that while both NO and prostanoids exert a vasodilator 
inﬂ uence on the systemic vascular bed during exercise, only NO, but not prostanoids, 
contributes to the exercise-induced pulmonary vasodilation [6, 7]. Furthermore, 
we recently observed in exercising swine that in the systemic circulation, the 
vasoconstrictor inﬂ uence of ET wanes with increasing exercise intensities, whereas 
in the pulmonary circulation an ET vasoconstrictor inﬂ uence emerges during 
exercise [8]. Since ET can increase the production of NO and prostanoids, which 
in turn can blunt the release of ET [9-11] or modify the responsiveness of its 
receptors [12], the present study was undertaken to investigate the integrated 
vasomotor control of pulmonary vascular resistance by NO, prostanoids and ET, 
in chronically instrumented swine under resting conditions and during graded 
treadmill exercise.
93
Chapter 4: NO, prostanoids and endothelin in normal swine 
Methods
    
Animals
Studies were performed in accordance with the Council of Europe Convention 
(ETS123)/ Directive (86/609/EEC) for the protection of vertebrate animals used 
for experimental and other scientiﬁ c purposes, and with approval of the Animal 
Care Committee of the Erasmus Medical Center. Fifteen 2-3-month-old Yorkshire X 
Landrace swine (22±1 kg at the time of surgery) of either sex entered the study. 
Surgery
Swine were sedated with ketamine (30 mg·kg-1 im), anaesthetized with 
thiopental (10 mg·kg-1 iv), intubated and ventilated with a mixture of O2 and 
N2O (1:2) to which 0.2-1% (v/v) isoﬂ urane was added [3, 13]. Anaesthesia was 
maintained with midazolam (2 mg·kg-1 + 1 mg·kg-1 per hour iv) and fentanyl (10 
µg·kg-1 per hour iv). Under sterile conditions, the chest was opened via the fourth 
left intercostal space and a ﬂ uid-ﬁ lled polyvinylchloride catheter was inserted 
into the aortic arch for aortic blood pressure measurement (Combitrans pressure 
transducers, Braun) and blood sampling. An electromagnetic ﬂ ow probe (14-15 
mm, Skalar) was positioned around the ascending aorta for measurement of cardiac 
output. Polyvinylchloride catheters were inserted into the left atrium to measure 
pressure, and into the pulmonary artery to measure pressure, administer drugs 
and collect mixed venous blood samples. Catheters were tunnelled to the back 
and animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine 
im) for 2 days and antibiotic prophylaxis (25 mg·kg-1 amoxicillin and 5 mg·kg-1 
gentamycin iv) for 5 days.
Experimental protocols
Studies were performed 1-3 weeks after surgery with animals exercising on 
a motor driven treadmill. The excellent reproducibility of consecutive exercise 
trials has been reported previously [2, 3, 7, 13]. In the present study, four exercise 
protocols were performed on different days and in random order.
Endothelin. With swine (n=11) lying quietly on the treadmill, resting 
hemodynamic measurements, consisting of heart rate, cardiac output, mean 
aortic pressure (MAP), mean pulmonary artery pressure (MPAP), and mean left 
atrial pressure (MLAP) were obtained and blood samples collected. Hemodynamic 
measurements were repeated and rectal temperature was measured with animals 
standing on the treadmill. Subsequently, a ﬁ ve-stage (1-5 km·h-1) treadmill 
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exercise protocol was started; each exercise stage lasted 2-3 min. Hemodynamic 
variables were continuously recorded and blood samples collected during the last 
45 s of each stage. After completing the exercise protocol animals were allowed 
to rest on the treadmill for 90 min after which the mixed ETA and ETB receptor 
(ETA/ETB) antagonist tezosentan (a gift from Dr Clozel, Actelion Pharmaceuticals 
Ltd.) was intravenously administered over 10 min in a dose of 3 mg·kg-1, followed 
by a continuous infusion of 6 mg·kg-1·h-1 iv [8], and the exercise protocol was 
repeated.
Prostanoids and endothelin. Ninety min after 9 swine had undergone a control 
exercise trial (as described above), animals received the cyclo-oxygenase inhibitor 
indomethacin ((Sigma) 10 mg·kg-1 iv over 10 min [6]) and 5 min later underwent a 
second exercise trial. Ninety min later, animals received indomethacin in a dose 
of 5 mg·kg-1 iv, which resulted in hemodynamic conditions that were identical to 
those following administration of 10 mg·kg-1 prior to the second exercise trial. 
Subsequently, animals received tezosentan (3 mg·kg-1 iv + 6 mg·kg-1·h-1 iv) and 
underwent a third exercise trial.
NO and endothelin. Ninety min after 7 swine had undergone a control exercise 
trial, animals received the NO-synthase inhibitor Nω-nitro-L-arginine (NLA (Sigma), 
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Figure 1. Effect of cyclo-oxygenase 
inhibition (indomethacin (Indo), left 
panels) and NO synthase inhibition 
(NLA, right panels) and combined 
inhibition of cyclo-oxygenase and 
NO synthase (Indo + NLA, right 
panels) on the relation between 
body O2 consumption and systemic 
vascular resistance (upper panels) 
and the mixed venous O2 saturation 
(lower panels). Dot inside symbol 
denotes P<0.05 vs corresponding 
value at rest, *P<0.05 vs control, 
†P<0.05 vs NLA
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20 mg·kg-1 iv; [7]), and underwent a second exercise trial. Ninety min later, animals 
received tezosentan (3 mg·kg-1 iv + 6 mg·kg-1·h-1 iv) and underwent a third exercise 
trial.
NO, prostanoids and endothelin. Ninety min after 5 swine underwent an 
exercise trial in the presence of NLA (20 mg·kg-1 iv), animals received indomethacin 
(10 mg·kg-1 iv) and underwent a second exercise trial. Ninety min later, animals 
received indomethacin (5 mg·kg-1 iv) and tezosentan (3 mg·kg-1 iv and 6 mg·kg-1·h-1 
iv) and underwent a third exercise trial.
Blood gas measurements 
Blood samples were kept in iced syringes until the conclusion of each exercise 
trial. Measurements of PO2 (mmHg), PCO2 (mmHg) and pH were then immediately 
performed with a blood gas analyser (Acid-Base Laboratory Model 505, Radiometer, 
Copenhagen, Denmark). Oxygen saturation (%) and hemoglobin (grams per 100 
ml) were measured with a hemoximeter (OSM3, Radiometer). Blood O2 content 
(mmol·ml-1) was computed as (Hb·0.621·O2-saturation) + (0.00131·PO2). Body 
O2 consumption (BVO2) was calculated as the product of cardiac output and the 
difference in O2 content between arterial and mixed venous blood [3, 13].
Data analysis
Digital recording and off-line analysis of hemodynamics have been described 
previously [2, 13]. Systemic vascular resistance was computed as mean aortic blood 
pressure divided by cardiac output. Pulmonary vascular resistance was computed 
as mean pulmonary artery pressure minus mean left atrial pressure divided by 
cardiac output [6].
Statistical analysis
Analysis of variance (ANOVA) for repeated measures or analysis of co-variance 
(ANCOVA) were used as appropriate. Post-hoc testing for exercise and drug effect 
was performed using Scheffe’s test. Statistical signiﬁ cance was accepted when 
P<0.05. Data are presented as mean±SEM.
 
Results
  
The role of prostanoids and NO in the regulation of vascular tone
Systemic circulation. Table 1 shows that exercise up to 5 km·h-1 resulted in 
more than a doubling of cardiac output which was principally due to an increase 
in heart rate (up to 85% of maximum heart rate), as stroke volume increased by 
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Table 1: Hemodynamics of swine at rest and during exercise 
    Rest             Exercise level (km·h-1)        
  Treatment lying standing   1     2     3     4     5   
HR Control 126 ± 5 147 ± 5* 169 ± 6* 186 ± 5* 202 ± 6* 232 ± 8* 265 ± 5* 
(bpm) Tezo 150 ± 5‡ 163 ± 5*‡ 184 ± 6* 198 ± 8* 214 ± 7*‡ 243 ± 9*‡ 267 ± 6* 
  Indo 86 ± 7†   97 ± 5*† 121 ± 6*† 134 ± 6*† 150 ± 6*† 174 ± 6*† 204 ± 7*† 
  Indo+Tezo 97 ± 7†‡ 112 ± 5*†‡ 128 ± 6*† 141 ± 6*† 157 ± 7*† 178 ± 8*† 212 ± 9*† 
  NLA 97 ± 5† 115 ± 3*† 129 ± 6*† 139 ± 6*† 156 ± 6*† 190 ± 9*† 225 ± 9*† 
  NLA+Tezo 112 ± 6† 136 ± 7*†‡ 146 ± 8*†‡ 154 ± 7*†‡ 176 ± 8*†‡ 201 ± 8*†‡ 234 ± 10*† 
  NLA+Indo 82 ±  7† 93 ± 8*† 110 ± 8*† 122 ± 12*† 134 ± 10*† 164 ± 13*† 193 ± 12*† 
  NLA+Indo+Tezo 100 ± 10† 116 ± 8*†‡ 127 ± 6*†‡ 138 ±  7*† 153 ± 13*†‡ 171 ± 11*† 194 ± 10*† 
CO Control 3.6 ± 0.2 4.5 ± 0.2* 5.3 ± 0.3* 5.9 ± 0.3* 6.4 ± 0.3* 7.1 ± 0.3* 7.8 ± 0.4* 
(l·min-1) Tezo 4.0 ± 0.2‡ 4.7 ± 0.3* 5.5 ± 0.3* 6.1 ± 0.4* 6.8 ± 0.4*‡ 7.6 ± 0.4*‡ 8.2 ± 0.4* 
  Indo 2.6 ± 0.3† 3.2 ± 0.3*† 4.1 ± 0.3*† 4.5 ± 0.3*† 5.1 ± 0.3*† 6.2 ± 0.3*† 7.2 ± 0.3* 
  Indo+Tezo 3.0 ± 0.2† 3.8 ± 0.3*†‡ 4.4 ± 0.3*† 5.2 ± 0.4*‡ 5.6 ± 0.4*‡ 6.4 ± 0.4* 7.5 ± 0.5* 
  NLA 3.1 ± 0.4† 3.8 ± 0.2*† 4.5 ± 0.3*† 4.9 ± 0.3*† 5.4 ± 0.3*† 6.4 ± 0.4*† 7.1 ± 0.4*†
  NLA+Tezo 3.8 ± 0.4‡ 4.7 ± 0.4*‡ 5.2 ± 0.4*†‡ 5.6 ± 0.4*†‡ 6.4 ± 0.3*†‡ 7.3 ± 0.4*†‡ 8.2 ± 0.5*‡
  NLA+Indo 2.0 ± 0.3† 2.3 ± 0.3† 3.1 ± 0.3*† 3.7 ± 0.4*† 4.1 ± 0.3*† 5.1 ± 0.5*† 6.0 ± 0.3* 
  NLA+Indo+Tezo 3.1 ± 0.3 3.8 ± 0.4‡ 4.2 ± 0.3*‡ 4.9 ± 0.3* 5.2 ± 0.3*‡ 5.8 ± 0.3* 6.6 ± 0.4*‡
MAP Control 97 ± 3 90 ± 3* 89 ± 2* 90 ± 3* 89 ± 2* 92 ± 2* 93 ± 2 
(mmHg) Tezo 91 ± 2 82 ± 3*‡ 81 ± 2*‡ 79 ± 2*‡ 82 ± 2*‡ 83 ± 2*‡ 85 ± 2*‡ 
  Indo 124 ± 7† 120 ± 7† 107 ± 6*† 106 ± 6*† 107 ± 5*† 104 ± 5* 101 ± 4* 
  Indo+Tezo 111 ± 3† 93 ± 3*†‡ 89 ± 2*†‡ 89 ± 3*†‡ 89 ± 3*‡ 88 ± 3*‡ 89 ± 3*‡ 
  NLA 124 ± 3† 118 ± 3† 115 ± 3† 115 ± 2*† 118 ± 2† 119 ± 2† 119 ± 3† 
  NLA+Tezo 112 ± 5† 103 ± 3†‡ 99 ± 4*†‡ 99 ± 3*†‡ 100 ± 3*†‡ 98 ± 3*†‡ 98 ± 2*†‡ 
  NLA+Indo 166 ± 8† 163 ± 8† 151 ± 6*† 145 ± 5† 140 ± 3*† 134 ± 4*† 128 ± 5*† 
  NLA+Indo+Tezo 128 ± 5†‡ 118 ± 7*†‡ 113 ± 6*†‡ 114 ± 6*†‡ 115 ± 7*†‡ 113 ± 6*†‡ 113 ± 8*†‡ 
MPAP Control 15 ± 1 15 ± 2 19 ± 1* 21 ± 1* 23 ± 1* 28 ± 2* 33 ± 1* 
(mmHg) Tezo 16 ± 1 13 ± 2 17 ± 2 18 ± 2 21 ± 2*‡ 25 ± 2*‡ 28 ± 2*‡ 
  Indo 19 ± 1 18 ± 2 18 ± 2 20 ± 2 22 ± 2* 26 ± 2* 29 ± 2* 
  Indo+Tezo 17 ± 2 14 ± 2*‡ 15 ± 2 17 ± 2 20 ± 2 23 ± 2* 26 ± 2* 
  NLA 25 ± 2† 22 ± 2 25 ± 2† 27 ± 2† 31 ± 2*† 38 ± 2*† 44 ± 1*† 
  NLA+Tezo 18 ± 2 19 ± 2 18 ± 2†‡ 21 ± 1‡ 25 ± 2*†‡ 29 ± 3*‡ 33 ± 3*‡ 
  NLA+Indo 24 ± 2† 26 ± 3† 27 ± 3 29 ± 3  31 ± 3* 35 ± 2*† 37 ± 3* 
  NLA+Indo+Tezo 19 ± 2 17 ± 3 20 ± 2 23 ± 3 25 ± 3  28 ± 4*‡ 31 ± 3*‡ 
MLAP Control 4 ± 1 2 ± 2 3 ± 1 4 ± 1 6 ± 1 7 ± 1* 11 ± 1* 
(mmHg) Tezo 4 ± 1 0 ± 1* 3 ± 1 3 ± 1 6 ± 1 8 ± 1* 10 ± 1* 
  Indo 10 ± 2† 7 ± 2 3 ± 2* 6 ± 1* 6 ± 1* 7 ± 1 8 ± 2 
  Indo+Tezo 8 ± 1 2 ± 1*‡ 3 ± 2* 4 ± 1* 6 ± 1* 7 ± 2 8 ± 2 
  NLA 11 ± 1† 5 ± 2* 7 ± 1* 8 ± 1* 9 ± 1* 10 ± 1* 12 ± 1* 
  NLA+Tezo 3 ± 3 5 ± 1* 4 ± 2* 7 ± 1* 9 ± 1* 11 ± 2* 13 ± 2* 
  NLA+Indo 16 ± 3† 15 ± 4† 13 ± 4 14 ± 3† 14 ± 3† 12 ± 3 10 ± 3 
  NLA+Indo+Tezo 7 ± 3‡ 4 ± 4 5 ± 2 8 ± 2 9 ± 2 11 ± 3 12 ± 2 
HR: Heart Rate, CO: Cardiac Output, MAP: Mean Arterial Pressure, MPAP: Mean Pulmonary Arterial 
Pressure, MLAP: Mean Left Atrial Pressure. Data are mean ± SEM; * P<0.05 vs rest (lying); † P<0.05 vs 
corresponding control, ‡ P<0.05 effect of Tezosentan
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only 15% (not shown). The increase in cardiac output, was balanced by a similar 
decrease in systemic vascular resistance (Fig. 1), so that mean aortic blood pressure 
was minimally affected (Table 1).
Administration of the NO synthase inhibitor NLA or the cyclo-oxygenase inhibitor 
indomethacin resulted in a marked increase in aortic blood pressure, which was 
due to systemic vasoconstriction (Table 1, Fig. 1). The accompanying decrease in 
cardiac output resulted from a (probably baroreﬂ ex-mediated) decrease in heart 
rate. The systemic vasoconstriction necessitated an increase in O2-extraction 
resulting in a decreased mixed venous O2-saturation. During exercise, the pressor 
and vasoconstrictor responses to cyclo-oxygenase inhibition were progressively 
blunted, whereas the responses to NO synthase inhibition were maintained (Table 
1, Fig. 1).
Pretreatment with NLA enhanced the indomethacin-induced vasoconstriction 
in the systemic circulation, as indicated by the exaggerated increase in systemic 
vascular resistance and exaggerated decrease in mixed venous O2-saturation. 
Importantly, despite the marked potentiation of the systemic vasoconstrictor 
response to cyclo-oxygenase inhibition by NO synthase inhibition under resting 
conditions, the exercise-induced vasodilation was unmitigated in the presence of 
indomethacin and NLA (Fig. 1).
Pulmonary circulation. Pulmonary artery pressure doubled during exercise 
(Table 1). However, the transpulmonary pressure gradient (MPAP-MLAP) increased 
slightly less than cardiac output, reﬂ ecting a 20% decrease in pulmonary vascular 
resistance (Fig. 2). In contrast to the systemic bed, inhibition of cyclo-oxygenase 
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had no effect on pulmonary vascular resistance either at rest or during exercise. 
NO synthase inhibition produced vasoconstriction in the pulmonary circulation, 
resulting in an increase in pulmonary artery pressure. Subsequent inhibition of 
cyclo-oxygenase had no additional effect on pulmonary vascular resistance (Fig. 
2).
The role of endothelin in the regulation of vascular tone
Systemic circulation. Administration of the mixed ETA/ETB antagonist tezosentan 
resulted in a small decrease in aortic blood pressure under resting conditions (Table 
1), which was caused by systemic vasodilation as demonstrated by a decrease of 
systemic vascular resistance and an increase in mixed venous O2 saturation (Fig. 
3). The vasodilator response to tezosentan waned progressively with incremental 
exercise intensity. Pretreatment with indomethacin enhanced the systemic 
vasodilation by tezosentan, particularly at rest. In contrast, pretreatment with the 
NO synthase inhibitor NLA enhanced the vasodilator response to tezosentan both 
at rest and during exercise. Finally, combined pretreatment with indomethacin 
and NLA caused a further increase in the vasodilator responses to tezosentan (Fig. 
3). These observations indicate that both prostanoids and NO blunt the endothelin 
vasoconstrictor inﬂ uence in the systemic circulation at rest and during exercise.
Pulmonary circulation. Tezosentan had no effect on the pulmonary circulation 
under resting conditions (Table 1, Fig. 4). In contrast during exercise, tezosentan 
reduced pulmonary artery pressure, with no effect on left atrial pressure and 
cardiac output (Table 1), reﬂ ecting a decrease in pulmonary vascular resistance 
(Fig. 4). Pre-treatment with indomethacin did not change the vasodilator response 
to tezosentan. In contrast, in the presence of NLA, the pulmonary vasodilator 
response to tezosentan was markedly enhanced. Additional pretreatment with 
indomethacin did not further enhance pulmonary vasodilation by tezosentan, as 
compared to NLA alone. These ﬁ ndings indicate that NO, but not prostanoids, blunts 
the vasoconstrictor response to ET in the pulmonary circulation during exercise.
Discussion   
The main ﬁ ndings in the present study in awake swine, free from the effects 
of anaesthesia and acute surgical trauma are that: (i) prostanoids blunt the 
vasoconstrictor inﬂ uence of ET in the systemic but not the pulmonary circulation, 
(ii) NO blunts the vasoconstrictor inﬂ uence of ET in both the systemic and 
pulmonary circulation, particularly during exercise, (iii) prostanoids and NO blunt 
the vasoconstrictor inﬂ uence of ET on the systemic bed in an additive manner, but 
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(iv) loss of NO does not unmask a role of prostanoids in blunting the vasoconstrictor 
inﬂ uence of ET in the pulmonary circulation.
Pulmonary vascular resistance during exercise
Exercise produced a small decrease in pulmonary vascular resistance, which 
was likely due to a decrease in vasomotor tone in the pulmonary resistance vessels. 
Pulmonary vasomotor tone is the resultant of an interplay between vasodilator 
and vasoconstrictor inﬂ uences, as is also illustrated by previous ﬁ ndings from 
our laboratory that α-adrenoceptor blockade [13] and ET-receptor blockade [8] 
induce pulmonary vasodilation, while β–adrenoceptor blockade [13] as well as NO 
synthase inhibition [6, 7] result in pulmonary vasoconstriction in exercising pigs. 
Importantly, the increase in pulmonary vascular resistance produced by blockade 
of vasodilator pathways was accompanied by an increase in pulmonary arterial 
pressure. Since an increase in pulmonary arterial pressure would act to cause a 
passive decrease in resistance, these studies indicate that the increase in pulmonary 
vascular resistance must have been the result of an increase in vasomotor tone, 
and further support the concept that the exercise-induced decrease in pulmonary 
vascular resistance is principally due to a decrease in pulmonary resistance vessel 
tone [14].
Role of endothelium in regulation of pulmonary vascular resistance
Nitric oxide. The role of endogenous NO in maintaining the low basal pulmonary 
vascular resistance is species dependent. Thus, while the majority of studies 
suggest a role for NO in the regulation of basal pulmonary vascular resistance in 
swine, sheep, horses and humans, most studies do not support such a role of NO 
in dogs (see [15] for references). The role of NO in the pulmonary vasodilation 
during exercise is similarly species dependent. Thus, despite causing a signiﬁ cant 
pulmonary vasoconstriction under resting conditions, NLA had no effect on the 
exercise-induced pulmonary vasodilation in sheep [16] or horses [17]. In contrast, we 
have consistently observed that NO synthase inhibition blunts the exercise-induced 
pulmonary vasodilation in swine [6, 7]. The results of the present study conﬁ rm our 
previous observations and indicate that signiﬁ cant interspecies differences exist 
with respect to vasomotor control mechanisms within the pulmonary resistance 
vessels [15].
Prostanoids. Inhibition of endogenous prostanoid production does not alter 
basal pulmonary vascular resistance in sheep [18] and swine [6], but causes 
vasoconstriction in dogs [19, 20]. In most species, endogenous prostanoids do also 
not appear to contribute to the exercise-induced pulmonary vasodilation [6, 18, 
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19]. It could be argued that the dose of indomethacin used in the present study 
was not sufﬁ cient to inhibit cyclo-oxygenase in the pulmonary circulation. This 
is unlikely, however, in view of our observation that indomethacin in a dose of 
10 mg·kg-1 does not produce a greater vasoconstrictor response in the systemic 
bed than 1 mg·kg-1 [6], suggesting a maximal effect. On the other hand, it 
cannot be excluded that cyclo-oxygenase inhibition may have gone without an 
apparent effect on pulmonary vascular resistance due to the opposing effects of 
simultaneously blocking vasodilator and vasoconstrictor prostanoids. Interestingly, 
the vasoconstrictor response to indomethacin in the systemic circulation was 
enhanced following NO synthase inhibition, which is likely due to the inhibition 
of prostacyclin synthase activity by NO and peroxynitrite [21]. In contrast, cyclo-
oxygenase inhibition in the presence of NLA still had no effect on pulmonary 
vascular resistance [22],[6] suggesting that prostacyclin activity was not increased 
following NO synthase inhibition. Future studies, using thromboxane A2 receptor 
antagonists or thromboxane A2 synthase inhibitors in conjunction with cyclo-
oxygenase inhibitors, are required to evaluate in detail the integrated control 
of pulmonary vascular resistance by vasodilator and vasocontrictor prostanoids 
during exercise.
Endothelin. ET-induced constriction is mediated by ETA receptors in the 
large pulmonary arteries, whereas it is mediated by ETB receptors in the smaller 
pulmonary resistance vessels [23]. In accordance with these ﬁ ndings, the density 
of ETA receptors in the lung decreases with decreasing vessel size, whereas the 
density of ETB receptors, both on the endothelium and the smooth muscle increases 
[24]. In our study, blockade of both ETA and ETB receptors did not affect pulmonary 
vascular resistance at rest, indicating that endogenous ET does not contribute to 
resting tone in the pulmonary resistance vessels. During exercise however, an ET-
mediated vasoconstriction became apparent, which contrasts with the blunted 
ET-mediated constriction in the systemic bed [8].
Interactions between NO, prostanoids and endothelin in the regulation of 
pulmonary vascular resistance
The present study shows that there is an interaction between NO and ET in 
the pulmonary and the systemic circulation. This interaction was demonstrated by 
the larger effect on systemic and pulmonary vascular resistance of combined ETA 
and ETB receptor blockade in the presence of NO synthase inhibition, as compared 
to the effect of combined ETA and ETB receptor blockade under control conditions. 
Possible mechanisms behind this interaction include modiﬁ cation by NO of ET 
production or ET receptor binding afﬁ nity [25, 26]. Indeed Kelly et al [27] showed 
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in vitro, that in pulmonary arterial endothelial cells, NO decreases endothelin-1 
secretion through the activation of soluble guanylyl cyclase. Moreover, Wiley and 
Davenport [12] showed that NO can modulate the binding of ET to the ET receptor. 
It has been suggested that the principal vasodilator effect of NO occurs through 
the inhibition of ET-induced constriction [25]. If this were the case, the level of 
vasodilation reached by ET-receptor blockade alone would be identical to the level 
of vasodilation obtained by the combined effect of ET-receptor blockade and NO 
synthase inhibition. At rest, pulmonary vascular resistance was signiﬁ cantly higher 
after combined administration of NLA and tezosentan compared to tezosentan 
alone, which indicates that NO acts predominantly in a direct manner (Fig. 5). 
However during exercise, pulmonary vascular resistance was only slightly higher 
(P<0.05 by ANCOVA) after combined administration of NLA and tezosentan as 
compared to administration of tezosentan alone. This suggests that, although a 
signiﬁ cant part of the vasodilator effect of NO on the pulmonary vasculature during 
exercise occurs via inhibition of ET, NO also has a direct vasodilator effect on the 
pulmonary circulation. In the systemic vasculature, the effect of NLA in control is 
approximately twice as large as the effect of NLA after tezosentan, indicating that 
the direct vasodilator effect of NO is approximately equal to the vasodilator effect 
of the NO-mediated inhibition of ET (Fig. 5).
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Figure 5: Effect of NO synthase 
inhibition (NLA) in the absence (left) 
and presence (right) of endothelin 
receptor blockade (Tezo) on the 
relation between body O2 consumption 
and systemic vascular resistance (upper 
panels) and on the relation between 
body O2 consumption and pulmonary 
vascular resistance (lower panels). 
*P<0.05 effect of NLA vs corresponding 
control, †P<0.05 effect of NLA in 
presence of Tezo vs NLA alone.
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In the systemic circulation, prostanoids limit ET-induced vasoconstriction, 
particularly after NO synthase inhibition. The mechanism behind the interaction 
between prostanoids and ET is not fully understood, but may involve inhibition 
of transcription, translation, secretion and/or action of ET by prostacyclin [28]. 
In contrast with the ﬁ ndings in the systemic circulation, our data do not support 
an interaction between prostanoids and ET in the pulmonary circulation under 
physiological conditions. Exogenous prostanoids can induce pulmonary vasodilation 
[22, 29, 30], indicating that prostacyclin receptors are present in the pulmonary 
circulation of swine, as. However, we previously found that inhibition of endogenous 
prostanoid production did not affect the low basal pulmonary vascular resistance 
either under normal conditions or in the presence of NO synthase inhibition 
[6]. Although we cannot exclude that cyclo-oxygenase inhibition may have 
gone without an apparent effect due to the opposing effects of simultaneously 
blocking vasodilator and vasoconstrictor prostanoids, it could also be argued that 
endogenous prostanoid production in the pulmonary circulation is too small under 
physiological conditions. This concept is supported by in vitro data by Wort et al 
[31], who found no cyclo-oxygenase protein in human pulmonary arterial smooth 
muscle cells under normal conditions. However, under stimulation with cytokines, 
which mimics pathological conditions, cyclo-oxygenase-2 protein expression could 
be detected, and inhibited the production of ET. Also the prostacyclin-mimetic 
cicaprost inhibited ET production [31]. Taken together, these data suggest that 
prostanoids can exert an inhibitory inﬂ uence on endothelin production in the 
pulmonary circulation, similar to what we found in the systemic vasculature. 
However, under physiological conditions, prostanoid levels may be insufﬁ cient 
to modulate pulmonary vasomotor tone and blunt the ET-induced pulmonary 
vasoconstriction during exercise.
Clinical relevance
Pulmonary arterial hypertension can arise from a multitude of etiologies. 
However, in the later stages of the disease, endothelial dysfunction becomes 
a central feature [5, 15]. Endothelial dysfunction is associated with a loss of 
endothelial vasodilator substances, including NO and prostanoids. The present study 
shows that under conditions of endothelial dysfunction, in particular a reduced NO 
bioavailability, exercise-induced pulmonary vasodilation is blunted and pulmonary 
hypertension during exercise is exacerbated, which is due to “unopposed” ET-
mediated pulmonary vasoconstriction. These observations support clinical studies 
that have shown the efﬁ cacy of ET-receptor antagonism and/or exogenous NO in 
the treatment of chronic pulmonary arterial hypertension [32-35].
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Abstract
We previously observed that pulmonary hypertension secondary to myocardial 
infarction (MI) in swine is characterized by elevated plasma endothelin (ET) levels 
and pulmonary vascular resistance (PVR). Consequently, we tested the hypothesis 
that an increased ET-mediated vasoconstrictor inﬂ uence contributes to secondary 
pulmonary hypertension after MI and investigated the involvement of ETA and ETB 
receptor subtypes. Chronically instrumented swine with (n=25) or without (n=19) 
MI were studied at rest and during treadmill exercise (up to 4 km h-1), in the 
absence and presence of the ETA antagonist EMD 122946 or the mixed ETA/ETB 
antagonist tezosentan. In normal swine, exercise caused a small decrease in PVR. 
ETA blockade had no effect on PVR at rest or during exercise. Conversely, ETA/
ETB blockade decreased PVR but only during exercise (from 3.0±0.1 mmHg min 
l-1 to 2.3±0.1 mmHg min l-1 at 4 km h-1; P≤0.05). MI increased pulmonary artery 
pressure and vascular resistance both at rest and during exercise (both P≤0.05). 
The increased pulmonary artery pressure correlated with the increased plasma 
ET levels in resting MI swine (r=0.71, P≤0.01). Furthermore, the pulmonary 
vasoconstrictor response to ET-1 infusion was enhanced after MI (P≤0.05). ETA/
ETB blockade decreased pulmonary resistance in MI swine from 3.6±0.3 to 3.1±0.5 
mmHg min l-1 at rest and from 3.4±0.3 to 2.4±0.2 mmHg min l-1 during exercise 
at 4 km h-1 (both P≤0.05). This increased response to mixed ETA/ETB blockade 
in MI compared to normal swine appeared to be the result of an increased ETA 
mediated vasoconstriction, as ETA blockade decreased pulmonary resistance in MI 
swine from 3.4±0.4 to 2.8±0.2 mmHg min l-1 at rest and from 3.1±0.3 to 2.6±0.2 
mmHg min l-1 at 4 km h-1 (both P≤0.05). In conclusion, increased plasma ET levels 
together with increased pulmonary resistance vessel responsiveness to ET result 
in an exaggerated pulmonary vasoconstrictor inﬂ uence of ET in swine with a 
recent MI. This vasoconstrictor inﬂ uence is the result of an emergent tonic ETA 
vasoconstriction in addition to the exercise-induced ETB vasoconstriction that is 
already present in normal swine. 
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Introduction
Congestive heart failure is the only major cardiovascular disorder of which 
the incidence has increased over the past decade, which is principally due to a 
reduction in mortality associated with acute myocardial infarction (MI) [1]. The 
loss of viable myocardial tissue after MI causes left ventricular dysfunction leading 
to an increase in left ventricular ﬁ lling pressure and neurohumoral activation 
particularly during exercise [2-4]. The increase in left ventricular ﬁ lling pressure 
is transmitted backwards into the pulmonary circulation, resulting in pulmonary 
congestion and an increase in pulmonary arterial blood pressure, thereby elevating 
right ventricular afterload [2, 5]. The resultant right ventricular hypertrophy is a 
risk factor for the development of right-sided heart failure [6].
In addition to the backward transmission of left atrial pressure into the pulmonary 
circulation, an elevated pulmonary vascular resistance, associated with activation 
of the endothelin system, also contributes to pulmonary hypertension secondary to 
MI [2, 7, 8]. Endothelin-1 (ET-1) is one of the most potent vasoconstrictors known 
to date and is produced in endothelial cells. Its role in pulmonary hypertension is 
supported by increased levels of circulating endothelin (ET), as well as increased 
local production [9-11].  Moreover, there is a correlation between ET plasma levels 
and severity of pulmonary hypertension in patients with  heart failure [12].
Both ETA and ETB receptors have been identiﬁ ed in the pulmonary vasculature 
[13, 14]. ETA and ETB receptors on vascular smooth muscle induce vasoconstriction, 
whereas ETB receptors on the endothelium induce vasodilation through production 
of NO and prostacyclin. We have previously shown, that endogenous ET-mediated 
pulmonary vasoconstriction in normal swine occurs predominantly through the 
ETB receptors [15], indicating that the vasoconstrictor effect of ETB receptors on 
vascular smooth muscle is larger than the vasodilator effect of ETB receptors on 
the endothelium, while ETA receptors have virtually no inﬂ uence on the pulmonary 
circulation. The endothelial ETB receptors are also responsible for the plasma 
clearance of ET in the lungs [16], which is reduced in relation with the severity of 
pulmonary hypertension in patients with chronic heart failure [17]. The reduced 
pulmonary clearance of ET and the increased plasma ET levels after MI suggest that 
ET can contribute to the aggravation of pulmonary hypertension. Indeed, studies 
in patients with pulmonary hypertension secondary to MI suggest that ETA as well 
as ETA/ETB receptor blockade are capable of improving clinical conditions [18]. 
However, to date no study has addressed the effect of ET receptor antagonists on 
pulmonary vascular resistance after MI.
The aim of the present study was therefore to test the hypothesis that an 
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increased ET vasoconstrictor inﬂ uence in the pulmonary circulation contributes to 
secondary pulmonary hypertension in swine with a recent MI. For this purpose, we 
ﬁ rst investigated in awake resting swine, whether plasma ET levels and pulmonary 
vascular responsiveness to exogenous ET are increased after MI. Subsequently, we 
investigated whether the vasoconstrictor inﬂ uence of endogenous ET was increased 
in the pulmonary circulation and assessed the role of ETA and ETB receptor subtypes 
in this process. Since in normal swine a pulmonary ET vasoconstrictor inﬂ uence 
emerges during exercise, but is negligible under resting conditions [15], the 
vasoconstrictor inﬂ uence of endogenous ET in MI swine was studied both at rest 
and during treadmill exercise.
Methods
Animals
Studies were performed in accordance with the Council of Europe Convention 
(ETS123)/ Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientiﬁ c purposes, and with approval of the Animal Care 
Committee at Erasmus Medical Center. A total of 47 Yorkshire X Landrace swine (2-
3-month-old, 22±1 kg at the time of surgery) of either sex entered the study. 
 
Surgery
Swine were sedated with ketamine (30 mg kg-1 im), anaesthetized with thiopental 
(10 mg kg-1 iv), intubated and ventilated with a mixture of O2 and N2O (1:2) to 
which 0.2-1% (v/v) isoﬂ urane was added [19, 20]. Anaesthesia was maintained 
with midazolam (2 mg/kg + 1 mg kg-1 per hour iv) and fentanyl (10 µg kg-1 per hour 
iv). Under sterile conditions, the chest was opened via the fourth left intercostal 
space and a ﬂ uid-ﬁ lled polyvinylchloride catheter was inserted into the aortic 
arch and pulmonary artery for blood pressure measurement (Combitrans pressure 
transducers, Braun, Melsungen, Germany) and blood sampling. An electromagnetic 
ﬂ ow probe (14-15 mm, Skalar) was positioned around the ascending aorta for 
measurement of cardiac output. A polyvinylchloride catheter was also inserted 
into the left atrium to measure pressure. In all 47 swine the proximal part of the 
left coronary circumﬂ ex artery (LCx) was exposed, but only in 22 animals the LCx 
was permanently occluded with a silk suture to produce an MI [2, 4]. Three MI 
swine died during surgery due to recurrent ﬁ brillation. Catheters were tunnelled 
to the back and animals were allowed to recover, receiving analgesia (0.3 mg 
buprenorphine im) for 2 days and antibiotic prophylaxis (25 mg kg-1 amoxicillin and 
5 mg kg-1 gentamycin iv) for 5 days.
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Resting protocols
Experimental Design. Resting studies were performed 17±1 days after surgery 
with animals resting quietly on the treadmill. A total number of 19 normal and 
18 MI swine were used in the resting protocols. In the ﬁ rst resting protocol we 
evaluated the effects of MI on resting hemodynamics and plasma ET levels. In the 
second resting protocol we evaluated the pulmonary resistance vessel responses to 
ET by intravenously infusing exogenous ET-1.
Pulmonary arterial pressure and plasma levels of ET. Plasma levels of ET were 
determined in 15 normal and 18 MI swine. Since we have recently shown that 
exercise does not affect plasma levels of ET in either normal swine or swine with 
MI [3], we elected to determine plasma ET levels only under resting conditions. 
Arterial blood samples (5 ml) in all swine were collected in tubes containing EDTA. 
Samples were centrifuged (3000g; 10 min; 4°C) and plasma was stored at -80°C. 
Plasma levels of ET-like immuno-reactivity were determined using a radio-immuno 
assay from Euro-Diagnostica (Malmö, Sweden), which has a cross reactivity of 100% 
toward ET-1, 48% toward ET-2 and 109% toward ET-3 [15]. Since production of ET-
2 and ET-3 appears to be absent in the cardiovascular system of the swine [21], 
the concentrations measured with the radio-immuno assay most likely represent 
ET-1. Resting hemodynamic measurements consisting of aortic, left atrial, and 
pulmonary artery blood pressures and cardiac output were obtained.
Exogenous ET-1 infusions. With swine (6 normal and 3 MI) resting quietly, 
resting hemodynamic measurements were obtained. Subsequently, ET-1 was 
infused iv via the pulmonary artery catheter at rates of 20 and 40 pmol kg-1 min-1 
and resting hemodynamic measurements were again obtained at the end of each 
10 min infusion period.
Exercise protocols
Experimental Design. Studies were performed 11±1 days after surgery with 
animals exercising on a motor-driven treadmill. The two exercise protocols were 
performed on different days and in random order. A total number of 14 normal and 
9 MI swine were used in the exercise protocols, of which 8 normal and 8 MI swine 
were also used in the resting protocols. In the ﬁ rst exercise protocol we evaluated 
the vasoconstrictor inﬂ uence of endogenous ET, using a mixed ETA/ETB receptor 
antagonist. In the second protocol we assessed the role of the ETA receptor subtype 
in the vasoconstrictor inﬂ uence of endogenous ET in MI swine, using a selective 
ETA receptor antagonist. We refrained from studying the effects of a selective ETB 
receptor antagonist, because the ETB receptor is responsible for clearance of ET in 
the lungs [16]. Hence, ETB blockade increases ET levels, which can then act through 
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the ETA receptor to cause vasoconstriction, thereby confounding interpretation of 
the results. Consequently, the contribution of the ETB receptor must be derived 
from the difference in response to the ETA and the ETA/ETB receptor antagonist.
Effects of combined ETA and ETB receptor blockade. With swine (13 normal 
and 9 MI) lying quietly on the treadmill, resting hemodynamic measurements 
consisting of left atrial, aortic and pulmonary artery blood pressures and cardiac 
output were obtained and arterial and mixed venous blood samples were 
collected. Hemodynamic measurements were repeated and rectal temperature 
measured with animals standing on the treadmill. Subsequently, a four stage 
exercise protocol (1, 2, 3, and 4 km h-1) was begun with each stage lasting 2-3 
min. Hemodynamic variables were measured and blood samples collected during 
the last 30 seconds of each exercise stage, when hemodynamics had reached a 
steady state. At the conclusion of the exercise protocol animals were allowed to 
rest for ninety min. Then, animals received the mixed ETA and ETB receptor (ETA/
ETB) antagonist tezosentan (a gift from Dr Clozel, Actelion Pharmaceuticals Ltd., 
Allschwill, Switzerland) intravenously over 10 min in a dose of 3 mg kg-1, followed 
by a continuous infusion of 6 mg kg-1 h-1 iv [15] and the exercise protocol was 
repeated. Tezosentan has a pA2 of 9.5 for ETA and a pA2 of 7.7 for ETB receptors, 
indicating only a 63-fold selectivity for ETA compared to ETB receptors [22, 23]. 
Moreover, we have previously shown that the employed dose of tezosentan blocks 
the pressor response to intravenous ET infusion and results in an increase in plasma 
ET levels, indicating that both ETA and ETB receptors are blocked [15].
Effects of ETA receptor blockade. Ninety min after swine (9 normal and 8 MI) 
underwent the exercise protocol under control conditions, swine received the ETA 
receptor antagonist EMD 122946 (a gift from Prof. Schelling, E. Merck Darmstadt, 
Darmstadt, Germany) in a dose of 3 mg kg-1 intravenously [15]. EMD122946 has 
a pA2 of 9.5 for ETA and a pA2 of 6.0 for ETB receptors, indicating a 3200-fold 
selectivity for ETA compared to ETB receptors [24]. EMD122946 in a dose of 3 mg 
kg-1 blocks the pressor response to intravenously infused ET. In contrast, this dose 
of EMD122946 does not block ETB receptors as ETB-mediated clearance of ET is 
not affected by administration of EMD122946 as evidence by unaltered ET-plasma 
levels [15]. Five minutes after completion of the infusion, resting measurements 
were obtained and the exercise protocol repeated.
Blood gas measurements 
Blood samples obtained in the exercise protocols, were kept in iced syringes 
until the conclusion of each exercise trial. Measurements of PO2 (mmHg), PCO2 
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(mmHg) and pH were then immediately performed with a blood gas analyser 
(Acid-Base Laboratory Model 505, Radiometer, Copenhagen, Denmark). Oxygen 
saturation (%) and haemoglobin (grams dl-1) were measured with a haemoximeter 
(OSM3, Radiometer). Blood O2 content (mmol ml
-1) was computed as (Hb·0.621·O2-
saturation) + (0.00131·PO2). Body O2 consumption (BVO2) was calculated as the 
product of cardiac output and the difference in O2 content between arterial and 
mixed venous blood [19, 20].
Data analysis
Digital recording and off-line analysis of hemodynamics have been described 
in detail elsewhere [19, 20]. Systemic vascular resistance was computed as mean 
aortic blood pressure divided by cardiac output. Pulmonary vascular resistance 
(PVR) was computed as mean pulmonary artery pressure minus mean left atrial 
pressure divided by cardiac output. 
Statistical analysis
The effect of MI on pulmonary arterial pressure and plasma ET levels was 
assessed using an unpaired t-test. The relation between endogenous ET and 
pulmonary arterial pressure was assessed using linear regression while statistical 
analysis of the effect of exogenous ET on systemic vascular resistance and PVR 
in normal versus MI swine was performed using analysis of variances (ANOVA). To 
test for the effects of MI and drug treatment (EMD 122946 or tezosentan) on the 
ET plasma level
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Figure 1: Pulmonary artery pressure (A) and ET plasma level (B) in 18 MI and 19 normal swine. C, shows 
the correlation between pulmonary artery pressure and ET plasma level in swine with MI (squares), 
while the data of normal swine are shown as mean±SEM (open circle). Inclusion of both MI and normal 
swine resulted in a highly similar correlation between pulmonary artery pressure (PAP) and ET plasma 
levels (PAP = 4.9ET + 3.5, r=0.703), as compared to inclusion of MI swine alone (PAP = 5.2ET + 3.6; 
r=0.708).*P≤0.05 MI versus normal swine
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relation between BVO2 and systemic vascular resistance or PVR, regression analysis 
was performed using MI, drug treatment and BVO2 as well as their interaction as 
independent variables and assigning a dummy variable to each animal. Statistical 
signiﬁ cance was accepted when P≤0.05. Data are presented as mean±S.E.M.
Results
Endothelin and myocardial infarction at rest
After MI, mean resting pulmonary artery pressure increased from 15±1 mmHg 
to 24±3 mmHg (Fig. 1A), which was in part the result of the increased mean left 
atrial pressure (4±1 mmHg in normal swine and 12±2 mmHg in MI swine). Resting 
ET plasma levels were elevated in MI (3.8±0.4 pmol l-1) compared to normal swine 
(2.7±0.3 pmol l-1, P≤0.05) (Fig. 1B). Furthermore, a signiﬁ cant correlation existed 
between pulmonary artery pressure and ET levels in MI swine (r=0.708; P≤0.01) 
(Fig. 1C), supporting a role for ET in pulmonary hypertension after MI. 
To investigate whether the responsiveness to ET is changed after MI, different 
dosages of ET-1 were infused. In the systemic circulation, ET-1 infusion resulted in 
a progressive increase in the vascular resistance that was similar in both normal 
and MI swine (Fig. 2). In contrast, whereas ET-1 in a dose of 20 pmol kg-1 min-1 
induced no signiﬁ cant change in PVR in either group of swine, ET-1 in a dose of 40 
pmol kg-1 min-1 produced a signiﬁ cantly greater increase in PVR in MI compared to 
normal swine (Fig. 2). 
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Changes in hemodynamics after a myocardial infarction at rest and exercise
Exercise up to 4 km h-1 in normal swine resulted in a tripling of BVO2 which 
was met by a doubling of cardiac output and a ~40% increase in O2 extraction 
(Fig. 3). The increase in cardiac output was principally due to an increase in heart 
rate, as stroke volume increased by only 7%. Mean aortic blood pressure was 
minimally affected (Table 1), implying that the increase in cardiac output was 
balanced by a similar decrease in systemic vascular resistance. Mean pulmonary 
artery pressure almost doubled in normal swine during exercise (Fig. 3). However, 
the transpulmonary pressure gradient (pulmonary artery pressure minus left atrial 
pressure) increased slightly less than cardiac output, reﬂ ecting a small decrease 
in PVR during exercise.
Despite a 17% lower stroke volume in MI compared to normal swine, cardiac 
output was virtually maintained both at rest and during treadmill exercise, which 
was the result of a higher heart rate (Fig. 3). The slightly lower cardiac output 
during exercise necessitated a small increase in O2-extraction, resulting in a 
decrease in mixed venous O2 saturation. Pulmonary artery pressure was elevated, 
which was due to a marked increase in left atrial pressure but also due to a ~15% 
increase in PVR (Fig. 3)
The role of endothelin in the regulation of vascular tone
In normal swine, ETA/ETB receptor blockade with tezosentan had no effect 
on the pulmonary circulation under resting conditions (Table 1, Fig. 4). During 
exercise, however, tezosentan reduced pulmonary arterial pressure with no effect 
on left atrial pressure and caused a small increase in cardiac output (Table 1), 
implying a decrease in PVR. The tezosentan-induced decrease in PVR increased 
progressively with incremental exercise intensity (Fig. 4). In contrast, the ETA 
receptor antagonist EMD 122946 had no effect on pulmonary artery or left atrial 
pressure in normal animals either at rest or during exercise (Table 2), so that PVR 
remained unchanged (Fig. 4). Hence in normal swine, the vasoconstrictor inﬂ uence 
of endothelin on the pulmonary circulation during exercise is mediated by ETB 
receptors.
In MI swine ETA/ETB receptor blockade caused a signiﬁ cant decrease in PVR at 
rest and during exercise (Fig. 4). ETA receptor blockade also resulted in vasodilation, 
demonstrated by a modest decrease in PVR at rest, which was maintained during 
exercise. The difference between the effect of ETA/ETB blockade and of ETA 
blockade alone (representing the ETB component) was unchanged in MI compared 
to normal swine (Fig. 4). Thus, the increased pulmonary vasoconstrictor inﬂ uence 
by endogenous ET in MI swine is principally mediated by ETA receptors
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Table 1: Haemodynamics of swine at rest and during exercise before and after administration of tezosentan 
      Rest           Exercise level (km h-1)        
  Treatment Infarct  lying standing   1     2     3     4   
HR Control -   128 ± 4 147 ± 4* 168 ± 5* 183 ± 5* 200 ± 5* 232 ± 7* 
(bpm) Tezosentan -   149 ± 4† 161 ± 5*† 183 ± 6*† 196 ± 7*† 212 ± 6*† 243 ± 7*† 
  Control +   147 ± 4‡ 158 ± 5* 187 ± 2*‡ 203 ± 4*‡ 219 ± 6*‡ 244 ± 8* 
  Tezosentan +   157 ± 4† 169 ± 4*† 190 ± 4* 205 ± 4* 222 ± 7* 243 ± 6* 
MAP Control -   95 ± 3 88 ± 3* 88 ± 2* 88 ± 2* 87 ± 2* 89 ± 2* 
(mmHg) Tezosentan -   88 ± 2† 79 ± 2*† 78 ± 2*† 77 ± 2*† 80 ± 2*† 81 ± 2*† 
  Control +   90 ± 2 83 ± 2* 81 ± 2*‡ 81 ± 2* 82 ± 3* 83 ± 3 
  Tezosentan +   80 ± 2†‡ 76 ± 2† 75 ± 2† 76 ± 2† 76 ± 2† 77 ± 2† 
PMAP Control -   15 ± 1 15 ± 1 19 ± 1* 21 ± 1* 23 ± 1* 28 ± 1* 
(mmHg) Tezosentan -   15 ± 1 13 ± 1* 17 ± 1† 18 ± 2*† 21 ± 1*† 25 ± 2*† 
  Control +   25 ± 3‡ 24 ± 2‡ 29 ± 2*‡ 31 ± 2*‡ 34 ± 2*‡ 38 ± 2*‡ 
  Tezosentan +   21 ± 2‡ 21 ± 2†‡ 25 ± 2†‡ 28 ± 2*†‡ 31 ± 2*‡ 33 ± 2*†‡ 
LAP Control -   4 ± 1 2 ± 1 4 ± 1 5 ± 1 6 ± 1* 8 ± 1* 
(mmHg) Tezosentan -   5 ± 1 0 ± 1* 3 ± 1 4 ± 1 6 ± 1* 9 ± 1* 
  Control +   12 ± 2‡ 10 ± 2‡ 13 ± 2‡ 14 ± 2‡ 16 ± 2*‡ 18 ± 2*‡ 
 Tezosentan +   11 ± 2‡ 10 ± 2‡ 12 ± 2‡ 15 ± 2*‡ 17 ± 2*‡ 18 ± 2*‡ 
CO Control -   3.3 ± 0.1 4.2 ± 0.2* 4.8 ± 0.2* 5.4 ± 0.2* 5.9 ± 0.2* 6.6 ± 0.3* 
(l min-1) Tezosentan -   3.7 ± 0.2† 4.4 ± 0.2*† 5.1 ± 0.3* 5.6 ± 0.3* 6.2 ± 0.3*† 7.0 ± 0.3*† 
  Control +   3.4 ± 0.1 3.9 ± 0.2* 4.7 ± 0.2* 5.0 ± 0.2* 5.5 ± 0.3* 5.9 ± 0.3* 
  Tezosentan +   3.5 ± 0.2 4.5 ± 0.3*† 5.1 ± 0.3* 5.5 ± 0.3*† 5.9 ± 0.3*† 6.3 ± 0.3*† 
SVR Control -  29 ± 1 22 ± 1* 19 ± 1* 17 ± 1* 15 ± 1* 14 ± 1* 
(mmHg min l-1) Tezosentan -  24 ± 1† 19 ± 1*† 16 ± 1*† 14 ± 1*† 13 ± 1*† 12 ± 1*† 
 Control +  27 ± 1 22 ± 1* 17 ± 1* 16 ± 1* 15 ± 1* 14 ± 0* 
 Tezosentan +  23 ± 1† 17 ± 1*† 15 ± 1* 14 ± 1*† 13 ± 1*† 12 ± 1*† 
Hb art Control -   8.0 ± 0.2  -  8.3 ± 0.2* 8.4 ± 0.2* 8.6 ± 0.2* 8.7 ± 0.2* 
(g dl-1) Tezosentan -   8.5 ± 0.3†  -  8.5 ± 0.2 8.6 ± 0.2 8.6 ± 0.2 8.6 ± 0.2 
  Control +   7.7 ± 0.3  -  8.0 ± 0.4 8.2 ± 0.4 8.5 ± 0.4* 8.6 ± 0.4 
  Tezosentan +   8.0 ± 0.3  -  8.4 ± 0.4* 8.2 ± 0.4 8.2 ± 0.3 8.3 ± 0.4 
O2Sat art Control -   93 ± 1  -  92 ± 1 92 ± 1 93 ± 1 92 ± 1 
(%) Tezosentan -   93 ± 1  -  92 ± 1* 93 ± 1 92 ± 1 92 ± 1 
  Control +   91 ± 1  -  89 ± 1 89 ± 1 90 ± 1‡ 90 ± 1‡ 
  Tezosentan +   91 ± 1  -  89 ± 1 90 ± 1‡ 89 ± 1‡ 89 ± 1‡ 
O2Sat mv Control -   49 ± 1  -  39 ± 1* 38 ± 1* 36 ± 1* 30 ± 1* 
(%) Tezosentan -   54 ± 1†  -  42 ± 1*† 41 ± 1*† 37 ± 1* 31 ± 2* 
  Control +   52 ± 2  -  34 ± 2* 33 ± 2*‡ 30 ± 2*‡ 23 ± 2*‡ 
  Tezosentan +   55 ± 1†  -  38 ± 1*‡ 35 ± 1*‡ 31 ± 2*‡ 23 ± 2*‡ 
BVO2 Control -  7.3 ± 0.3  -  13.1 ± 0.6* 15.3 ± 0.7* 17.6 ± 0.7* 21.8 ± 0.7* 
(mmol min-1) Tezosentan -  7.7 ± 0.3  -  13.5 ± 0.7* 15.3 ± 0.6* 18.3 ± 0.8* 22.5 ± 0.9* 
 Control +  6.8 ± 0.5  -  13.0 ± 0.8* 14.6 ± 0.9* 17.5 ± 1.3* 21.2 ± 1.2* 
 Tezosentan +  6.4 ± 0.4‡  -  13.6 ± 0.7* 15.5 ± 0.8* 17.9 ± 1.1* 21.8 ± 1.0* 
HR: Heart Rate, MAP: Mean Arterial Pressure, PMAP: Mean Pulmonary Arterial Pressure, LAP: Mean Left Atrial 
Pressure, CO: Cardiac Output. SVR: Systemic Vascular Resistance, Hb art:  Arterial Hemoglobin, O2sat art: Arterial 
Oxygen Saturation, O2Sat mv: Mixed Venous Oxygen Saturation, BVO2: Body Oxygen Consumption. Data are mean± 
S.E.M. from 13 normal and 9 MI swine; * P≤0.05 vs rest (lying); † P≤0.05 vs corresponding control, ‡ P≤0.05 vs 
corresponding normal swine
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Table 2: Haemodynamics of swine at rest and during exercise before and after administration of EMD 122946 
      Rest           Exercise level (km h-1)        
  Treatment Infarct  lying standing   1     2     3     4   
HR Control -   132 ± 6 146 ± 7* 168 ± 6* 182 ± 6* 201 ± 8* 232 ± 8* 
(bpm) EMD 122946 -   133 ± 5 150 ± 5* 173 ± 7* 190 ± 8* 211 ± 8* 247 ± 8*† 
  Control +   144 ± 5 159 ± 5* 190 ± 6*‡ 200 ± 7* 218 ± 8* 239 ± 6* 
  EMD 122946 +   152 ± 5‡ 163 ± 5* 177 ± 6* 199 ± 5* 215 ± 4* 241 ± 5* 
MAP Control -   90 ± 2 86 ± 3 82 ± 2* 83 ± 2* 84 ± 2* 87 ± 2 
(mmHg) EMD 122946 -   82 ± 2† 73 ± 2*† 72 ± 1*† 74 ± 2*† 76 ± 2*† 79 ± 1† 
  Control +   95 ± 2 84 ± 2* 81 ± 2* 81 ± 2* 83 ± 2* 83 ± 3* 
  EMD 122946 +   85 ± 2† 75 ± 2*† 74 ± 2*† 73 ± 2*† 75 ± 2*† 77 ± 2*† 
PMAP Control -   14 ± 1 15 ± 1 18 ± 1* 20 ± 2* 24 ± 2* 27 ± 2* 
(mmHg) EMD 122946 -   15 ± 1 14 ± 1 17 ± 1 20 ± 2* 23 ± 2* 27 ± 2* 
  Control +   21 ± 3 22 ± 2‡ 26 ± 2*‡ 28 ± 2*‡ 31 ± 2*‡ 34 ± 1*‡ 
  EMD 122946 +   20 ± 2‡ 19 ± 2 22 ± 2 26 ± 2*‡ 29 ± 2*‡ 33 ± 1*†‡ 
LAP Control -   4 ± 1 3 ± 2 4 ± 1 5 ± 1 8 ± 1* 9 ± 1* 
(mmHg) EMD 122946 -   2 ± 2 2 ± 2 2 ± 1 4 ± 2 6 ± 2* 9 ± 2* 
  Control +   10 ± 3‡ 9 ± 2‡ 11 ± 3‡ 12 ± 2‡ 15 ± 2‡ 17 ± 2*‡ 
  EMD 122946 +   10 ± 2‡ 7 ± 2* 9 ± 3‡ 12 ± 2‡ 14 ± 2*‡ 17 ± 2*‡ 
CO Control -   3.5 ± 0.2 4.3 ± 0.3* 4.9 ± 0.3* 5.4 ± 0.3* 5.9 ± 0.4* 6.7 ± 0.4* 
(l min-1) EMD 122946 -   3.6 ± 0.2 4.4 ± 0.2* 5.2 ± 0.2* 5.6 ± 0.3* 6.2 ± 0.4* 7.0 ± 0.4*† 
  Control +   3.3 ± 0.2 4.1 ± 0.3* 4.8 ± 0.3* 5.1 ± 0.3* 5.5 ± 0.3* 6.0 ± 0.3* 
  EMD 122946 +   3.6 ± 0.2 4.4 ± 0.2* 4.7 ± 0.2* 5.3 ± 0.3* 5.7 ± 0.3*† 6.3 ± 0.3*† 
SVR Control -  27 ± 2 21 ± 1* 17 ± 1* 16 ± 1* 15 ± 1* 14 ± 1* 
(mmHg min l-1) EMD 122946 -  23 ± 2† 17 ± 1*† 14 ± 1*† 14 ± 1*† 13 ± 1*† 12 ± 1*† 
 Control +  29 ± 2 21 ± 1* 17 ± 1* 16 ± 1* 15 ± 1* 14 ± 1* 
 EMD 122946 +  24 ± 1† 17 ± 1*† 16 ± 1* 14 ± 1*† 13 ± 1*† 12 ± 1*† 
Hb art Control -   7.9 ± 0.3  -  8.2 ± 0.3* 8.5 ± 0.3* 8.5 ± 0.3* 8.7 ± 0.3* 
(g dl-1) EMD 122946 -   8.0 ± 0.2  -  8.3 ± 0.2 8.4 ± 0.2* 8.5 ± 0.2* 8.4 ± 0.3 
  Control +   7.8 ± 0.5  -  7.9 ± 0.4 8.3 ± 0.4* 8.2 ± 0.5 8.4 ± 0.5 
  EMD 122946 +   8.0 ± 0.4  -  8.3 ± 0.3 8.3 ± 0.3 8.2 ± 0.3 8.4 ± 0.3 
O2Sat art Control -   93 ± 1  -  93 ± 1 92 ± 1 93 ± 1 92 ± 1 
(%) EMD 122946 -   92 ± 1  -  92 ± 0 92 ± 1 93 ± 1 92 ± 1 
  Control +   91 ± 1  -  91 ± 1‡ 91 ± 1 92 ± 1* 92 ± 1 
  EMD 122946 +   91 ± 1  -  90 ± 1 91 ± 1 91 ± 1† 91 ± 1† 
O2Sat mv Control -   49 ± 2  -  38 ± 2* 36 ± 1* 35 ± 2* 30 ± 2* 
(%) EMD 122946 -   53 ± 1†  -  41 ± 1* 39 ± 1*† 38 ± 1*† 32 ± 1*† 
  Control +   51 ± 1  -  36 ± 2* 35 ± 1 33 ± 1 26 ± 2* 
  EMD 122946 +   53 ± 2  -  40 ± 1* 37 ± 2* 33 ± 2* 25 ± 2* 
BVO2 Control -  7.6 ± 0.4  -  14.1 ± 1.2* 16.0 ± 0.7* 18.0 ± 1.3* 22.7 ± 1.5* 
(mmol min-1) EMD 122946 -  7.2 ± 0.5  -  13.9 ± 0.8* 15.6 ± 1.0* 18.1 ± 1.1* 22.4 ± 1.6* 
 Control +  6.6 ± 0.3  -  13.0 ± 0.7* 14.9 ± 0.8* 16.8 ± 1.3* 20.7 ± 1.2* 
 EMD 122946 +  7.1 ± 0.4  -  12.6 ± 0.5* 15.0 ± 0.6* 16.9 ± 0.8 21.8 ± 0.7* 
 HR: Heart Rate, MAP: Mean Arterial Pressure, PMAP: Mean Pulmonary Arterial Pressure, LAP: Mean Left Atrial 
Pressure, CO: Cardiac Output. SVR: Systemic Vascular Resistance, Hb art:  Arterial Hemoglobin, O2sat art: Arterial 
Oxygen Saturation, O2Sat mv: Mixed Venous Oxygen Saturation, BVO2: Body Oxygen Consumption. Data are mean 
± S.E.M. from 9 normal and 8 MI swine; * P≤0.05 vs rest (lying); † P≤0.05 vs corresponding control, ‡ P≤0.05 vs 
corresponding normal swine
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Administration of the ETA/ETB receptor antagonist tezosentan to normal swine 
resulted in a decrease in systemic vascular resistance, reﬂ ecting vasodilation in 
the systemic vasculature at rest and during exercise. There were no differences 
between the response to tezosentan and EMD 122946 in the systemic circulation 
of normal swine (Tables 1 and 2). In MI swine the ETA/ETB receptor blockade and 
ETA receptor blockade resulted in similar decreases of systemic vascular resistance 
compared to normal swine. These ﬁ ndings indicate that the ET vasoconstrictor 
inﬂ uence in the systemic circulation is principally ETA mediated and is not increased 
after MI.  
Discussion
The main ﬁ ndings in the present study in awake swine with pulmonary 
hypertension secondary to MI are that (i) circulating plasma levels of ET as well as 
the pulmonary vascular responsiveness to exogenous ET-1 are increased; (ii) the 
increase in ET-mediated vasoconstrictor inﬂ uence after MI is principally mediated 
by the ETA receptor; (iii) the pulmonary vasoconstrictor inﬂ uence of ET that is 
mediated through the ETB receptor is not altered as compared to normal swine; 
(iv) the vasoconstrictor inﬂ uence of endogenous ET in the systemic circulation did 
not change after MI. Since the role of ET in the systemic circulation, which has 
been discussed extensively in one of our previous papers [15], was not altered 
after MI, we will focus on the pulmonary circulation.
In agreement with previous studies from our laboratory [2, 25]), MI swine with 
a 2 wk old MI have LV dysfunction, characterized by a lower stroke volume and 
increased left atrial pressure. The accompanying increase in heart rate resulted in 
an essentially maintained cardiac output, indicating that overt congestive heart 
failure is absent [2, 25]. In agreement with clinical observations [12], and with 
previous observations from our own laboratory [2, 25], MI swine were characterized 
by increases in pulmonary arterial pressure and PVR. Furthermore, similar to clinical 
observations [12], we also found that the severity of pulmonary hypertension and 
the increase in plasma levels of ET were highly correlated. Moreover, the range 
of plasma ET levels after MI, which demonstrate increases of up to four-fold as 
compared to normal swine, is similar to that found in patients with pulmonary 
hypertension secondary to MI [12]. These observations indicate that our porcine 
model recapitulates several aspects of secondary pulmonary hypertension observed 
in patients after MI.
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Figure 4: The effects of the ETA/
ETB receptor antagonist tezosentan 
(13 normal and 9 MI swine) and the 
ETA receptor antagonist EMD122946 
(9 normal and 8 MI swine) on 
pulmonary vascular resistance (PVR) 
plotted as a function of body O2 
consumption (BVO2). Normal swine 
are represented by circles and MI 
swine are represented by squares. 
Control exercise trials are shown 
as open symbols, exercise trials 
in the presence of antagonists are 
shown as solid symbols. *P≤0.05 
effect of EMD 122946 or tezosentan 
vs corresponding Control, †P≤0.05 
effect of EMD 122946 vs effect of 
tezosentan, ‡P≤0.05 effect of EMD 
122946 or tezosentan in MI versus 
normal swine.
Elevation of plasma ET levels in pulmonary hypertension
In agreement with previous studies from our laboratory [2, 25], circulating 
levels of ET were increased after MI. These elevated ET levels could have been the 
result from decreased ET clearance, increased ET production, or both.
ET clearance. The pulmonary circulation, together with the kidneys and the 
liver, is the predominant site in the body for clearance of ET, with single pass-
clearance reaching values of up to 30-50% [11, 26]. This clearance is mediated 
through binding of ET to the ETB receptor on the pulmonary endothelium [16]. In 
the pulmonary circulation of healthy individuals the ET-production and clearance 
are balanced, such that there is no net difference between pulmonary arterial and 
venous ET plasma levels [11, 26]. In secondary pulmonary hypertension, increased 
plasma ET levels can be the result of decreased clearance of ET in the lungs. 
Indeed, in both experimental models and humans with heart failure, clearance of 
ET was shown to be reduced [17, 27, 28] although this was not a unanimous ﬁ nding 
[29].
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ET production. ET is produced from big-ET by endothelin-converting-enzym 
(ECE)-1, while big-ET is produced from preproendothelin by furin-like enzymes 
[30]. Hence, increases in either ECE activity or in preproendothelin levels could 
have contributed to an increase in ET production. The rate-limiting step in the ET 
production is thought to be the conversion from big-ET to ET by ECE-1. Increased 
ET-production in pigs with pacing-induced heart failure was attributed to an 
increased ECE-1 activity [29]. The ECE-1-isoform that is involved is still incompletely 
understood, but is most likely the ECE-1a isoform, as ECE-1a mRNA is upregulated, 
while ECE-1c mRNA appears to remain unaltered [31]. However, an upregulation 
of ECE-1 mRNA could not be conﬁ rmed in rats with either mild LV dysfunction or 
overt heart failure [32]. Conversely, the latter authors [32] as well as others [33] 
reported that increased preproendothelin mRNA levels in the lungs contribute to 
increased ET production in rats with MI-induced heart failure. However, in animals 
with mild LV dysfunction (resembling the porcine MI model in the present study) 
preproendothelin mRNA levels were still normal [32], suggesting that increased 
preproendothelin expression might be a feature of more advanced stages of heart 
failure. It should be noticed that in all these studies, involving protein and/or 
mRNA expression, total lung tissue is used. Since ECE-1 as well as preproendothelin 
are also present in bronchial epithelial cells [34-37] , interpretation of these 
studies using total lung tissue is difﬁ cult. Future studies using only pulmonary 
resistance vessels, are required to investigate the molecular alterations underlying 
an increased production of ET in more detail.
The mechanisms underlying the reported increases in ECE activity and/or 
preproendothelin levels in pulmonary hypertension secondary to LV failure are 
incompletely understood, but could be caused, at least in part, by endothelial 
dysfunction. Thus, in patients with secondary pulmonary hypertension due to heart 
failure, basal pulmonary NO production is reduced [10]. NO is capable of limiting 
ET-production [38-40], and in support of this concept, we recently found that loss 
of NO-synthesis, resulted in an enhanced pulmonary vasoconstrictor inﬂ uence of 
ET in normal swine [41]. However, we previously failed to observe a loss of the 
vasodilator inﬂ uence of NO in the pulmonary circulation after MI [25], suggesting 
that at this stage of LV dysfunction, the increased plasma ET levels are not the 
result of loss of NO bioavailability. Future studies, investigating the effects of ET 
receptor antagonists following NO synthase inhibition in swine with pulmonary 
hypertension after MI, are required to test this hypothesis more rigorously.
ET-receptor subtypes involved in pulmonary hypertension
ET-induced constriction of large pulmonary arteries is principally mediated by 
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ETA receptors [14, 42], whereas constriction in the smaller pulmonary resistance 
vessels is mediated by ETB receptors [14]. These ﬁ ndings are supported by 
observations that the density of ETA receptors in the lung decreases with decreasing 
vessel size, whereas the density of ETB receptors, both on the endothelium and the 
smooth muscle increases [13].
In normal swine, blockade of either ETA receptors alone or combined blockade 
of ETA and ETB receptors had no effect on PVR at rest, indicating that endogenous 
ET does not contribute to resting tone in the pulmonary resistance vessels [15]. 
During exercise, however, an ET-mediated vasoconstriction became apparent that 
was ETB receptor-mediated with no contribution of ETA receptors [15, 41]. This 
ETB-mediated vasoconstriction that limits the pulmonary vasodilation in response 
to exercise [15], is consistent with the localization of the ETB receptors on the 
pulmonary resistance vessels [13].
In swine with secondary pulmonary hypertension, the increased pulmonary 
vasodilator response to mixed ETA/ETB receptor blockade was increased in MI 
compared to normal swine. Both plasma ET levels and sensitivity of the pulmonary 
circulation to exogenous ET (via intravenous infusion) were increased, and likely 
acted in concert to increase the pulmonary vasoconstrictor inﬂ uence of ET in MI 
swine. Although we cannot entirely exclude that other neurohormones, including 
noradrenaline and angiotensin II, contributed to the increased pulmonary resistance 
vessel tone after MI, it is important to note that mixed ETA/ETB receptor blockade 
abolished the differences in pulmonary vascular resistance between normal and MI 
swine (see Fig. 4). This ﬁ nding is consistent with the concept that an increased ET 
vasoconstrictor inﬂ uence was principally responsible for the increase in pulmonary 
resistance vessel tone after MI.
Although the ETA receptor does not contribute to the regulation of pulmonary 
vasomotor tone in normal swine at rest or during exercise, an ETA-mediated 
vasoconstriction emerged after MI. This ETA-mediated vasoconstriction appeared 
tonic in nature, so that it did not increase further during exercise. This increased 
vasoconstrictor inﬂ uence of the ETA receptor may also have contributed to the 
increased pulmonary sensitivity to exogenous ET. This is in accordance with a study 
in pigs with pacing-induced heart failure, that showed that ETA receptor mRNA and 
ETA binding are increased [31]. Similarly, data in dogs show that, while pulmonary 
vasoconstriction in response to exogenous ET is predominantly mediated through 
the ETB receptor in normal dogs, there is an ETA-mediated component in dogs 
with pacing-induced heart failure [43]. Conversely, Docherty and MacLean [44] 
investigated the effect of ET on isolated pulmonary arterioles in animals with MI 
using ET receptor agonists and antagonists, and found no contribution of the ETA 
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receptor to pulmonary vasoconstriction in either normal rabbits or rabbits with MI. 
Similarly, several studies in rats show no alterations in ETA mRNA and/or protein 
expression in the lung after myocardial infarction [32, 45]. However, in all studies, 
involving protein and/or mRNA expression, total lung tissue is used. Since ETA as 
well as ETB receptors are also present in bronchial airway smooth muscle and lung 
alveoli [46], interpretation of these studies using total lung tissue is difﬁ cult.
Comparison of the vasodilator effect of ETA and ETA/ETB receptor blockade 
in normal and MI swine suggests that the contribution of the ETB receptor to the 
regulation of pulmonary vasomotor tone remained unaltered after MI. These data 
are in apparent contrast with the majority of studies on ETB receptor expression, 
both at the level of mRNA [32, 47] and the level of protein binding [31, 45], that 
indicate that ETB receptor expression as well as ETB mediated clearance are 
reduced in lungs of animals with heart failure. However, in these studies, ETB 
receptors on the endothelial cells and on the vascular smooth muscle cells cannot 
be distinguished. It is therefore possible that ETB receptors on the endothelium, 
which are responsible for vasodilation and clearance, are reduced to the same 
extent as ETB receptors on vascular smooth muscle, which induce vasoconstriction. 
The net effect would then be that the ETB-mediated vasoconstriction to endogenous 
ET would remain more or less constant, while clearance is reduced.
Clinical relevance
In the treatment of pulmonary hypertension, ET antagonism is a promising 
therapy. There are several clinical trials that demonstrate improvement in 
hemodynamics and exercise capacity and reduction in the number of clinical 
events after administration of an ETA receptor antagonist or a mixed ETA/ETB 
receptor antagonist [48-51]. It has been proposed that ETA receptor blockade would 
be favourable because it leaves the ETB-mediated clearance of ET as well as the 
endothelium ETB mediated pulmonary vasodilation unaffected. However, comparison 
of clinical trials using either ETA or combined ETA/ETB receptor antagonists [18], 
suggests that exercise capacity of patients with pulmonary hypertension improves 
more with combined ETA/ETB than with ETA receptor antagonists. The observations 
in the present study in MI swine provide further rationale for the use of combined 
ETA/ETB receptor antagonism in patients with secondary pulmonary hypertension. 
This important issue is currently being investigated in the prospective STRIDE-2 
clinical trial, comparing treatment with ETA receptor antagonism versus combined 
ETA/ETB receptor antagonism [52, 53].
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Abstract
Secondary pulmonary hypertension after myocardial infarction (MI) has been 
associated with endothelial dysfunction and activation of the endothelin (ET) sys-
tem. Here, we investigated whether an increased ET-mediated pulmonary vaso-
constrictor inﬂ uence contributes to pulmonary hypertension after MI, and whether 
this increased ET vasoconstriction is caused by impaired NO and prostanoid pro-
duction. For this purpose, chronically instrumented swine with and without MI 
ran on a treadmill at 0-4 km h-1.  Mixed ETA /ETB receptor blockade (tezosentan) 
was performed in the absence and presence of single or combined endothelial NO 
synthase (eNOS, with Nω-Nitro-L-arginine) and cyclo-oxygenase (COX, with indo-
methacin) inhibition. In normal swine, mixed ETA /ETB blockade decreased pul-
monary vascular resistance, but only during exercise. In MI swine, an increased 
ET-mediated vasoconstrictor inﬂ uence was observed in the pulmonary circulation 
both at rest and during exercise. Inhibition of COX resulted in pulmonary vasocon-
striction at rest in MI, but not in normal swine; this vasoconstriction in MI swine 
was normalized by ETA /ETB receptor blockade. Inhibition of eNOS enhanced the 
vasodilator response to ETA /ETB blockade, indicating that NO blunts the pulmonary 
vasoconstrictor inﬂ uence of ET. However, this vasodilator response was enhanced 
to a similar degree in MI and normal swine. In summary, swine with a recent MI are 
characterized by an exaggerated pulmonary vasoconstrictor inﬂ uence of ET. This 
increased ET- mediated pulmonary vasoconstrictor inﬂ uence is not caused by a loss 
of NO bioavailability, and is blunted by an increased prostanoid-mediated vasodila-
tion. In conclusion, an increased ET-mediated vasoconstriction, which does not ap-
pear to be the result of loss of endothelial vasodilators, contributes to pulmonary 
hypertension after MI.
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Introduction   
Myocardial infarction (MI) results in decreased left ventricular (LV) function, 
thereby increasing LV ﬁ lling pressures. These increased LV ﬁ lling pressures are 
transmitted backwards into the pulmonary circulation, leading to an increase 
in pulmonary arterial pressure (PAP). This so called “secondary pulmonary 
hypertension” is frequently associated with a ‘reactive’ increase in pulmonary 
vascular resistance (PVR), resulting in a further increase in PAP [1]. Thus, the 
pulmonary circulation after MI is characterized by elevated PAP and PVR, which 
increase the afterload of the right ventricle (RV) and may contribute to RV 
dysfunction and eventually RV failure [2].
Pulmonary hypertension is exacerbated during exercise, as the vasodilator 
capacity of the pulmonary vasculature is reduced [3-5]. Moreover, in patients with 
heart failure, exercise capacity is inversely correlated with PVR and the failure 
to decrease PVR during exercise [6]. The mechanism underlying the pulmonary 
vasoconstriction after MI is still incompletely understood, but may involve 
alterations in serotonin, thromboxane A2, angiotensin-II [7] as well as endothelial 
dysfunction [1, 8]. Under normal, physiological conditions, the endothelium plays a 
key role in maintaining vascular homeostasis by carefully balancing the production 
of vasodilators such as nitric oxide (NO) and prostacyclin, and vasoconstrictors 
such as endothelin (ET). Moreover, NO [9-12] and prostacyclin [13, 14] can limit 
the production and/or reduce receptor sensitivity of ET, while ET, by binding to the 
ETB receptor on the endothelium, stimulates the production of NO and prostanoids 
[9, 15-18]. Indeed, we have recently shown that in the pulmonary circulation of 
normal swine endogenous NO blunts the vasoconstrictor inﬂ uence of ET, thereby 
maintaining a low PAP and PVR particularly during exercise [19].
In general, an increase in shear stress results in an increased production of 
NO and prostanoids [20], while an increase in intravascular pressure may increase 
the production of ET [21, 22]. Hence, following MI, a lower cardiac output may 
contribute to a reduced production of NO and prostanoids [23-25] while the 
increased PAP may contribute to an increased production of ET [26], by the 
pulmonary endothelial cells. This imbalance between production of vasodilators 
and vasoconstrictors likely contributes to the sustained state of pulmonary 
vasoconstriction after MI. In support of this concept, we recently observed an 
increased ET-mediated vasoconstrictor inﬂ uence in the pulmonary circulation after 
MI [27]. Interestingly, the vasodilator inﬂ uence of endogenous NO appeared to be 
maintained [28], while perturbations in the vasomotor inﬂ uence of prostanoids 
have not been investigated to date.
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In light of these considerations, the aim of the present study was to 
investigate alterations in integrated endothelial control of pulmonary vascular 
tone in swine with secondary pulmonary hypertension following a recent MI. 
Speciﬁ cally, we investigated whether the increased pulmonary vasoconstrictor 
inﬂ uence of endogenous ET after MI is due to a decreased inﬂ uence of NO and/or 
prostanoids, or whether the increased ET vasoconstriction occurs independent of 
these endothelial vasodilators. For this purpose we investigated the effects of ET 
receptor blockade in the absence and presence of single or combined NO synthase 
(NOS) and cyclo-oxygenase (COX) inhibition. In view of the increased contribution 
of ET to pulmonary vasomotor tone during exercise [27], and the close correlation 
between plasma ET levels and exercise capacity in patients with heart failure [29] 
we investigated the interaction between NO, prostanoids and ET at rest and during 
graded treadmill exercise.
Methods
Animals 
Studies were performed in accordance with the Council of Europe Convention 
(ETS123)/ Directive (86/609/EEC) for the protection of vertebrate animals used for 
experimental and other scientiﬁ c purposes, and with approval of the Animal Care 
Committee of the Erasmus Medical Center. Thirty-four 2-3-month-old Yorkshire X 
Landrace swine (22±1 kg at the time of surgery) of either sex entered the study. 
After completing all experimental protocols, animals were killed by an intravenous 
overdose of pentobarbitone sodium.
Surgery 
Swine were sedated with ketamine (30 mg·kg-1 im), anaesthetized with 
thiopental (10 mg·kg-1  iv), intubated and ventilated with a mixture of O2 and N2O 
(1:2) to which 0.2-1% (v/v) isoﬂ urane was added [30]. Anaesthesia was maintained 
with midazolam (2 mg kg-1 + 1 mg kg-1 h-1 iv) and fentanyl (10 µg kg-1 h-1  iv); 
depth of anaesthesia was checked regularly using a pain stimulus (toe-pinch). 
Under sterile conditions, the chest was opened via the fourth left intercostal 
space and a ﬂ uid-ﬁ lled polyvinylchloride catheter was inserted into the aortic arch 
for aortic blood pressure measurement (Combitrans pressure transducers, Braun) 
and blood sampling. A calibrated electromagnetic ﬂ ow probe (14-15 mm, Skalar) 
was positioned around the ascending aorta for measurement of cardiac output. 
Polyvinylchloride catheters were inserted into the left atrium to measure pressure, 
and into the pulmonary artery to measure pressure, administer drugs and collect 
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mixed venous blood samples. In 14 swine the circumﬂ ex artery was permanently 
occluded with a suture to induce MI of the lateral left ventricular wall (infarct 
size ~20% of the left ventricle [28, 31]). Catheters were tunnelled to the back and 
animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine im) for 
2 days and antibiotic prophylaxis (25 mg kg-1 amoxicillin and 5 mg kg-1 gentamycin 
iv) for 5 days. Three MI swine died in the ﬁ rst week after surgery.
 
Experimental protocols 
Studies were performed ~2 weeks after surgery with animals exercising on 
a motor driven treadmill. We previously demonstrated excellent reproducibility 
of the cardiovascular response to consecutive exercise trials with 90 minutes of 
rest in between in both normal swine [30] and MI swine [28, 32]. In the present 
study, four exercise protocols were performed on different days and in random 
order. Most swine participated in several protocols. Overlap of animals between 
protocols is shown in Table 1. We have previously published part of our data on 
endothelial control of pulmonary vasomotor tone in normal swine [19] and on the 
role of endothelin in control of pulmonary vasomotor tone in MI swine [27].
Endothelin. With swine (Normal, n=17 and MI, n=9) lying quietly on the 
treadmill, resting hemodynamic measurements, consisting of heart rate, cardiac 
output, mean aortic pressure (MAP), mean pulmonary arterial pressure (PAP), 
and mean left atrial pressure (LAP) were obtained and blood samples collected. 
Hemodynamic measurements were repeated and rectal temperature was measured 
with animals standing on the treadmill. Subsequently, a four-stage (1-4 km h-1) 
treadmill exercise protocol was started; each exercise stage lasted 2-3 min. This 
exercise protocol results in heart rates of 230-240 beats per minute, which equals 
approximately 85% of the estimated maximal heart rate of these animals [31, 32]. 
Hemodynamic variables were continuously recorded and blood samples collected 
during the last 45 s of each stage. The signal of the electromagnetic ﬂ ow probe 
was calibrated using an electric signal and the zero-value was set during diastole. 
Fluid-ﬁ lled pressure-transducers were positioned on the back of the animals and 
calibrated at mid-chest level. After completing the exercise protocol animals 
were allowed to rest on the treadmill for 90 min after which the mixed ETA /ETB 
receptor antagonist tezosentan (a gift from Dr Clozel, Actelion Pharmaceuticals 
Ltd.) was intravenously administered over 10 min in a dose of 3 mg kg-1, followed 
by a continuous infusion of 6 mg kg-1 h-1  iv [33], and the exercise protocol was 
repeated. We have previously shown that this dose of tezosentan abolished the 
~35 mmHg increase in arterial pressure in response to administration of exogenous 
endothelin in a dose of 50 ng kg-1 min-1 [33].
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Prostanoids and endothelin. Ninety min after 10 Normal and 9 MI swine had 
undergone a control exercise trial (as described above), animals received the cyclo-
oxygenase inhibitor indomethacin ((Sigma) 10 mg kg-1  iv over 10 min [34]) and 5 
min later underwent a second exercise trial. Ninety min later, animals received 
indomethacin in a dose of 5 mg kg-1 iv, which resulted in hemodynamic conditions 
that were identical to those following administration of 10 mg kg-1 prior to the 
second exercise trial [19]. Subsequently, animals received tezosentan (3 mg kg-1  iv 
+ 6 mg kg-1 h-1  iv) and underwent a third exercise trial. 
NO and endothelin. Ninety min after 10 Normal and 7 MI swine had undergone 
a control exercise trial, animals received the NO-synthase inhibitor Nω-nitro-L-
arginine (NLA (Sigma), 20 mg kg-1  iv; [30, 34]), and underwent a second exercise 
trial. Ninety min later, animals received tezosentan (3 mg kg-1  iv + 6 mg kg-1 h-1  iv) 
and underwent a third exercise trial. 
NO, prostanoids and endothelin. Ninety min after 7 Normal and 7 MI swine 
underwent an exercise trial in the presence of NLA (20 mg kg-1  iv) and indomethacin 
(10 mg kg-1  iv), animals received indomethacin (5 mg kg-1  iv) and tezosentan (3 mg 
kg-1  iv and 6 mg kg-1 h-1  iv) and underwent a second exercise trial [19]. 
Blood gas measurements 
Blood samples were kept in iced syringes until the conclusion of each exercise 
trial. Measurements of PO2 (mmHg), PCO2 (mmHg) and pH were then immediately 
performed with a blood gas analyser (Acid-Base Laboratory Model 505, Radiometer, 
Copenhagen, Denmark), and corrected for body temperature. O2 saturation (%) 
and haemoglobin (grams per 100 ml) were measured with a hemoximeter (OSM3, 
Radiometer). Blood O2 content (μmol ml
-1) was computed as (Hb 0.621 O2-saturation) 
+ (0.00131 PO2). Body O2 consumption (BVO2) was calculated as the product of 
cardiac output and the difference in O2 content between arterial and mixed venous 
blood [30, 35].
 
Table 1 Schematic representation of the overlap of animals used in the various protocols 
Protocol Con-Tezo Indo-Tezo NLA-Tezo NLA-Indo-Tezo Total 
Con-Tezo 17N / 9MI 8N 9N 7N  
Indo-Tezo 8MI 10N / 9MI 3N 3N  
NLA-Tezo 6MI 7MI 10N / 7MI 6N  
NLA-Indo-Tezo 5MI 6MI 6MI 7N / 7MI  
Total     20N / 11MI 
:
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Data analysis 
Digital recording and off-line analysis of hemodynamics have been described 
previously [30, 35]. Systemic vascular resistance (SVR) was computed as mean 
aortic blood pressure divided by cardiac output. Pulmonary vascular resistance 
(PVR) was computed as mean pulmonary arterial pressure minus mean left atrial 
pressure divided by cardiac output [34].
Statistical analysis 
Hemodynamic data were digitally recorded and analysed off-line. Hemodynamic 
variables were analysed using analysis of variance (ANOVA) for repeated measures. 
Post-hoc testing was done using Dunnett’s test. The relationships between BVO2 
and SVR and PVR were analysed using multiple regression analysis with BVO2, 
tezosentan, NLA, indomethacin and their interactions as independent variables 
and with each animal as a dummy variable for normal animals and animals with 
MI separately (Statview). Subsequently, interaction between the drugs and MI was 
included in the regression analysis. Statistical signiﬁ cance was accepted when P≤ 
0.05. Data are presented as mean ± S.E.M. Since no signiﬁ cant differences were 
found between male and female swine, data from both sexes were pooled.
Results
Hemodynamic responses to exercise in normal and MI swine
Exercise up to 4 km h-1 in normal swine resulted in a tripling of BVO2 which was 
met by a doubling of cardiac output and an increase in O2 extraction from 47±1% 
to 67±1% (Fig. 1). The increase in cardiac output was principally due to an increase 
in heart rate, as stroke volume increased by only 7%. Mean aortic blood pressure 
was minimally affected, implying that the increase in cardiac output was balanced 
by a similar decrease in systemic vascular resistance (Table 2). In contrast, mean 
pulmonary arterial pressure almost doubled in normal swine during exercise (Fig. 
1). The transpulmonary pressure gradient (pulmonary arterial pressure minus left 
atrial pressure) increased commensurate with cardiac output, so that PVR did not 
change during exercise.
The 18% lower stroke volume in MI compared to normal swine was accompanied 
by an increase in heart rate. Yet, the increase in heart rate did not fully compensate 
for the decrease in stroke volume. Hence, cardiac output was slightly lower at all 
levels of treadmill exercise, which necessitated a small increase in O2-extraction 
that resulted in a further decrease in mixed venous O2 saturation during exercise 
in MI compared to normal swine (Fig. 1, Table 3). However, aerobic metabolism 
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was still maintained as arterial (Table 4 and 5) and mixed venous (not shown) pH 
and HCO3
- were not different between normal swine and swine with MI. Pulmonary 
arterial pressure was signiﬁ cantly elevated in MI swine both at rest and during 
exercise, which was principally due to a marked increase in left atrial pressure but 
also due to a ~20% increase in PVR (Fig. 1). 
Regulation of pulmonary vascular tone in health and disease
140
Role of NO and prostanoids in the regulation of vascular tone 
Systemic circulation. Administration of the eNOS inhibitor NLA or the cyclo-
oxygenase inhibitor indomethacin resulted in a pressor response due to systemic 
vasoconstriction as evidenced by marked increases in mean arterial pressure and 
SVR in both normal and MI swine (Fig. 2, Table 2 and 3). As a result heart rate 
decreased, while stroke volume was not altered, resulting in a decrease in cardiac 
output. During exercise the systemic vasoconstriction and the pressor response 
to indomethacin were progressively blunted, whereas the pressor response and 
systemic vasoconstriction in response to NLA was unaltered (Fig. 2,Table 2 and 3).
Pretreatment with NLA enhanced the vasoconstriction induced by indomethacin 
particularly at rest, as evidenced by an exaggerated increase in SVR in normal 
swine, indicating that NO and prostanoids act synergistically to maintain a low 
vasomotor tone. Yet, despite the enhanced response at rest, exercise-induced 
vasodilation was unmitigated in the presence of both NLA and indomethacin (Fig. 
2). In contrast to the ﬁ ndings in normal swine, the vasoconstrictor response to 
indomethacin was not altered by pretreatment with NLA in swine with MI either at 
rest or during exercise.
Pulmonary circulation. Indomethacin had no effect on the PVR either during 
rest or exercise in normal swine; however PVR increased by 42±8% in response to 
indomethacin at rest, but not during exercise in MI swine (P≤0.05). Administration 
of NLA produced a similar rise in PVR in normal and MI swine at rest, which persisted 
during exercise (Fig. 3). Subsequent inhibition of COX with indomethacin resulted 
in a 71±18% increase in PVR in MI swine at rest (P≤0.05), but did not increase PVR 
in either normal or MI swine during exercise (Fig. 3).
The pulmonary hemodynamic effects of indomethacin and NLA did not result 
in impaired pulmonary gas exchange in either normal (Table 4) or MI swine (Table 
5). Thus, arterial PO2 was not altered by NLA in either group, while indomethacin 
actually produced a small increase in arterial PO2 that was however similar in both 
groups of swine. In view of the small indomethacin-induced decrease in arterial 
PCO2, it is likely that this was caused by mild hyperventilation.
The role of endothelin in the regulation of vascular tone
Systemic circulation. Administration of the mixed ETA/ETB antagonist tezosentan 
resulted in a decrease of mean arterial pressure and SVR in both normal and MI 
swine. The systemic vasodilation resulted in a compensatory, probably baroreﬂ ex 
mediated increase in heart rate and cardiac output (Table 2 and 3).  The tezosentan-
induced vasodilator response diminished with increasing exercise levels (Fig. 2). 
Pretreatment with the eNOS inhibitor NLA enhanced the vasodilator response 
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to tezosentan at rest and during exercise in both normal and MI swine (Fig. 2). 
Administration of COX-inhibitor indomethacin prior to tezosentan, increased the 
vasodilator response to tezosentan at rest, but only in MI swine, however this 
effect waned with exercise (Fig. 2). In normal swine, combined administration 
of indomethacin and NLA increased the vasodilator responses to tezosentan even 
further, particularly at rest (Fig. 2). These observations suggest that both NO and 
prostanoids blunt the vasoconstrictor effects of ET in the systemic circulation. 
Although plasma-ET levels were increased following MI (3.9±0.5 pM vs 2.3±0.3 pM 
in normal swine, P≤0.05), myocardial infarction did not change the vasodilator 
effect of tezosentan on the systemic circulation after administration of NLA or 
indomethacin alone (Fig. 2), indicating that after MI, NO and prostanoids still exert 
part of their vasodilator effect through inhibition of ET-induced vasoconstriction. 
However, the effect of tezosentan after combined administration of NLA and 
indomethacin was reduced in swine with MI as compared to normal swine, and 
was similar to the effect of tezosentan in the presence of NLA or indomethacin 
alone (Fig. 2). Thus, the vasoconstrictor effect of ET in the systemic circulation 
is limited by NO and prostanoids, but loss of both NO and prostanoids does not 
result in further activation of the ET system as compared to loss of one of these 
compounds (Fig. 2).
Pulmonary circulation. Administration of tezosentan did not exert any effect 
on the pulmonary circulation of normal swine at rest. However, during exercise 
pulmonary arterial pressure and pulmonary vascular resistance decreased in 
response to administration of tezosentan (Fig. 3). In agreement with our previous 
observations [27], the vasodilator response to tezosentan was more pronounced 
in MI swine as compared to normal swine (Fig. 3). Tezosentan had no effect on 
arterial blood gas values in either normal (Table 4) or MI swine (Table 5).
Pretreatment with NLA markedly augmented the vasodilator effect of tezosentan 
at rest as well as during exercise in normal swine and swine with MI (Fig. 3), 
indicating that NO limits the ET-induced pulmonary vasoconstriction to the same 
extent in both groups. Pretreatment with indomethacin did not affect vasodilation 
in response to tezosentan in normal swine. However, indomethacin resulted in an 
increase in the vasodilator response to tezosentan in MI swine particularly at rest 
(Fig. 3), indicating that prostanoids limit ET-induced pulmonary vasoconstriction 
in swine with MI. In the presence of NLA, the pulmonary vasodilator effect of 
tezosentan in normal swine was not affected by administration of indomethacin 
(Fig. 3). In contrast, in swine with MI, the effect of tezosentan was smaller in the 
presence of NLA and indomethacin as compared to the presence of NLA alone (Fig. 
3).
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    Rest Exercise level (km/h)
Treatment bl      standing 1 2 3 4
HR (bpm)
Control 131 ± 4 148 ± 4* 170 ± 4* 185 ± 4* 202 ± 5* 233 ± 6*
Tezo 150 ± 4‡ 162 ± 4*‡ 185 ± 5*‡ 185 ± 7*‡ 215 ± 6*‡ 244 ± 7*‡
Indo 86 ± 7† 97 ± 5*† 121 ± 6*† 134 ± 6*† 150 ± 6*† 174 ± 5*†
Indo + Tezo 97 ± 7†‡ 112 ± 5*†‡ 128 ± 6*† 141 ± 6*† 157 ± 7*† 178 ± 8*†
LNNA 103 ± 6† 120 ± 4*† 132 ± 5*† 142 ± 5*† 159 ± 5*† 191 ± 6*†
LNNA + Tezo 118 ± 5‡ 141 ± 6*‡ 152 ± 6*†‡ 160 ± 6*†‡ 179 ± 6*†‡ 204 ± 6*†‡
LNNA + Indo 82 ± 4† 95 ± 6*† 112 ± 6*† 121 ± 8*† 134 ± 7*† 164 ± 9*†
LNNA + Indo + Tezo 101 ± 8 116 ± 7*‡ 128 ± 6*‡ 141 ± 8* 155 ± 10*†‡ 179 ± 9*†
CO (l/min)
Control 3.8 ± 0.2 4.6 ± 0.2* 5.3 ± 0.3* 5.9 ± 0.3* 6.5 ± 0.3* 7.3 ± 0.3*
Tezo 4.2 ± 0.2‡ 4.8 ± 0.3* 5.7 ± 0.3* 6.2 ± 0.3* 6.9 ± 0.4*‡ 7.7 ± 0.4*‡
Indo 2.6 ± 0.3† 3.2 ± 0.3*† 4.1 ± 0.3*† 4.5 ± 0.3*† 5.1 ± 0.3*† 6.2 ± 0.3*†
Indo + Tezo 3.0 ± 0.2† 3.8 ± 0.3*†‡ 4.4 ± 0.3*† 5.2 ± 0.4*‡ 5.6 ± 0.4*†‡ 6.4 ± 0.4*†
LNNA 3.1 ± 0.3† 3.8 ± 0.2*† 4.5 ± 0.3*† 4.9 ± 0.4*† 5.5 ± 0.4*† 6.4 ± 0.4*†
LNNA + Tezo 3.8 ± 0.3‡ 4.8 ± 0.4*‡ 5.3 ± 0.4*†‡ 5.6 ± 0.4*†‡ 6.4 ± 0.4*‡ 7.3 ± 0.5*†‡
LNNA + Indo 1.9 ± 0.2 2.4 ± 0.2* 3.1 ± 0.2*† 3.5 ± 0.3* 4.0 ± 0.2*† 4.9 ± 0.4*
LNNA + Indo + Tezo 2.8 ± 0.3‡ 3.5 ± 0.3*‡ 4.0 ± 0.2*‡ 4.6 ± 0.3*‡ 5.0 ± 0.3*‡ 5.7 ± 0.2*‡
SV (l/min)
Control 29 ± 2 31 ± 2* 32 ± 2* 32 ± 2* 32 ± 2* 32 ± 2*
Tezo 28 ± 2 30 ± 2* 31 ± 2* 31 ± 2* 33 ± 2* 32 ± 2*
Indo 30 ± 2 32 ± 2* 34 ± 2* 34 ± 2* 35 ± 2*† 36 ± 1*†
Indo + Tezo 31 ± 2† 34 ± 2* 34 ± 1* 37 ± 1*† 36 ± 2*† 36 ± 1*†
LNNA 30 ± 3 32 ± 2* 34 ± 2* 34 ± 2* 35 ± 2* 34 ± 2
LNNA + Tezo 32 ± 3 34 ± 3* 35 ± 3* 35 ± 3* 36 ± 2‡ 36 ± 3*‡
LNNA + Indo 23 ± 1 25 ± 1 27 ± 1* 28 ± 1* 29 ± 1* 30 ± 1*†
LNNA + Indo + Tezo 27 ± 1 30 ± 1‡ 31 ± 1*‡ 32 ± 2* 32 ± 1*†‡ 31 ± 1*†
MAP(mmHg)
Control 95 ± 2 89 ± 3* 87 ± 2* 88 ± 2* 88 ± 2* 90 ± 2*
Tezo 89 ± 2‡ 79 ± 2*‡ 79 ± 2*‡ 79 ± 2*‡ 81 ± 2*‡ 82 ± 1*‡
Indo 124 ± 7† 120 ± 7† 107 ± 6*† 106 ± 6*† 107 ± 5*† 104 ± 5*†
Indo + Tezo 111 ± 3† 93 ± 3*‡ 89 ± 2*‡ 89 ± 3*‡ 89 ± 3*‡ 88 ± 3*‡
LNNA 122 ± 2† 120 ± 3† 118 ± 3† 118 ± 2† 121 ± 2† 123 ± 2†
LNNA + Tezo 111 ± 4†‡ 104 ± 2†‡ 98 ± 3*†‡ 99 ± 2*†‡ 102 ± 3†‡ 101 ± 2*†‡
LNNA + Indo 161 ± 7† 156 ± 8† 146 ± 6*† 142 ± 5*† 137 ± 4*† 132 ± 4*†
LNNA + Indo + Tezo 131 ± 7‡ 121 ± 7*‡ 114 ± 5*‡ 114 ± 5*‡ 115 ± 5*‡ 113 ± 5*‡
PAP(mmHg)
Control 15 ± 1 15 ± 1 18 ± 1* 21 ± 1* 23 ± 1* 28 ± 1* 
Tezo 15 ± 1 13 ± 1 17 ± 1‡ 17 ± 1*‡ 21 ± 1*‡ 25 ± 1*‡ 
Indo 19 ± 1† 18 ± 2 18 ± 2 20 ± 2 22 ± 2* 26 ± 2* 
Indo + Tezo 17 ± 2 14 ± 2*‡ 15 ± 2† 17 ± 2† 20 ± 2† 23 ± 2*† 
LNNA 23 ± 2† 23 ± 2† 27 ± 3† 29 ± 3† 34 ± 3*† 41 ± 2*†
LNNA + Tezo 16 ± 2‡ 17 ± 2 17 ± 2†‡ 19 ± 2‡ 25 ± 2*†‡ 29 ± 3*‡
LNNA + Indo 24 ± 2† 26 ± 3 27 ± 3 29 ± 3* 32 ± 3* 37 ± 3*
LNNA + Indo + Tezo 21 ± 2 18 ± 3 20 ± 2‡ 24 ± 3 26 ± 3* 31 ± 3*†‡ 
LAP(mmHg)
Control 4 ± 1 2 ± 1 3 ± 1 5 ± 1 6 ± 1* 8 ± 1* 
Tezo 4 ± 1 0 ± 1* 3 ± 1 3 ± 1 6 ± 1* 8 ± 1* 
Indo 10 ± 2† 7 ± 2 3 ± 2* 6 ± 1* 6 ± 1* 7 ± 1 
Indo + Tezo 8 ± 1† 2 ± 1*‡ 3 ± 1* 4 ± 1* 6 ± 1* 7 ± 1 
LNNA 10 ± 1† 5 ± 1 7 ± 1 8 ± 1 9 ± 1 10 ± 1
LNNA + Tezo 2 ± 2 3 ± 2 4 ± 1 6 ± 1 9 ± 1* 10 ± 1*
LNNA + Indo 15 ± 2† 13 ± 3 12 ± 3† 12 ± 2*† 13 ± 2* 12 ± 2*
LNNA + Indo + Tezo 8 ± 2‡ 4 ± 3 5 ± 2‡ 8 ± 2‡ 9 ± 1 11 ± 2
Table 2: Hemodynamic variables in normal swine at rest and during exercise before and after single 
or combined blockade of eNOS, cyclooxygenase and/or ETA/ETB receptors
HR, heart rate; CO, cardiac output; MAP, mean arterial pressure; PAP, pulmonary arterial pressure; LAP, 
left atrial pressure; Data are mean ± S.E.M. * P≤0.05 versus Rest (Lying); † P≤0.05 versus corresponding 
Control; ‡ P≤0.05 effect of Tezo
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Rest Exercise level (km/h)
bl     standing 1 2 3 4
HR (bpm)
Control 147 ± 4§ 158 ± 5* 187 ± 2*§ 203 ± 4*§ 219 ± 6*§ 244 ±8*
Tezo 157 ± 4‡ 169 ± 4*‡ 190 ± 4* 205 ± 4* 222 ± 7* 243 ±6*
Indo 104 ± 3†§ 124 ± 3*†§ 139 ± 3*†§ 143 ± 4*† 150 ± 6*† 181 ±5*†
Indo + Tezo 112 ± 7† 125 ± 2†§ 135 ± 7† 148 ± 5*† 159 ± 4*† 175 ±7*†
LNNA 111 ± 4† 139 ± 6 155 ± 7*†§ 167 ± 6*†§ 180 ± 6*†§ 209 ±8*
LNNA + Tezo 131 ± 5‡ 152 ± 5 165 ± 5* 176 ± 8 190 ± 9 216 ±10
LNNA + Indo 91 ± 6 99 ± 6* 115 ± 6* 125 ± 6* 142 ± 5* 165 ±5*
LNNA + Indo + Tezo 86 ± 5 100 ± 4* 122 ± 4* 133 ± 4* 148 ± 4* 173 ±3*‡
CO (l/min)
Control 3.5 ± 0.2 4.0 ± 0.3* 4.7 ± 0.3* 5.1 ± 0.3* 5.6 ± 0.4* 6.0 ±0.4*§
Tezo 3.6 ± 0.3 4.6 ± 0.4*‡ 5.2 ± 0.4*‡ 5.6 ± 0.4*‡ 6.0 ± 0.4*‡ 6.4 ±0.4*‡
Indo 2.8 ± 0.2† 3.6 ± 0.3*† 4.2 ± 0.3*† 4.6 ± 0.3*† 4.9 ± 0.3*† 5.8 ±0.3*†
Indo + Tezo 3.4 ± 0.3‡ 4.2 ± 0.3*‡ 4.7 ± 0.3*† 5.2 ± 0.3*†‡ 5.6 ± 0.3*†‡ 6.2 ±0.3*†
LNNA 3.0 ± 0.3† 3.9 ± 0.3 4.4 ± 0.3*† 4.6 ± 0.3*† 5.1 ± 0.3*† 5.8 ±0.4*†
LNNA + Tezo 3.7 ± 0.2‡ 4.8 ± 0.3 5.2 ± 0.3*‡ 5.8 ± 0.4 6.1 ± 0.5 6.8 ±0.4
LNNA + Indo 2.6 ± 0.3† 3.3 ± 0.3† 4.2 ± 0.3*† 4.6 ± 0.3*† 5.2 ± 0.3*† 6.2 ±0.4*†
LNNA + Indo + Tezo 3.4 ± 0.3‡ 4.5 ± 0.3*‡ 5.1 ± 0.2*‡ 5.6 ± 0.3*‡ 6.2 ± 0.3*‡ 7.1 ±0.4*‡
MAP(mmHg)
Control 90 ± 2 83 ± 2* 81 ± 2*§ 81 ± 2*§ 82 ± 3* 83 ±3
Tezo 80 ± 2‡§ 76 ± 2‡ 75 ± 2‡ 76 ± 2‡ 76 ± 2‡ 77 ±2‡
Indo 126 ± 5† 114 ± 4† 104 ± 4*† 101 ± 4*† 99 ± 4*† 94 ±5*†
Indo + Tezo 103 ± 4†‡ 97 ± 5†‡ 94 ± 3*†‡ 90 ± 4*‡ 87 ± 4*‡ 85 ±4*‡
LNNA 125 ± 5† 112 ± 5 113 ± 4*† 115 ± 4*† 115 ± 3*† 111 ±3*†
LNNA + Tezo 115 ± 5†‡ 97 ± 4 94 ± 5*†‡ 94 ± 5* 94 ± 5*‡ 93 ±4*
LNNA + Indo 147 ± 5† 141 ± 8† 133 ± 7* 132 ± 7* 127 ± 7* 118 ±5*
LNNA + Indo + Tezo 129 ± 4‡ 117 ± 4*‡ 112 ± 5*‡ 109 ± 5*‡ 108 ± 5* 105 ±5*
SV(ml)
Control 24 ± 2 26 ± 2* 24 ± 1 25 ± 2 25 ± 2* 25 ±1
Tezo 23 ± 1 27 ± 2* 27 ± 2* 27 ± 2*‡ 27 ± 2*‡ 27 ±2*‡
Indo 30 ± 2 32 ± 2* 34 ± 2* 34 ± 2* 35 ± 2*† 36 ±1*†
Indo + Tezo 31 ± 2† 34 ± 2* 34 ± 1* 37 ± 1*† 36 ± 2*† 36 ±1*†
LNNA 26 ± 2 28 ± 2 29 ± 2*† 28 ± 2†§ 29 ± 2 28 ±2
LNNA + Tezo 28 ± 1 32 ± 2 32 ± 2*‡ 33 ± 3 33 ± 3 32 ±3
LNNA + Indo 27 ± 1 33 ± 1† 36 ± 1 36 ± 1 36 ± 1 37 ±1
LNNA + Indo + Tezo 39 ± 2†‡ 43 ± 2*†‡ 41 ± 1†‡ 42 ± 1†‡ 42 ± 1†‡ 41 ±2†‡
PAP(mmHg)
Control 25 ± 3§ 24 ± 2§ 29 ± 2*§ 31 ± 2*§ 34 ± 2*§ 38 ±2*§
Tezo 21 ± 2§ 21 ± 2‡§ 25 ± 2‡§ 28 ± 2*‡§ 31 ± 2*§ 33 ±2*‡§
Indo 28 ± 3†§ 29 ± 3†§ 32 ± 3§ 33 ± 3§ 35 ± 3*§ 37 ±3*§
Indo + Tezo 21 ± 2‡ 22 ± 3‡§ 28 ± 4*‡§ 29 ± 3*§ 29 ± 3*†‡§ 33 ±3*†‡§
LNNA 29 ± 2† 35 ± 2 38 ± 3*†§ 41 ± 3*†§ 44 ± 3*†§ 48 ±2*†§
LNNA + Tezo 25 ± 2 24 ± 3 26 ± 2‡§ 30 ± 2‡ 33 ± 3‡ 37 ±3‡
LNNA + Indo 35 ± 4†§ 34 ± 4 37 ± 5 39 ± 5 43 ± 5* 45 ±4*
LNNA + Indo + Tezo 29 ± 3‡ 27 ± 4*‡ 31 ± 3*‡§ 34 ± 4*‡ 38 ± 4*‡§ 42 ±4*§
LAP(mmHg)
Control 12 ± 2§ 10 ± 2§ 13 ± 2§ 14 ± 2§ 16 ± 2*§ 18 ±2*§
Tezo 11 ± 2§ 10 ± 2§ 12 ± 2§ 15 ± 2*§ 17 ± 2*§ 18 ±2*§
Indo 17 ± 3† 15 ± 3† 18 ± 3†§ 20 ± 3§ 20 ± 3§ 20 ±2§
Indo + Tezo 11 ± 2‡ 11 ± 3§ 15 ± 2*†§ 16 ± 2*†§ 17 ± 2*§ 19 ±2*§
LNNA 17 ± 1†§ 14 ± 2§ 14 ± 1§ 16 ± 1§ 17 ± 0§ 18 ±1§
LNNA + Tezo 13 ± 1‡§ 9 ± 2* 10 ± 1*†‡§ 13 ± 1 15 ± 1 17 ±1
LNNA + Indo 14 ± 3† 14 ± 3 15 ± 3 16 ± 3 17 ± 3 18 ±3
LNNA + Indo + Tezo 15 ± 3†‡ 13 ± 2 14 ± 2§ 15 ± 3 18 ± 3 18 ±3
HR, heart rate; CO, cardiac output; MAP, mean arterial pressure; PAP, pulmonary arterial pressure; 
LAP, left atrial pressure; Data are mean ± S.E.M.* P≤0.05 versus Rest (Lying); † P≤0.05 versus 
corresponding Control; ‡P≤0.05 effect of Tezo; § P≤0.05 MI vs Normal
Table 3: Hemodynamic variables in swine with MI at rest and during exercise before and after 
single or combined blockade of eNOS, cyclooxygenase and/or ETA/ETB receptors
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Rest Exercise level (km/h)
Lying 1 2 3 4
PO2 (mmHg)
Control 97 ± 2 96 ± 2 95 ± 2 95 ± 2 91 ± 2*
Tezo 98 ± 2 95 ± 4 95 ± 2 93 ± 2* 92 ± 2*
Indo 115 ± 5† 110 ± 5† 116 ± 4† 109 ± 7 107 ± 5†
Indo + Tezo 115 ± 4† 104 ± 4* 107 ± 5† 105 ± 5 100 ± 5*†
NLA 98 ± 2 163 ± 68 94 ± 3 92 ± 4 93 ± 5
NLA + Tezo 95 ± 3 92 ± 3 92 ± 4 92 ± 4 88 ± 2
NLA + Indo 125 ± 6† 128 ± 8† 120 ± 3† 112 ± 3† 106 ± 3*†
NLA + Indo + Tezo 111 ± 8 114 ± 11 109 ± 4‡ 106 ± 3 103 ± 5
SO2 (%)
Control 93 ± 1 92 ± 1 93 ± 1 93 ± 1 93 ± 1
Tezo 93 ± 1 92 ± 1* 93 ± 1 92 ± 1 92 ± 1
Indo 93 ± 1† 93 ± 1† 94 ± 1† 93 ± 1† 93 ± 1†
Indo + Tezo 93 ± 1† 92 ± 1† 93 ± 1† 93 ± 1† 93 ± 1†‡
NLA 93 ± 1 92 ± 1 93 ± 1 93 ± 1 93 ± 1
NLA + Tezo 93 ± 1 92 ± 1 93 ± 1 93 ± 1 93 ± 1
NLA + Indo 94 ± 1† 95 ± 1 95 ± 1 95 ± 1 94 ± 1
NLA + Indo + Tezo 94 ± 1 93 ± 1 94 ± 1 94 ± 1 94 ± 1
pH
Control 7.439 ± 0.019 7.467 ± 0.008 7.474 ± 0.007 7.484 ± 0.007 7.490 ± 0.007*
Tezo 7.454 ± 0.006 7.455 ± 0.006 7.473 ± 0.008* 7.481 ± 0.008* 7.490 ± 0.007*
Indo 7.500 ± 0.008† 7.501 ± 0.007† 7.509 ± 0.008† 7.505 ± 0.009† 7.511 ± 0.007†
Indo + Tezo 7.486 ± 0.007† 7.490 ± 0.008† 7.494 ± 0.007 7.502 ± 0.007*† 7.503 ± 0.007
NLA 7.495 ± 0.011 7.502 ± 0.014 7.512 ± 0.013† 7.513 ± 0.014 7.527 ± 0.009
NLA + Tezo 7.478 ± 0.009‡ 7.488 ± 0.013 7.503 ± 0.010* 7.501 ± 0.007 7.516 ± 0.011*
NLA + Indo 7.494 ± 0.011 7.493 ± 0.013 7.495 ± 0.010 7.489 ± 0.012 7.476 ± 0.017
NLA + Indo + Tezo 7.477 ± 0.006 7.484 ± 0.009 7.494 ± 0.008 7.507 ± 0.009 7.502 ± 0.009
PCO2 (mmHg)
Control 44 ± 1 44 ± 1 43 ± 1 42 ± 1* 41 ± 1*
Tezo 46 ± 1 46 ± 1 45 ± 1 42 ± 1* 42 ± 1*
Indo 39 ± 4 39 ± 4 39 ± 4 39 ± 4 38 ± 4
Indo + Tezo 37 ± 1† 37 ± 1† 36 ± 1† 35 ± 1*† 35 ± 1†
NLA 43 ± 1 42 ± 1 41 ± 1 41 ± 1 37 ± 1
NLA + Tezo 44 ± 1 42 ± 1 41 ± 1* 41 ± 1* 38 ± 1*
NLA + Indo 31 ± 1† 33 ± 2† 32 ± 2† 34 ± 2† 34 ± 1
NLA + Indo + Tezo 37 ± 2†‡ 37 ± 1† 37 ± 1† 35 ± 1† 35 ± 1
HCO3 (mmol/L)
Control 30 ± 1 31 ± 1 31 ± 1 30 ± 1 30 ± 1
Tezo 36 ± 5 36 ± 5 36 ± 5 35 ± 5 35 ± 5
Indo 29 ± 3 30 ± 3 30 ± 4 30 ± 3 30 ± 3
Indo + Tezo 27 ± 1† 27 ± 1* 27 ± 1* 26 ± 1 26 ± 1
NLA 33 ± 1 32 ± 1 32 ± 1 32 ± 1 30 ± 1
NLA + Tezo 32 ± 1 32 ± 1 31 ± 1 31 ± 0 30 ± 0
NLA + Indo 23 ± 1† 24 ± 2† 24 ± 2† 25 ± 2† 25 ± 2†
NLA + Indo + Tezo 27 ± 1† 27 ± 1† 28 ± 1† 27 ± 1† 27 ± 1†
Table 4: Arterial blood gas values in normal swine at rest and during exercise before and after single 
or combined blockade of eNOS, cyclooxygenase and/or ETA/ETB receptors
* P≤0.05 versus Rest (Lying); † P≤0.05 versus corresponding Control; ‡ P≤0.05 effect of Tezo
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Rest Exercise level (km/h)
Lying 1 2 3 4
PO2 (mmHg)
Control 101 ± 2 89 ± 5* 86 ± 4*§ 90 ± 3* 86 ± 3*
Tezo 93 ± 2† 87 ± 3 87 ± 4* 86 ± 3* 84 ± 3*
Indo 122 ± 7† 121 ± 7 117 ± 5† 109 ± 3† 105 ± 6
Indo + Tezo 109 ± 4 102 ± 5* 108 ± 7‡ 106 ± 4 101 ± 3
NLA 95 ± 3 93 ± 4 93 ± 5 93 ± 4 91 ± 5
NLA + Tezo 92 ± 5 90 ± 5 94 ± 3 93 ± 3 85 ± 4
NLA + Indo 117 ± 3† 113 ± 9 104 ± 6*§ 103 ± 6 102 ± 5*
NLA + Indo + Tezo 104 ± 3‡ 104 ± 5 97 ± 5 99 ± 5 92 ± 7
SO2 (%)
Control 91 ± 1 89 ± 1§ 89 ± 1*§ 90 ± 1§ 90 ± 1§
Tezo 91 ± 1 89 ± 1§ 90 ± 1*§ 89 ± 1§ 89 ± 1§
Indo 93 ± 1 94 ± 1† 94 ± 1† 94 ± 1† 92 ± 2
Indo + Tezo 93 ± 1 92 ± 1 93 ± 1 94 ± 1† 93 ± 1†
NLA 91 ± 1 92 ± 1 92 ± 1 92 ± 1 92 ± 1
NLA + Tezo 91 ± 1 92 ± 2 94 ± 1 93 ± 2 92 ± 2
NLA + Indo 96 ± 1 96 ± 1 95 ± 1 95 ± 1 95 ± 1
NLA + Indo + Tezo 95 ± 1‡ 94 ± 1‡ 94 ± 1‡ 94 ± 1 92 ± 2
pH
Control 7.457 ± 0.006 7.457 ± 0.009 7.460 ± 0.009 7.482 ± 0.015* 7.480 ± 0.013*
Tezo 7.455 ± 0.005 7.464 ± 0.010 7.462 ± 0.005 7.474 ± 0.009* 7.474 ± 0.011
Indo 7.479 ± 0.012 7.502 ± 0.013† 7.514 ± 0.012*† 7.511 ± 0.015 7.488 ± 0.026
Indo + Tezo 7.464 ± 0.007 7.487 ± 0.017 7.489 ± 0.014 7.507 ± 0.013*† 7.508 ± 0.015*
NLA 7.467 ± 0.005 7.491 ± 0.009 7.503 ± 0.011*† 7.505 ± 0.008*† 7.516 ± 0.011*†
NLA + Tezo 7.472 ± 0.007 7.490 ± 0.005* 7.495 ± 0.007 7.494 ± 0.011 7.494 ± 0.011
NLA + Indo 7.508 ± 0.016 7.516 ± 0.011 7.504 ± 0.012 7.503 ± 0.013 7.505 ± 0.014
NLA + Indo + Tezo 7.463 ± 0.008‡ 7.555 ± 0.060 7.486 ± 0.010 7.500 ± 0.010* 7.489 ± 0.011
PCO2 (mmHg)
Control 45 ± 1 44 ± 1 45 ± 1 42 ± 1* 41 ± 1*
Tezo 46 ± 1 45 ± 1 44 ± 1 43 ± 1* 42 ± 1*
Indo 33 ± 1† 33 ± 1† 32 ± 1† 34 ± 1† 36 ± 2
Indo + Tezo 39 ± 1†‡ 39 ± 1†‡ 38 ± 1†‡ 37 ± 0†‡ 36 ± 1*†
NLA 47 ± 3 44 ± 2* 42 ± 2* 42 ± 2* 40 ± 2*
NLA + Tezo 50 ± 3 48 ± 4* 47 ± 4 48 ± 5 55 ± 9
NLA + Indo 34 ± 3 35 ± 3 36 ± 3* 34 ± 1 33 ± 1
NLA + Indo + Tezo 43 ± 4‡ 40 ± 3*‡ 41 ± 4‡ 40 ± 3* 40 ± 3
HCO3 (mmol/L)
Control 30 ± 1 30 ± 1 30 ± 1 30 ± 1 29 ± 1*
Tezo 31 ± 1 31 ± 1 30 ± 1 31 ± 1 30 ± 1*
Indo 24 ± 1† 25 ± 1* 25 ± 1 26 ± 1* 25 ± 1
Indo + Tezo 27 ± 1‡ 28 ± 1*‡ 28 ± 1‡ 28 ± 1‡ 27 ± 1
NLA 32 ± 2 32 ± 2 91 ± 56 32 ± 2 31 ± 2
NLA + Tezo 35 ± 3 35 ± 3 35 ± 3 36 ± 4 41 ± 7
NLA + Indo 26 ± 2 28 ± 3 28 ± 3 26 ± 1 26 ± 1
NLA + Indo + Tezo 30 ± 3‡ 31 ± 4‡ 31 ± 3‡ 31 ± 3 31 ± 3
Table 5: Arterial blood gas values in MI swine at rest and during exercise before and after single or 
combined blockade of eNOS, cyclooxygenase and/or ETA/ETB receptors
* P≤0.05 versus Rest (Lying); † P≤0.05 versus corresponding Control; ‡ P≤0.05 effect of Tezo; § P≤0.05 
MI vs Normal 
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Discussion
The main ﬁ ndings of the present study are that in swine with pulmonary 
hypertension secondary to myocardial infarction: (i) the contribution of endogenous 
ET to pulmonary vasomotor tone is enhanced as compared to normal swine, (ii) 
prostanoids exert a vasodilator inﬂ uence on the pulmonary vasculature and 
attenuate the vasoconstrictor inﬂ uence of endogenous ET, but only under resting 
conditions and not during exercise, while in normal swine prostanoids do not 
appear to play a role in control of pulmonary resistance vessel tone either at rest 
or during exercise and do not modulate the pulmonary vasoconstrictor inﬂ uence 
of ET; (iii) the contribution of endogenous NO to control of pulmonary resistance 
vessel tone is not altered as compared to normal swine, while endogenous NO 
blunts the vasoconstrictor inﬂ uence of ET to a similar extent as in normal swine.
Vasomotor control of the pulmonary vasculature: matching of ventilation to 
perfusion
For the lungs to perform their gas-exchange function efﬁ ciently, the pulmonary 
circulation must maintain low pulmonary arterial and capillary pressure, while 
accommodating the entire cardiac output. In addition, perfusion must be 
distributed among the ventilated units through local variations in pulmonary 
vascular resistance so that ﬂ ow matches local ventilation, [36]. The pulmonary 
vascular resistance is determined by passive distension as well as active regulation 
of vasomotor tone [36]. During exercise, the increase in cardiac output results in 
an increased ﬂ ow through the pulmonary vasculature. Moreover, exercise results 
in an increase in left atrial pressure that is progressive with exercise intensity and 
accounts for the majority of the increase in pulmonary arterial pressure. In the 
human lung with its large base and small top, the well-ventilated base is mainly 
perfused in the upright posture under resting conditions, while the increase in 
pressure during exercise recruits perfusion of the smaller top and results in a 
~40% decrease in pulmonary vascular resistance [37, 38]. In contrast to humans, 
quadruped lungs have small ventral volumes but large dorsal volumes. As a result, 
resting pulmonary pressure is slightly higher in quadrupeds, but ventilation and 
perfusion are more evenly distributed across the entire lung [38]. During exercise, 
ﬂ ows in all lung areas increase proportionally to their resting ﬂ ows so that ﬂ ow 
distribution does not change and hence pulmonary vascular resistance decreases 
by only 10-20% [38]. Another consequence of the body posture of quadrupeds is 
that perfusion and ventilation are already matched under resting conditions, with 
little additional recruitment of lung areas during exercise [38]. This may explain 
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our observation of a small decrease in arterial PO2 at the highest level of exercise, 
which is in accordance with reports from various laboratories [39-41], although 
this is not a uniform ﬁ nding [42, 43]. It is important to note that small changes 
in arterial PO2 contribute little to the arterial oxygen content, since the arterial 
oxygen-haemoglobin dissociation curve operates at its upper plateau. Consequently, 
arterial haemoglobin oxygen saturation was maintained (Table 4 and 5).
The changes in pulmonary vascular resistance induced by ET receptor blockade 
and eNOS inhibition do not affect arterial PO2, suggesting that matching between 
ventilation and perfusion is not affected. In contrast, cyclooxygenase inhibition 
did not affect pulmonary vascular resistance, but increased arterial PO2, which 
may have been the result of the increased pulmonary retention time of the blood 
due to the decrease in cardiac output, in conjunction with mild hyperventilation. 
Vasomotor control of the pulmonary vasculature following MI
MI results in neurohumoral activation, i.e. activation of the sympathetic nervous 
system and the renin-angiotensin system. In our model, elevations of adrenaline, 
noradrenaline and angiotensin-II are most pronounced during exercise [31, 41]. 
Additionally, MI increases LV ﬁ lling pressures that are transmitted backwards into 
the pulmonary circulation [1]. Although the secondary increase in pulmonary 
arterial pressure may initially act to passively decrease PVR, it also results in a 
‘reactive’ increase in PVR and inward remodelling and stiffening of the pulmonary 
vasculature [1]. This reactive increase in PVR may be caused by increased 
contribution of vasoconstrictors or a decreased contribution of vasodilators to 
pulmonary vasomotor tone and may limit the decrease in PVR during exercise [1]. This 
reduced vasodilator capacity of the pulmonary vasculature results in exacerbation 
of pulmonary hypertension during exercise, which increases RV afterload and 
contributes to RV hypertrophy and RV failure [1]. Moreover, it has been reported 
that exercise capacity is inversely correlated with PVR and with the failure to 
decrease PVR during exercise in patients with heart failure [6].  The pathogenesis 
of the increased PVR in pulmonary hypertension is incompletely understood, but 
may involve alterations in serotonin, thromboxane A2 and/or angiotensin-II [7]. 
Additionally, it may be mediated in part by downregulation or desensitization of 
β-adrenoceptors. In the pulmonary vasculature of healthy swine, the sympathetic 
nervous system exerts a vasodilator inﬂ uence that is mediated through b-
adrenoceptors [35]. Although the increased sympathetic drive following MI may 
initially counteract the increase in PVR,  β-blockade does not affect pulmonary 
vascular resistance in patients with chronic heart failure [44, 45], suggesting that 
prolonged β-adrenergic stimulation may have caused desensitization of the β-
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adrenoceptors, thereby contributing to the increase in PVR following pulmonary 
hypertension. Additionally, endothelial dysfunction may play a role in this process 
[1, 8, 46]. With endothelial dysfunction, the production of the vasodilators NO and 
prostacyclin decreases, while the production of the vasoconstrictor ET increases. 
This imbalance between vasodilators and vasoconstrictors is likely to contribute to 
an increase in pulmonary vascular tone, thereby increasing PVR. In agreement with 
a previous study from our laboratory [27], we observed an enhanced ET-mediated 
vasoconstriction in the present study. 
ET and secondary pulmonary hypertension following MI
Activation of the ET-system can contribute to the progression of the disease and 
has been shown to occur in various animal models as well as patients with pulmonary 
hypertension. Thus, production of ET is increased in the pulmonary endothelium 
of subjects with pulmonary hypertension [47], while pulmonary clearance of ET is 
reduced [48-51]. The increased production and decreased clearance of ET together 
result in increased circulating levels of ET, which is an independent predictor of 
clinical prognosis and survival [52]. Moreover, the ET-plasma levels correlate closely 
with the exercise capacity of patients with pulmonary hypertension [29].
In addition to increased plasma-levels of ET, which in itself could be sufﬁ cient to 
explain the increased vasoconstrictor inﬂ uence of ET on the pulmonary circulation, 
we found that the sensitivity of the pulmonary circulation to administration 
of exogenous ET was increased after MI [27]. Moreover, while the response to 
endogenous ET was exclusively ETB-receptor mediated in normal swine, an ETA-
receptor mediated component emerged in swine with MI [27]. In contrast, studies 
on isolated pulmonary resistance vessels from rats [53] and rabbits [54] with and 
without MI show no difference in response to ET or in ETA or ETB receptor expression 
[53]. However, the response of isolated arterioles to administration of ET may be 
different from the response of the intact vasculature [55]. This could be due to 
factors such as NO [9, 11] and possibly prostacyclin, that are capable of modifying 
ET receptor sensitivity and are present in vivo, while they are reduced in the in 
vitro preparations. 
Prostanoids and pulmonary hypertension
Prostacyclin has very potent pulmonary vasodilator properties [56]. Moreover, 
both cyclooxygenase-1 and 2 have been shown to be expressed in the pulmonary 
vasculature of rats [57] and mice [58]. Yet, in agreement with other studies 
[34, 56, 59], endogenous prostanoids did not contribute to regulation of basal 
pulmonary tone and did not inﬂ uence ET-mediated pulmonary vasoconstriction 
151
Chapter 6: NO, prostanoids and endothelin in swine with pulmonary hypertension after MI 
[19], suggesting that endogenous prostanoid production is absent in the normal 
healthy pulmonary circulation. However, after MI, inhibition of cyclooxygenase 
resulted in pulmonary vasoconstriction at rest both in the absence and presence 
of inhibition of NO-synthesis, suggesting that after MI, prostanoids exert a basal 
vasodilator inﬂ uence and therefore act to limit the pulmonary vasoconstriction that 
occurs after MI. These data are in accordance with a study on isolated pulmonary 
smooth muscle cells, showing that stimulation of these cells with cytokines, to 
mimic pathological pulmonary conditions can induce COX-2 expression, and 
thereby increase production of prostanoids [13]. Because prostanoids have been 
shown to improve the balance between ET-clearance and production [60], and 
because blockade of cyclooxygenase has been shown to affect pulmonary vascular 
tone only when ET-receptors are unblocked [61], this slight increase in pulmonary 
prostanoids may have acted to limit ET-induced pulmonary vasoconstriction [13] 
rather than to induce pulmonary vasodilation itself. Indeed, the present study also 
shows that, in the presence of tezosentan, PVR is not different before and after 
inhibition of cyclooxygenase, suggesting that the main action of prostanoids in the 
pulmonary vasculature is to suppress the ET-system. 
In contrast to the ﬁ ndings under resting conditions, there was no effect of 
cyclooxygenase inhibition on pulmonary vasomotor tone during exercise in the 
presence or absence of eNOS inhibition, suggesting that the vasodilator effect of 
prostanoids is lost during exercise. In accordance with these ﬁ ndings, the pulmonary 
vasodilator effect of tezosentan during exercise was similar in the presence and 
absence of cyclooxygenase inhibition.
NO and pulmonary hypertension
NO is a very potent vasodilator of the pulmonary vasculature and endogenous NO 
contributes to the regulation of pulmonary vascular tone in normal swine [30, 56]. 
Physiologically, NO is produced by eNOS in response to increases in shear stress and/
or in response to receptor activation and produces vasodilation through activation 
of soluble guanylyl cyclase in vascular smooth muscle, followed by reduction in 
intracellular calcium concentrations as well as reduction in myosin light chain 
phosphorylation, both of which are essential for smooth muscle cell contraction 
[62]. Besides its direct vasodilator effect on the pulmonary vasculature, NO can 
also cause vasodilation through inhibition of the ET system. Thus, NO inhibits the 
production of ET through endothelin converting enzyme [17] and modulates ETA 
receptor sensitivity [11]. Indeed, the vasodilation in response to ETA/ETB receptor 
blockade with tezosentan is larger after inhibition of NO-synthesis (present study, 
[19], suggesting that part of the vasodilator effect of NO is exerted through 
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inhibition of ET-mediated vasoconstriction.
The direct vasoconstrictor effect of inhibition of NO-synthesis within the 
pulmonary vascular bed may be modiﬁ ed by the central effects of inhibition of 
eNOS. Thus, inhibition of central NO will result in an increase in sympathetic 
outﬂ ow [63]. Conversely, the systemic pressor response was accompanied by a 
decrease in heart rate, likely mediated via the baroreceptor reﬂ ex. In both normal 
and MI swine NLA resulted in similar decrements in heart rate, indicating that 
in both groups the baroreceptor reﬂ ex outweighed any effects of central eNOS 
inhibition. The resultant attenuated sympathetic activity will result in blunted β-
receptor mediated pulmonary vasodilation [35], thereby potentially enhancing the 
vasoconstriction produced by inhibition of endothelial NO-production. However, 
the increase in pulmonary vascular resistance produced by NLA was much more 
pronounced than that previously observed following complete β-adrenergic 
receptor blockade [35], suggesting that the NLA-induced increase in  pulmonary 
vascular resistance was principally the result of inhibition of local NO synthesis.
Studies on the role of NO in regulation of pulmonary vasomotor tone in 
pulmonary hypertension have yielded variable results in that the contribution 
of NO is either increased, decreased or unaltered, depending on the model of 
pulmonary hypertension as well as the severity and duration of the disease. In 
early stages of pulmonary hypertension, pulmonary vasoconstriction may increase 
shear stress, thereby increasing NO production and counteracting the development 
of pulmonary hypertension [62]. However, when pulmonary hypertension persists 
for longer periods of time, the chronically elevated pressure may contribute to 
endothelial dysfunction, thereby decreasing NO production and promoting the 
development of pulmonary hypertension [24, 25, 64]. The present study shows 
that, in accordance with a previous study from our laboratory [28], the pulmonary 
vasoconstriction induced by inhibition of eNOS with NLA was similar in swine with 
MI as compared to normal swine, suggesting that basal NO-production is maintained 
~2 weeks after induction of MI. Apparently, the MI-induced pulmonary hypertension 
is not severe enough and/or did not last long enough to provoke perturbations in 
the NO system. These data are in accordance with a study in humans, showing that 
basal NO-activity is reduced in patients with congestive heart failure and severely 
elevated levels of pulmonary arterial pressure and pulmonary vascular resistance 
but not in patients with mildly elevated levels of pulmonary arterial pressure and 
pulmonary vascular resistance [24]. 
In accordance with the maintained basal NO production in swine with MI 
[28], the present study shows that the vasodilation induced by ETA/ETB receptor 
blockade in MI swine was increased after inhibition of NO-synthesis to a similar 
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extent as in normal swine. These ﬁ ndings indicate that NO acts to limit the ET-
induced pulmonary vasoconstriction to a similar degree in MI and normal swine. 
Thus, the increased sensitivity of the pulmonary vasculature to ET as observed in 
our swine model [27] cannot be explained by a loss of NO-mediated inhibition of 
ET-induced vasoconstriction.
Endothelial control of the systemic resistance vessels after MI
NO and prostanoids exert a vasodilator inﬂ uence on the systemic vasculature 
of normal swine, while ET exerts a vasoconstrictor inﬂ uence. The effects of 
endogenous NO, prostanoids and ET on systemic vasomotor tone are similar in 
normal swine and swine with MI. Moreover, in both normal swine and swine with 
MI, the vasodilation induced by endogenous NO and prostanoids is in part mediated 
through inhibition of ET-mediated vasoconstriction [12, 13, 17, 60] as evidenced 
by a larger effect of ETA/ETB receptor blockade after blocking NO or prostanoid 
production and in part a direct effect, as SVR does not return to baseline levels 
after ETA/ETB receptor blockade. 
In normal swine, the vasoconstrictor effect of combined inhibition of NO 
and prostanoids is larger than the sum of the individual effects, suggesting that 
inhibition of one endogenous vasodilator is compensated by increased production 
of the other dilator [34]. These data are in accordance with ﬁ ndings in isolated 
endothelial cells as well as in vivo [20, 65, 66]. Additionally, the effect of ETA/
ETB receptor blockade is signiﬁ cantly enhanced when production of both NO and 
prostanoids is inhibited, suggesting that NO and prostanoids act in concert to limit 
ET-induced vasoconstriction.  In contrast, in swine with MI the effects of inhibition 
of NO and prostanoid production on systemic vasomotor tone are additive. 
Moreover, the effect of ETA/ETB receptor blockade is not further enhanced after 
combined inhibition of NO and prostanoids. These ﬁ ndings could be interpreted to 
suggest that after MI, the effect of loss of NO or prostanoids on vasomotor tone 
and on ET-mediated vasoconstriction is not compensated by increased production 
of the other endothelial vasodilator.
Conclusion
The present study demonstrates that 2-3 weeks after MI, there is an increased 
pulmonary vasoconstrictor inﬂ uence of endogenous ET. We have previously shown 
that this increased pulmonary vasoconstrictor inﬂ uence is likely due to increased 
plasma ET levels in combination with an increased sensitivity of the pulmonary 
vasculature to ET [27]. In contrast, the pulmonary vasodilator inﬂ uence of NO was 
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well maintained after MI, while the inhibition of the ET-mediated vasoconstrictor 
inﬂ uence by NO was also unmitigated. Moreover, increased production of prostanoids 
after MI acted to limit the increase in pulmonary vascular resistance under resting 
conditions. This effect of prostanoids was mediated by a reduction of the ET-
induced pulmonary vasoconstriction. Taken together these ﬁ ndings indicate that 
the increased vasoconstrictor inﬂ uence of ET in the pulmonary circulation after MI 
is not the result of a loss of vasodilator inﬂ uence of NO or prostanoids. Moreover, 
our ﬁ ndings provide a rationale for the therapeutic use of endothelin receptor 
blockers to alleviate pulmonary hypertension.
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Chapter 7: Phosohodiesterase 5 inhibition in normal swine
Abstract
Pulmonary hypertension is a major risk factor for right-sided heart failure. 
Phosphodiesterase (PDE) 5 inhibition has emerged as a promising novel vasodilator 
therapy by prolonging the half-life of cGMP. In this study we assessed the pulmonary 
vasodilator effects of PDE5 inhibitor EMD360527 in chronically instrumented awake 
swine at rest and during exercise. Since pulmonary hypertension is often associated 
with endothelial dysfunction, and hence a reduced bioavailability of nitric oxide 
(NO), we also studied the effect of EMD360527 in the presence of NO synthase 
inhibition. The PDE5 inhibitor EMD360527 was infused intravenously at 10, 30, 100 
and 300 µg min kg-1 in resting pigs while the highest dose was also administered 
during exercise in the absence and presence of the NO synthase inhibitor Nω- nitro-
L-arginine (NLA, 20 mg min kg-1). Finally vascular responsiveness to the NO donor 
nitroprusside in the absence and presence of NLA was investigated.
EMD360527 decreased dose-dependently pulmonary and systemic vascular 
resistance in resting pigs, by up to 16±8% and 18±5%. The vasodilator responses 
were maintained during exercise. Prior inhibition of NO enhanced the EMD360527-
induced decreases in pulmonary and systemic vascular resistance (32±12% and 
23±5% respectively), which correlated well with the basal level of vasomotor tone. 
Furthermore, NLA, increased the pulmonary and systemic vasodilator responses to 
nitroprusside. In conclusion, EMD360527 causes vasodilation in the pulmonary and 
systemic vascular bed, which is maintained during exercise. The level of dilatation 
depends on the initial level of vasomotor tone, indicating that this vasodilator 
therapy might be most effective in patients with severe pulmonary hypertension.
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Introduction
Pulmonary hypertension is a major risk factor for right-sided heart failure, and 
constitutes a life-threatening disease with a poor prognosis. [1-3]. The elevation in 
pulmonary pressure is caused, at least in part, by an elevated pulmonary vascular 
resistance [4]. Consequently, therapy is principally aimed at reducing pulmonary 
vascular resistance. Currently available therapies include inhaled nitric oxide 
(NO), Ca2+-channel blockers, prostacyclin and endothelin-receptor blockade. 
However, these therapies have short-duration, limited efﬁ cacy, are expensive and/
or associated with signiﬁ cant side-effects, indicating that there is a continued 
need for novel vasodilator therapies of pulmonary hypertension [5]. In recent 
years, phosphodiesterase (PDE) 5 inhibition has emerged as a promising novel 
vasodilator therapy [5-7]. The vasodilator inﬂ uence of PDE5 inhibition is achieved 
by prolonging the half-life of cyclic guanosine monophosphate (cGMP), a second 
messenger which results in vasodilation through various pathways [8]. Since PDE5 
is abundantly expressed in lung vascular smooth muscle [9, 10], PDE5 inhibition 
may provide a powerful tool to selectively reduce pulmonary vascular resistance, 
while leaving systemic vascular resistance unperturbed [6]. In support of this 
notion, a number of patient studies reported a signiﬁ cant vasodilator effect within 
the pulmonary vascular bed, with minimal systemic effects [7, 11, 12]. However, 
some PDE5 inhibitors appear to be more selective for the pulmonary circulation 
than others, which may depend in part on the dosage used [13, 14]. Therefore, 
the ﬁ rst aim of the present study was to assess the vasodilator effects of various 
dosages of the novel PDE5 inhibitor EMD360527 [15] and to assess its selectivity in 
the pulmonary versus the systemic vascular bed of chronically instrumented awake 
swine.
The pulmonary circulation is a low-pressure system due to a low resistance. As 
a result, it has less capacity for additional vasodilation as compared to the systemic 
circulation, which is especially notable during exercise, when the increased cardiac 
output causes a marked increase in pulmonary artery pressure [16]. Since in 
patients with pulmonary hypertension exercise can lead to exaggerated increases in 
pulmonary pressure, it is important to know the efﬁ cacy of vasodilator therapy not 
only under resting conditions but particularly during exercise [17]. Consequently, 
the second aim of the present study was to investigate the pulmonary and systemic 
vasodilator effect of EMD360527 during exercise.
NO is considered as one of the major sources of cGMP [18]. Since pulmonary 
hypertension has been proposed to be associated with endothelial dysfunction, 
and reduced endothelial NO synthase (eNOS) activity [19-21], it is eminent to 
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determine to what the extent the efﬁ cacy of PDE5 inhibitors depends on the 
activity of endothelial NO synthase. Consequently, the third aim of the study was 
to evaluate the vasodilator effect of EMD360527 in the presence of NO synthase 
inhibition.
Methods
Studies were performed in accordance with the “Guiding Principles in the 
Care and Use of Laboratory Animals” as approved by the Council of the American 
Physiological Society, and with approval of the Animal Care Committee of the 
Erasmus MC Rotterdam. Fifteen crossbred Landrace x Yorkshire swine of either 
sex (2-3 months old) entered the study. Daily adaptation of animals to laboratory 
conditions started 1 wk before surgery and continued during the ﬁ rst week after 
surgery.
Surgical procedures
Swine were sedated with ketamine (30 mg kg-1 im), anaesthetized with thiopental 
(10 mg kg-1 iv), intubated and ventilated with a mixture of O2 and N2O (1:2) to 
which 0.2-1% (v/v) isoﬂ urane was added [22-24]. Anaesthesia was maintained with 
midazolam (2 mg/kg + 1 mg kg-1 per hour iv) and fentanyl (10 µg kg-1 per hour 
iv). Under sterile conditions, the chest was opened via the fourth left intercostal 
space and a ﬂ uid-ﬁ lled polyvinylchloride catheter was inserted into the aortic 
arch and pulmonary artery for blood pressure measurement (Combitrans pressure 
transducers, Braun, Melsungen, Germany) and blood sampling. An electromagnetic 
ﬂ ow probe (14-15 mm, Skalar) was positioned around the ascending aorta for 
measurement of cardiac output. A polyvinylchloride catheter was also inserted 
into the left atrium to measure pressure. Catheters were tunnelled to the back 
and animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine 
im) for 2 days and antibiotic prophylaxis (25 mg kg-1 amoxicillin and 5 mg kg-1 
gentamycin iv) for 5 days. Studies were performed 1-2 weeks after surgery.
Experimental protocols
Effect of EMD360527 in resting swine. With swine (n=10) resting quietly in 
a cage, the vasodilator responses in the systemic and pulmonary circulation to 
the PDE5 inhibitor EMD360527 [15] were studied. EMD360527 was administered in 
consecutive 15 min infusions of 10, 30, 100 and 300 µg min kg-1 iv, and heart rate, 
cardiac output, and aortic, pulmonary arterial and left atrial blood pressures were 
recorded. EMD360527 was dissolved in a ﬁ nal concentration of 0.1 mg min ml-1  in 
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a 1:1 (v:v) mixture of saline and NaHCO3 (4.2%). We have previously shown that 
saline infusions do not affect hemodynamic variables in awake resting swine [25, 
26].
Effect of EMD360527 during treadmill exercise. After hemodynamic 
measurements (lying and standing), consisting of left atrial, aortic and pulmonary 
arterial blood pressures, heart rate and cardiac output, blood samples (lying) and 
rectal temperature (standing) had been obtained, swine (n=11, of which 6 had also 
participated in the resting study) were subjected to a ﬁ ve-stage exercise protocol 
(1-5 km h-1) on a motor driven treadmill. Hemodynamic variables were continuously 
recorded and blood samples collected during the last 60 s of each 3-min exercise 
stage, at a time when hemodynamics had reached a steady state. After 90 minutes 
of rest, the EMD360527 was infused continuously in a dose of 300 µg min kg-1 iv, 
and 10 minutes after starting the infusion the exercise protocol was repeated. We 
have previously observed excellent reproducibility of two consecutive exercise 
protocols [23, 27].
Effects of EMD360527 during treadmill exercise in the presence of NO synthase 
inhibition. On a different day, the eNOS inhibitor Nω-nitro-L-Arginine (NLA) was 
administered to swine (n=8, all of which had participated in the above described 
protocol) in a dose of 20 mg kg-1 iv prior to the ﬁ rst exercise protocol [24, 27]. After 
90 minutes of rest, EMD360527 (300 µg min kg-1 iv) was administered as described 
above and the ﬁ ve-stage exercise protocol was repeated.
Effects of SNP in the presence of NO synthase inhibition. With swine (n=4) 
resting quietly, the NO donor nitroprusside was infused in consecutive doses of 0.5, 
1.0, 2.0 and 3.0 µg min kg-1 lasting 10 min per dose, in the absence and presence 
of eNOS inhibitor Nω-nitro-L-Arginine (NLA, 20 mg min kg-1iv) and systemic and 
pulmonary hemodynamic responses were studied.
Data Analysis
Digital recording and off-line analysis of hemodynamics have been described 
previously [23, 27]. Systemic vascular resistance (SVR) was computed as mean 
aortic blood pressure (MAP) divided by cardiac output (CO). Pulmonary vascular 
resistance (PVR) is deﬁ ned as mean pulmonary artery pressure (PAP) minus mean 
left atrial pressure (LAP) divided by cardiac output.
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Statistical analysis
The effects of EMD360527 in resting swine were assessed using analysis of 
variance (ANOVA) for repeated measures followed by post-hoc testing using 
Scheffe’s test. The effects of EMD360527 during exercise were analyzed using 
two-way ANOVA (exercise level x EMD360527) for repeated measures. Post-hoc 
testing for exercise and drug effect was performed using Scheffe’s test. The 
effect of NO-synthase inhibition on the responses to EMD360527 during exercise, 
were tested using three-way ANOVA (exercise level x EMD360527 x NLA). Linear 
regression analysis was used to test the dependency of the effect of EMD360527 on 
the initial level of pressure and resistance in the pulmonary and systemic vascular 
bed. Finally, the effect of NO-synthase inhibition on the vasodilator responses to 
SNP was assessed by two-way ANOVA (SNP dose x NLA). Statistical signiﬁ cance was 
accepted when P≤0.05. Data are presented as mean± S.E.M.
  Mean Aortic
Blood Pressure
40
60
80
100
Heart rate
EMD (µg min kg-1)
0 10 30 100 300
80
120
160
200
Cardiac Output
(l/
m
in
)
3
4
5
6
Mean  Blood Pressure
EMD (µg min kg-1)
0 10 30 100 300
(m
m
H
g)
0
6
12
18
Systemic Vascular
   Resistance
(m
m
H
g/
m
l/m
in
)
8
16
24
32
Pulmonary Vascular
     Resistance
EMD (µg min kg-1)
0 10 30 100 300
(m
m
H
g/
m
l/m
in
)
1
2
3
4
PA
LA
*
*
*
*
*
**
**
*
*
(m
m
H
g)
(b
ea
ts
/m
in
)
Figure 1: Effect of different doses of PDE5 inhibitor EMD360527 (EMD) on different hemodynamic 
parameters in awake swine (n=10, except for LA pressure and  PVR: n=7). PA: pulmonary artery; LA: 
left atrium *P<0.05 vs baseline (0 mg min kg-1). 
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Figure 2: Relative effect of 
different doses of PDE5 inhibitor 
EMD360527 (EMD) on different 
hemodynamic parameters in 
awake swine (n=10, except 
for PVR: n=7). PAP: pulmonary 
artery pressure; MAP: mean 
arterial pressure, SVR: systemic 
vascular resistance; PVR: 
pulmonary vascular resistance. 
*P<0.05 vs baseline (0 mg min 
kg-1); †P<0.05 by ANOVA, effect 
PDE5 inhibition on MAP vs PAP; 
‡P=0.054 by ANOVA, effect PDE5 
inhibition on SVR vs PVR for 
dosages 30-300 mg min kg-1.
Results
Effects of EMD360527 in resting swine
Intravenous infusion of EMD360527 resulted in a dose-dependent decrease in 
AoP of up to 12±2%, which was the result of a 19±3% decrease in SVR, as cardiac 
output increased by up to 10±3% due to a, probably baroreﬂ ex-mediated, increase 
in heart rate (Fig. 1). EMD360527 also caused a dose-dependent decrease in PAP 
of up to 17±7%, which was due to a decrease in PVR of up to 24±4% as LAP was not 
affected and CO increased (Fig. 1). The relative decreases in arterial pressure and 
vascular resistance in response to EMD360527 were slightly larger in the pulmonary 
than in the systemic vascular bed (Fig. 2).
Effects of EMD360527 during treadmill exercise
Exercise up to 5 km h-1 in swine resulted in a 105±5 % increase in cardiac output 
that was principally due to an increase in heart rate (Table 1). AoP was minimally 
affected, implying that the increase in CO was accompanied by an equivalent 
decrease in SVR (Table 1). PAP almost doubled during exercise. However, the 
transpulmonary pressure gradient (PAP minus LAP) increased to the same extent as 
cardiac output, resulting in an unchanged PVR during exercise (Table 1).
Ten min after the onset of intravenous infusion of EMD360527, in a dose of 
300 µg min kg-1, systemic and pulmonary pressures and vascular resistances had 
decreased signiﬁ cantly (Table 1). During the subsequent exercise protocol, the 
vasodilator effect of EMD360527 on the pulmonary vasculature tended to increase 
(P=0.08 by ANOVA), while the vasodilator effect in the systemic vasculature 
decreased (P<0.05 by ANOVA), compared to the effects of EMD365027 during 
resting conditions (Fig. 3).
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Effects of EMD360527 during exercise in the presence of NO synthase 
inhibition
Administration of the NO synthase inhibitor NLA resulted in marked increases 
in aortic (37±2%) and pulmonary arterial (41±14%) blood pressures, which were the 
result of a 94±9% and 90±23% increase in SVR and PVR, respectively (Table 1). The 
vasoconstrictor responses to NLA were similar at rest and during exercise.
Subsequent infusion of EMD360527 caused vasodilator responses in the systemic 
(23±5%) and pulmonary (31±12%) circulations that were enhanced compared to 
            Rest          Exercise level (km·h-1)    
  Treatment lying standing   1     2     3     4     5   
                                        
HR Control 124 ± 1 139 ± 3* 172 ± 3* 185 ± 4* 204 ± 7* 242 ± 8* 263 ± 7* 
(bpm) EMD 143 ± 6† 156 ± 5*† 179 ± 5* 194 ± 6* 220 ± 8*† 245 ± 9* 270 ± 8* 
  NLA 91 ± 4 113 ± 4* 127 ± 3* 132 ± 3* 151 ± 4* 197 ± 8* 234 ± 7* 
  NLA+EMD 105 ± 8 125 ± 7* 138 ± 7*† 151 ± 6*† 168 ± 7*† 203 ± 8* 240 ± 7* 
                                      
MAP Control 87 ± 2 85 ± 3 83 ± 2* 84 ± 2 85 ± 2 87 ± 3 89 ± 3 
(mmHg) EMD 80 ± 2† 75 ± 3† 74 ± 2*† 76 ± 3† 78 ± 2† 79 ± 2† 82 ± 3† 
  NLA 120 ± 3 112 ± 3* 111 ± 3* 112 ± 3* 114 ± 4 115 ± 3 115 ± 3 
  NLA+EMD 105 ± 5† 105 ± 5 104 ± 4† 105 ± 4† 105 ± 4† 106 ± 4† 105 ± 4† 
                                       
CO Control 5.0 ± 0.3 5.4 ± 0.3* 6.4 ± 0.3* 7.0 ± 0.3* 7.4 ± 0.3* 8.4 ± 0.3* 9.0 ± 0.3* 
(l·min-1) EMD 5.0 ± 0.3 5.7 ± 0.3* 6.6 ± 0.3* 7.0 ± 0.3* 8.2 ± 0.3*† 9.0 ± 0.3*† 9.5 ± 0.4*† 
  NLA 3.1 ± 0.2 4.1 ± 0.3* 4.9 ± 0.4* 5.4 ± 0.4* 6.1 ± 0.4* 7.2 ± 0.4* 7.9 ± 0.5* 
  NLA+EMD 3.6 ± 0.2† 4.9 ± 0.4* 5.6 ± 0.4* 6.2 ± 0.4*† 6.9 ± 0.5*† 8.0 ± 0.5*† 8.8 ± 0.5*† 
                       
SVR Control 20 ± 1 16 ± 1* 13 ± 1* 12 ± 1* 11 ± 0* 10 ± 0* 10 ± 0* 
(mmHg min l-1) EMD 16 ± 1† 13 ± 1*† 11 ± 1*† 11 ± 0*† 9 ± 0*† 9 ± 0*† 8 ± 0*† 
  NLA 39 ± 3 28 ± 2* 23 ± 2* 21 ± 2* 19 ± 1* 16 ± 1* 15 ± 1* 
  NLA+EMD 30 ± 3† 22 ± 2*† 19 ± 2* 17 ± 1*† 15 ± 1*† 13 ± 1*† 12 ± 0*† 
                                       
PAP Control 17 ± 1 19 ± 1* 22 ± 1* 25 ± 1* 27 ± 1* 34 ± 1* 36 ± 1* 
(mmHg) EMD 15 ± 1† 14 ± 1† 17 ± 1*† 19 ± 1*† 23 ± 1*† 26 ± 1*† 30 ± 1*† 
  NLA 22 ± 3 26 ± 2* 28 ± 2* 28 ± 2* 34 ± 3* 40 ± 4* 43 ± 3* 
  NLA+EMD 15 ± 2† 17 ± 2† 19 ± 2† 22 ± 2*† 24 ± 2*† 29 ± 2*† 33 ± 2*† 
                                       
LAP Control 7 ± 1 5 ± 1 6 ± 1 7 ± 1 9 ± 1* 11 ± 1* 13 ± 1* 
(mmHg) EMD 4 ± 1 3 ± 1† 5 ± 1 7 ± 1* 9 ± 1* 11 ± 1* 13 ± 1* 
  NLA 8 ± 1 7 ± 1 7 ± 1 9 ± 1 10 ± 1 10 ± 1 11 ± 1 
  NLA+EMD 6 ± 1 6 ± 2 7 ± 1 9 ± 1* 9 ± 1* 11 ± 1* 12 ± 1* 
                       
PVR Control 2.5 ± 0.2 2.6 ± 0.2 2.6 ± 0.2 2.6 ± 0.2 2.6 ± 0.2 2.7 ± 0.2 2.7 ± 0.2 
(mmHg min l-1) EMD 2.1 ± 0.2 2.0 ± 0.2† 1.9 ± 0.2† 1.8 ± 0.2† 1.8 ± 0.2† 1.8 ± 0.2† 1.9 ± 0.2† 
  NLA 4.1 ± 0.6 4.7 ± 0.6 4.3 ± 0.7 4.1 ± 0.7 4.3 ± 0.8 4.4 ± 0.8 4.4 ± 0.7 
  NLA+EMD 2.7 ± 0.6 2.3 ± 0.4† 2.2 ± 0.3† 2.2 ± 0.3† 2.2 ± 0.3† 2.5 ± 0.4† 2.5 ± 0.4† 
Table 1: Hemodynamics of swine at rest and during exercise before and after administration of 
EMD360527 and NLA
HR: Heart Rate, MAP: Mean Arterial Pressure, CO: Cardiac Output, SVR: Systemic Vascular Resistance, 
PAP: Mean Pulmonary Arterial Pressure, LAP: Mean Left Atrial Pressure, PVR: Pulmonary Vascular 
Resistance, NLA: NO synthase inhibitor Nω- nitro-L-arginine, EMD: PDE5 inhibitor EMD360527 Data are 
mean ± S.E.M.; *P≤0.05 vs rest (lying); †P≤0.05 effect of PDE5 inhibition with EMD360527
Regulation of pulmonary vascular tone in health and disease
170
the vasodilator responses to EMD360527, in the absence of NLA (Fig. 3). During 
exercise, the pulmonary vasodilation by EMD360527 was maintained, while the 
systemic vasodilation by EMD360527 decreased, compared to the vasodilation by 
EMD365027 during resting conditions (Fig. 3).
The vasodilator responses of individual animals to EMD360527 in the systemic 
and pulmonary vascular beds, both at rest and during exercise and both in absence 
or presence of NLA, correlated well with the baseline values obtained just prior to 
administration of EMD360527, while the depressor responses correlated much less, 
reaching statistical signiﬁ cance only in the pulmonary circulation (Fig. 4).
Effects of SNP in the presence of NO synthase inhibition
To investigate whether the vasculature becomes more sensitive to the 
vasodilator inﬂ uence of NO/cGMP after increased inhibition of NO synthase, the 
NO donor SNP was infused intravenously under control conditions and after NO 
synthase inhibition with NLA. Under control conditions, SNP in a dose range of 0.5-
3.0 µg min kg-1 iv resulted in mild vasodilator responses in systemic (16±5%) and 
pulmonary (4±8%) circulation (Fig. 5). Conversely, following NLA, the vasodilator 
responses were enhanced in both the systemic (47±5%) and pulmonary (34±13%) 
vascular bed (all P<0.05 by ANOVA).
Discussion
The main ﬁ ndings of the present study are that (i) the PDE5-inhibitor EMD360527 
resulted in dose-dependent vasodilation in the pulmonary and systemic circulation 
of awake swine under resting conditions; (ii) the pulmonary circulation displayed 
slightly higher sensitivity to the vasodilator inﬂ uence of EMD360527 than the 
systemic circulation; (iii) the effect of EMD360527 in the pulmonary circulation 
was well maintained during exercise, while it decreased slightly in the systemic 
circulation; (iv) inhibition of NO-synthase increased the vasodilator effect of 
EMD360527 and of nitroprusside in both pulmonary and systemic circulation. The 
implications of these ﬁ ndings will be discussed.
Effects of PDE5-inhibition on pulmonary vascular resistance
Many vasoactive substances inﬂ uence vascular resistance by increasing the 
production of the second messengers cAMP and/or cGMP within vascular smooth 
muscle cells. These second messengers are short-lived because they are degraded 
by PDE allowing tight control of vascular tone [28]. At least eleven different gene 
families of PDE are currently known to exist in mammalian tissues but the tissue 
171
Chapter 7: Phosohodiesterase 5 inhibition in normal swine
Fi
gu
re
 3
: 
Th
e 
ef
fe
ct
s 
of
 t
he
 P
D
E5
 i
nh
ib
it
or
 E
M
D
36
05
27
 a
lo
ne
 a
nd
 a
ft
er
 p
ri
or
 a
dm
in
is
tr
at
io
n 
of
 t
he
 N
O
 s
yn
th
as
e 
in
hi
bi
to
r 
N
LA
 i
n 
sw
in
e 
on
 
m
ea
n 
ar
te
ri
al
 b
lo
od
 p
re
ss
ur
e 
(M
A
P,
 n
=1
1 
w
it
ho
ut
 N
LA
 a
nd
 n
=9
 w
it
h 
N
LA
),
 s
ys
te
m
ic
 v
as
cu
la
r 
re
si
st
an
ce
 (
SV
R,
 n
=9
 w
it
ho
ut
 N
LA
 a
nd
 n
=6
 w
it
h 
N
LA
),
 p
ul
m
on
ar
y 
ar
te
ry
 p
re
ss
ur
e 
(P
A
P,
 n
=1
1 
w
it
ho
ut
 N
LA
 a
nd
 n
=9
 w
it
h 
N
LA
) 
an
d 
pu
lm
on
ar
y 
va
sc
ul
ar
 r
es
is
ta
nc
e 
(P
VR
, 
n=
9 
w
it
ho
ut
 N
LA
 a
nd
 
n=
6 
w
it
h 
N
LA
) 
at
 r
es
t 
(0
S:
 s
ta
nd
in
g 
an
d 
0 L
: 
ly
in
g)
 a
nd
 d
ur
in
g 
ex
er
ci
se
 (
1-
5 
km
 h
-1
).
 *
 P
<0
.0
5 
by
 A
N
O
VA
, 
ef
fe
ct
 o
f 
PD
E5
 i
nh
ib
it
io
n 
di
ff
er
en
t 
du
ri
ng
 e
xe
rc
is
e,
 ‡
 P
=0
.0
8 
by
 A
N
O
VA
, 
ef
fe
ct
 o
f 
PD
E5
 i
nh
ib
it
io
n 
di
ff
er
en
t 
du
ri
ng
 e
xe
rc
is
e,
 †
P<
0.
05
 b
y 
A
N
O
VA
, 
ef
fe
ct
 o
f 
PD
E5
 i
nh
ib
it
io
n 
af
te
r 
N
LA
 v
s 
ef
fe
ct
 o
f 
PD
E5
 i
nh
ib
it
io
n 
al
on
e.
0
0
1
2
3
4
5
MAP mmHg)
608010
0
12
0
14
0
0
0
1
2
3
4
5
SVR (mmHg/ml/min)
010203040
E
xe
rc
is
e 
le
ve
l (
km
/h
)
0
0
1
2
3
4
5
PVR (mmHg/ml/min)
0246
0
0
1
2
3
4
5
PAP (mmHg)
01020304050
C
on
tr
ol
E
M
D
0
0
1
2
3
4
5
608010
0
12
0
14
0
N
LA
N
LA
+E
M
D
0
0
1
2
3
4
5
010203040
E
xe
rc
is
e 
le
ve
l (
km
/h
)
0
0
1
2
3
4
5
0246
0
0
1
2
3
4
5
01020304050
L
S
L
S
L
S
L
S
L
L
S
L
S
L
SSC
on
tr
ol
E
M
D
N
LA
N
LA
+E
M
D
E
xe
rc
is
e 
le
ve
l (
km
/h
)
E
xe
rc
is
e 
le
ve
l (
km
/h
)
S
ys
te
m
ic
 c
irc
ul
at
io
n
P
ul
m
on
ar
y 
ci
rc
ul
at
io
n
*
* ‡
*
* *† †
)
Regulation of pulmonary vascular tone in health and disease
172
distribution of the PDE-isoforms as well as their speciﬁ city for cAMP and cGMP 
varies [29]. Inhibition of PDE in vascular smooth muscle can provide a powerful 
tool to reduce vascular resistance, by prolonging the half-life of cAMP and/or 
cGMP. The PDE isoforms that are predominantly present in vascular smooth muscle 
are PDE1, 3, 4, 5, 7 and 9. [30, 31]. PDE1, PDE4 and PDE7 are cAMP-speciﬁ c, while 
PDE3 has a 4-10 times higher afﬁ nity for cAMP than for cGMP. PDE5 and PDE9 
are cGMP-speciﬁ c [29]. However, PDE9 is abundantly expressed throughout the 
body [29], whereas PDE5 expression is 10 times more abundant in the pulmonary 
vasculature as compared to the heart [9, 10]. Thus, PDE5 inhibition may provide a 
tool to preferentially reduce pulmonary vascular resistance, while leaving systemic 
vascular resistance principally unchanged.
In the present study we found that the PDE5 inhibitor EMD360527 decreased 
both systemic and pulmonary vascular resistance. Yet, the pulmonary circulation 
appeared to be slightly more sensitive to EMD360527, as the relative decreases in 
PAP and PVR were greater than the decreases in MAP and SVR. These ﬁ ndings are 
in agreement with several other experimental studies [32, 33]. Similarly, most 
studies in patients with pulmonary hypertension show that pulmonary pressure 
decreases more in response to PDE5 inhibition as compared to systemic arterial 
pressure [7, 11, 12]. The degree of selectivity may depend, at least in part, on the 
particular PDE5 inhibitor and/or dosage that is used [13, 14].
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Figure 4: Responses of mean 
arterial pressure (MAP), 
systemic vascular resistance 
(SVR), pulmonary arterial 
pressure (PAP) and pulmonary 
vascular resistance (PVR) to 
PDE5 inhibitor EMD360527 in 
the absence (open symbols) and 
presence (closed symbols) of 
inhibition of NO synthase.  Each 
point in the ﬁ gure shows a data 
point of an individual animal at 
1 exercise level. Regression lines 
are shown as solid lines. The 
relation between parameters 
within one ﬁ gure was assessed 
using linear regression.
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Effects of PDE5 inhibition on pulmonary vascular resistance during treadmill 
exercise
In agreement with previous observations from our laboratory [24, 34], we found 
that exercise had minimal effects on PVR. Consequently, in parallel to the increase 
in cardiac output, PAP almost doubled during exercise, whereas the exercise-
induced systemic vasodilation maintained MAP constant. The modest exercise-
induced pulmonary vasodilation is enhanced by endothelin receptor blockade 
[35], and is blunted by NO synthase inhibition [24, 27, 34], demonstrating that 
pulmonary vasomotor tone is the resultant of an interplay between vasodilator and 
vasoconstrictor inﬂ uences. The pulmonary vasodilator effect of PDE5-inhibition 
observed under resting conditions was well maintained during exercise. Since 
the exercise capacity in the patients with pulmonary hypertension is inversely 
correlated with PVR [36], these observations, may explain the PDE5-inhibitor-
induced improvement in exercise capacity that is observed in patients with 
pulmonary hypertension [14, 37].
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Effects of PDE5 inhibition on pulmonary and systemic resistance in the presence 
of NO inhibition
Pulmonary hypertension may be accompanied by endothelial dysfunction, 
resulting in decreased eNOS activity and consequently cGMP production may 
decrease [19-21]. To simulate this condition we administered NLA to block 
endothelial NO synthase and compared the effect of PDE5 inhibition before and 
after NLA. We found that the effect of EMD360527 inhibition both at rest and during 
exercise was larger after prior inhibition of NO synthase. This observation appears 
at odds with several studies in anesthetized animal preparations, which reported 
that inhibition of NO synthase blunted the pulmonary vasodilator responses PDE5-
inhibition. For example, Mc Mahon et al reported that the NO synthase inhibitor 
L-NAME blunted the vasodilator effect of zaprinast in the cat pulmonary vascular 
bed [38]. Also, in lambs with acute pulmonary hypertension produced with either 
the thromboxane A2 analogue U46619 or the NO synthase inhibitors L-NAME or NLA, 
the vasodilator effects of PDE5 inhibition by zaprinast or sildenaﬁ l were reported 
to be signiﬁ cantly lower in the presence of NO synthase inhibition as compared to 
U46619 [32, 33]. An explanation for these disparate results is not readily found, 
but may be due to the type of PDE5 inhibitor or may be species-dependent. This 
is supported by observations in anaesthetized rabbits, in which the vasodilation 
produced by EMD360527 was not affected by pretreatment with L-NAME (personal 
communication with Dr. P. Schelling, E. Merck Darmstadt).
Several reasons could be forwarded to explain the unperturbed vasodilator 
response to EMD360527 in the presence of NLA. First, a large number of other 
mediators cause vasodilation via stimulation of sGC, including carbon monoxide [39] 
and hydrogen peroxide [40, 41]. Furthermore, there is evidence that blockade of 
NO production may result in increased carbon monoxide [42] and hydrogen peroxide 
[40] production, which could act to compensate for the loss of NO-induced cGMP 
production. Second, the natriuretic peptide family of proteins (consisting of atrial, 
brain and C-terminal natriuretic peptide (ANP, BNP and CNP)) cause increases in 
cGMP by activating particulate GC [43] and may exert an increased vasodilator 
inﬂ uence after NO synthase inhibition [44]. Third, it has been suggested that 
inhibition of NO synthase results in supersensitization of the NO/cGMP pathway 
[45], thereby resulting in enhanced response to vasodilators acting via the NO/cGMP 
pathway [46, 47]. This concept is supported by our observation that the pulmonary 
and systemic vasodilator responses to the NO donor nitroprusside were enhanced 
by pretreatment with NLA and could in part explain the enhanced vasodilator 
response to PDE5. Finally, it is also possible that the increased vasodilator response 
to EMD360527 was increased following NLA, simply due to an increase in basal 
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tone. This is illustrated in ﬁ gure 4, which suggests that the initial level of PVR is a 
strong determinant of the degree of vasodilation produced by EMD360527.
Conclusions
The PDE5 inhibitor EMD360527 produced pulmonary vasodilation in awake 
resting swine that was maintained during treadmill exercise. Inhibition of NO 
synthase enhanced the vasodilator response not only to nitroprusside, but also to 
EMD360527. Patients with severe pulmonary hypertension, often have endothelial 
dysfunction and therefore a decreased NO synthase activity [19-21]. The 
observation that inhibition of PDE5 was enhanced following NO synthase inhibition 
and correlated well with the basal level of pulmonary resistance vessel tone, 
suggests that PDE5 inhibition may be most effective in patients with the severest 
degree of pulmonary hypertension.
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Chapter 8
Pulmonary vasodilator effect of 
phosphodiesterase 5 inhibition is enhanced in 
swine with pulmonary hypertension after a recent 
myocardial infarction
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Abstract
Myocardial infarction (MI) results in secondary pulmonary hypertension, which 
poses an increased workload for the right ventricle and may ultimately lead to right 
ventricular failure. In swine, after induction of MI, pulmonary artery pressures 
are increased reﬂ ecting pulmonary hypertension. Inhibition of phosphodiesterase 
5 (PDE5), the enzyme responsible for the breakdown of cGMP in vascular smooth 
muscle, has been proposed to be of beneﬁ t for the alleviation of pulmonary 
hypertension. In the present study, we investigated the pulmonary hemodynamic 
effect of PDE5 inhibition in swine with pulmonary hypertension secondary to MI.
 Nitric oxide (NO) is an important source of cGMP via soluble guanylate cyclase, 
while other sources can produces cGMP also, for example atrial natriuretic peptides 
(ANP) produce cGMP via particulate guanylate cylase. Since NO production can be 
enhanced in early pulmonary hypertension and decreased in severe pulmonary 
hypertension, we investigated the role of NO as a source of cGMP in the pulmonary 
circulation in swine with pulmonary hypertension after MI. The PDE5 inhibitor 
EMD360527 (300 µg min kg-1 iv) was administered in chronically instrumented swine 
with (n=8) and without (n=13) MI. 
Inhibition of PDE5 resulted in pulmonary vasodilation as evidenced by a 
decrease in pulmonary arterial pressure as well as a decrease in pulmonary 
vascular resistance (PVR). This response was slightly larger in MI compared to 
normal swine. Inhibition of NO resulted in similar increases in PVR in normal and MI 
swine. Furthermore, prior NO synthase inhibition enhanced pulmonary vasodilation 
by PDE5 inhibition in both normal and MI swine so that a larger effect of PDE5 
inhibition was still apparent in swine with MI. This suggests that the increase in 
vasodilator response to PDE5 inhibition after MI was not due to an increase in NO 
mediated cGMP production. In conclusion, PDE5 inhibition may be a useful strategy 
to treat pulmonary hypertension secondary to MI. The greater vasodilator response 
to PDE5 inhibition in MI swine does not appear to be the result of an increased NO 
production early after MI. 
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Introduction
Pulmonary hypertension after myocardial infarction is a severe disease 
with a poor prognosis if untreated [1]. In pulmonary hypertension, endothelial 
dysfunction accounts for an imbalance between vasodilators (nitric oxide (NO) and 
prostacyclin) and vasoconstrictors (endothelin) resulting in impaired vasodilation 
and exaggerated vasoconstriction [2-4]. This imbalance between production 
of vasodilators and vasoconstrictors likely contributes to the sustained state of 
pulmonary vasoconstriction after MI.
However, endothelial dysfunction appears to be present in severe pulmonary 
hypertension, while in the early stages NO production can be enhanced. In these 
early stages the pulmonary vasoconstriction may increase shear stress, thereby 
increasing NO production and counteracting the development of pulmonary 
hypertension [5-7]. This is in accordance with a study in humans, showing that 
basal NO-activity is reduced in patients with severe pulmonary hypertension, but 
not in patients with mild pulmonary hypertension [8]. These observations suggest 
that the normal response of the pulmonary circulation to pulmonary hypertension 
is to increase the synthesis of NO in an attempt to restore normal tone until 
sustained vasoconstriction eventually results in endothelial dysfunction. Indeed, 
in our swine model of pulmonary hypertension as a result of a recent MI, NO-
induced vasodilation appears to be unaltered [9], although we have recently shown 
that endothelin-induced pulmonary vasoconstriction [10] and prostanoid-induced 
vasodilation [Chapter 6] are enhanced after MI. 
NO-induced vasodilation is mediated through production of cGMP by soluble 
gyanylate cyclase (GC) and reduction in intracellular Ca2+ concentration. NO 
signaling is terminated through removal of cGMP by phosphodiesterase 5 (PDE5), 
which removes cGMP by hydrolyzing it to 5’ GMP [11]. Therefore, inhibition of PDE5 
has been proposed to be of beneﬁ t for the alleviation of pulmonary hypertension 
by prolonging the action of NO. In a previous study we showed that in normal 
swine, inhibition of PDE5 results in vasodilation of the pulmonary vascular bed 
[Chapter 7]. Another enzyme that produces cGMP is particulate GC, which is 
activated through atrial natriuretic peptide (ANP) [12]. ANP levels are elevated in 
patients with cardiovascular diseases and pulmonary hypertension [13, 14] and in 
our animal model after MI [15, 16]. This could lead to increased levels of cGMP after 
MI thereby further enhancing the potential beneﬁ cial effects of PDE5 inhibition.
The increased ANP levels after MI, in combination with the unaltered NO-
induced vasodilation, led us to hypothesize that the vasodilator effect of inhibition 
of PDE5 in the pulmonary circulation would be increased after MI. Results of the 
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present study indeed showed an increased vasodilator effect of inhibition of PDE5 
in the pulmonary circulation. Hence, since we hypothesized that this increased 
response was not the result of altered NO induced cGMP production, we secondly 
investigated the role of NO by inhibiting NO synthase with Nω-nitro-L-Arginine 
(NLA) prior to inhibition of PDE5.
Methods
Studies were performed in accordance with the “Guiding Principles in the 
Care and Use of Laboratory Animals” as approved by the Council of the American 
Physiological Society, and with approval of the Animal Care Committee of the 
Erasmus MC Rotterdam. Twenty-one crossbred Landrace x Yorkshire swine of either 
sex (2-3 months old) entered the study. 
Surgical procedures
Swine were sedated with ketamine (30 mg kg-1 im), anaesthetized with 
thiopental (10 mg kg-1 iv), intubated and ventilated with a mixture of O2 and 
N2O (1:2) to which 0.2-1% (v/v) isoﬂ urane was added [17, 18]. Anaesthesia was 
maintained with midazolam (2 mg/kg + 1 mg kg-1 per hour iv) and fentanyl (10 µg 
kg-1 per hour iv). Under sterile conditions, the chest was opened via the fourth left 
intercostal space and a ﬂ uid-ﬁ lled polyvinylchloride catheter was inserted into the 
aortic arch and pulmonary artery for blood pressure measurement (Combitrans 
pressure transducers, Braun, Melsungen, Germany) and blood sampling. 
An electromagnetic ﬂ ow probe (14-15 mm, Skalar) was positioned around the 
ascending aorta for measurement of cardiac output. A polyvinylchloride catheter 
was also inserted into the left atrium to measure pressure. In all 28 swine the 
proximal part of the left coronary circumﬂ ex artery (LCx) was exposed, but only in 
12 animals the LCx was permanently occluded with a silk suture to produce an MI 
[16, 19]. One MI swine died during surgery due to recurrent ﬁ brillation. Catheters 
were tunnelled to the back and animals were allowed to recover, receiving 
analgesia (0.3 mg buprenorphine im) for 2 days and antibiotic prophylaxis (25 mg 
kg-1 amoxicillin and 5 mg kg-1 gentamycin iv) for 5 days.
Experimental  protocols
Studies were performed approximately 2 weeks after surgery. 
Effect of PDE5-inhibition: After hemodynamic measurements (lying and 
standing) consisting of left atrial, aortic and pulmonary artery blood pressures, heart 
rate and cardiac output, blood samples (lying), and rectal temperature (standing) 
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had been obtained, swine (12 normal and 6 MI) were subjected to a four-stage 
exercise protocol on a motor driven treadmill (1-4 km h-1). Hemodynamic variables 
were continuously recorded and blood samples collected during the last 60 s of 
each 3 min exercise stage, at a time when hemodynamics had reached a steady 
state. After 90 minutes of rest, the PDE5 inhibitor EMD360527, was administered 
by an infusion of 300 mg min kg-1 iv and after ten minutes of infusion the exercise 
protocol was repeated, with continuous infusion of the EMD 360527 during the 
entire protocol [Chapter 7].  
Effect of PDE5-inhibition after NO-inhibition: On a different day, the eNOS 
inhibitor Nω-nitro-L-Arginine (NLA) was administered to swine (10 normal and 5 MI, 
of which 9 normal and 3 MI had also participated in the above described protocol) 
in a dose of 20 mg kg-1 iv prior to the ﬁ rst exercise protocol. After 90 minutes of 
rest, the PDE5 inhibitor was administered as described above and the exercise 
protocol was repeated. 
Blood Gas Measurements
Blood samples were kept in iced syringes until the conclusion of each exercise 
trial. Measurements of PO2 (mmHg), PCO2 (mmHg) and pH were then immediately 
performed with a blood gas analyser (Acid-Base Laboratory Model 505, Radiometer, 
Copenhagen, Denmark). Oxygen saturation and hemoglobin (grams per 100 ml) were 
measured with a hemoximeter (OSM2, Radiometer). Blood O2 content (mmol/ml) 
was computed as (Hb·0.621·O2-saturation) + (0.00131·PO2). Body O2 consumption 
(BVO2) was calculated as the product of cardiac output and the difference in O2 
content between arterial and mixed venous blood [17, 18].
Data Analysis
Digital recording and off-line analysis of hemodynamics have been described 
previously [18, 20]. Systemic vascular resistance (SVR) was computed as mean 
aortic blood pressure (MAP) divided by cardiac output (CO). Pulmonary vascular 
resistance (PVR) is deﬁ ned as mean pulmonary artery pressure (PAP) minus mean 
left atrial pressure (LAP) divided by cardiac output. 
Statistical analysis
To test for the effects of MI and drug treatment (EMD 360527 in presence 
or absence of NLA) on the relation between BVO2 and PVR, regression analysis 
was performed using MI, drug treatment and BVO2 as well as their interaction as 
independent variables and assigning a dummy variable to each animal. Statistical 
signiﬁ cance was accepted when P<0.05. Data are presented as mean±S.E.M.
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Results
Effects of EMD 360527 during exercise
Exercise up to 4 km h-1 in normal swine resulted in an increase in cardiac 
output of 105±5% that was principally due to an increase in heart rate by 114±6% 
(table 1). Mean aortic blood pressure was minimally affected (Table 1), implying 
that the increase in cardiac output was balanced by a similar decrease in systemic 
vascular resistance. Mean pulmonary artery pressure almost doubled in normal 
swine during exercise. However, the transpulmonary pressure gradient (pulmonary 
artery pressure minus left atrial pressure) increased in approximately the same 
amount as cardiac output, reﬂ ecting an unchanged PVR during exercise (Fig. 1).
After MI, mean resting pulmonary arterial pressure increased from 17 ±1 to 
23±2 mmHg (table 1), which was in part the result of the increased mean left 
atrial pressure (normal swine, 6±1 mmHg; MI swine, 12±2 mmHg, table 1). Cardiac 
output was virtually maintained both at rest and during treadmill exercise in MI 
compared to normal swine (table 1) despite a 21% lower stroke volume. Pulmonary 
arterial pressure was elevated by 35%, which was partly due to an increase in left 
atrial pressure of 50% and partly due to a 37% increase in PVR 
Administration of the PDE5 inhibitor EMD360527 caused vasodilation in the 
systemic and pulmonary bed of normal and MI swine (table 1, Fig. 1). Mean arterial 
pressure decreased and cardiac output increased both in normal and MI swine, 
resulting in a decreased systemic vascular resistance at rest (18±5% in normal and 
20±5% in MI swine), which slighly waned during exercise (respectively to 15±2% and 
17±3% at 4 km h-1) Pulmonary artery pressure and pulmonary vascular resistance 
decreased after administration of the PDE5 inhibitor EMD360527, indicating 
vasodilation in the pulmonary vascular bed (table 1, Fig. 1), which was signiﬁ cantly 
larger in the MI swine than in normal swine. During exercise the vasodilator effect 
of EMD360527 on the pulmonary vascular resistance increases in normal swine 
(from 15±9% at rest to 29±3% at 4 km h-1) and was maintained in MI swine (Fig. 1).
Effects of combined NLA and EMD 360527 during exercise
Administration of the NO synthase inhibitor NLA resulted in a marked increase in 
aortic blood pressure, which resulted from systemic vasoconstriction in both normal 
and MI swine (table 1). This vasoconstriction was maintained during exercise. In 
the pulmonary circulation NO inhibition also resulted in marked vasoconstriction, 
demonstrated by an increase in pulmonary vascular resistance, which was 
maintained in normal and increased in MI swine during exercise (Fig.1).
Administration of the PDE5 inhibitor EMD360527 after prior administration of 
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MAP
(mmHg)
SVR
(mmHg/l/min)
PAP
(mmHg)
LAP
(mmHg)
      Rest           Exercise level (km h-1)  
 n Treatment Infarct lying standing   1     2     3     4   
12 Control - 124 ± 1 139 ± 3*   170 ± 3* 183 ± 4* 202 ± 7* 240 ± 8* 
 EMD - 144 ± 5† 156 ± 5*†   178 ± 4* 193 ± 5* 218 ± 8*† 244 ± 8* 
6 Control + 142 ± 5‡ 155 ± 7*‡   181 ± 3* 188 ± 3* 206 ± 3* 233 ± 8* 
 EMD + 150 ± 8 165 ± 3   187 ± 3* † 199 ± 3* † 215 ± 4* † 232 ± 6* 
10 NLA - 89 ± 4 112 ± 3*   125 ± 3* 132 ± 2* 150 ± 3* 193 ± 8* 
  NLA+ EMD - 102 ± 8†  122 ± 6*   135 ± 7* 147 ± 7*† 164 ± 7*† 199 ± 8* 
5 NLA + 106 ± 6‡ 128 ± 8*   149 ± 6*‡ 158 ± 6*‡ 179 ± 9*‡ 195 ± 9* 
  NLA+ EMD + 121 ± 6‡ 149 ± 6*†‡   155 ± 4†‡ 176 ± 12‡ 183 ± 9‡ 204 ± 10‡ 
10 Control - 4.4 ± 0.2 5.4 ± 0.3*   6.4 ± 0.3* 6.9 ± 0.3* 7.4 ± 0.3* 8.5 ± 0.3* 
 EMD - 5.0 ± 0.2† 5.7 ± 0.3*   6.6 ± 0.3* 7.0 ± 0.3* 8.2 ± 0.3*† 9.1 ± 0.3*† 
6 Control + 4.1 ± 0.1 4.9 ± 0.1*   5.8 ± 0.2* 6.2 ± 0.2* 6.8 ± 0.2* 7.5 ± 0.2* 
 EMD + 4.6 ± 0.2 5.7 ± 0.2* †   6.3 ± 0.1* † 6.8 ± 0.2* † 7.5 ± 0.2* † 8.0 ± 0.2* 
7 NLA - 3.1 ± 0.2 4.3 ± 0.3*   5.0 ± 0.3* 5.6 ± 0.4* 6.2 ± 0.4* 7.3 ± 0.4* 
 NLA+ EMD - 3.6 ± 0.2† 5.0 ± 0.3*   5.6 ± 0.4* 6.1 ± 0.4*† 6.9 ± 0.4*† 8.1 ± 0.4*† 
4 NLA + 3.1 ± 0.2 4.2 ± 0.2   4.8 ± 0.2* 5.1 ± 0.1* 5.7 ± 0.4* 6.1 ± 0.2* 
 NLA+ EMD + 4.0 ± 0.2‡ 5.5 ± 0.4†‡   5.6 ± 0.2†‡ 6.6 ± 0.7‡ 6.7 ± 0.4‡ 7.3 ± 0.6‡ 
12 Control - 89 ± 2 87 ± 3   84 ± 2* 85 ± 2* 86 ± 3 89 ± 3 
 EMD - 80 ± 2† 76 ± 3*†   74 ± 2*† 76 ± 2† 78 ± 2† 80 ± 2† 
6 Control + 89 ± 5 81 ± 5*   79 ± 3 77 ± 2 79 ± 2 79 ± 2 
 EMD + 80 ± 4† 67 ± 2*†   69 ± 2*† 69 ± 2*† 70 ± 2† 69 ± 2†‡ 
10 NLA - 121 ± 3 111 ± 3*   111 ± 2* 112 ± 3* 115 ± 3 116 ± 3 
 NLA+ EMD - 106 ± 4† 105 ± 5   104 ± 4† 106 ± 4† 105 ± 3† 106 ± 3† 
5 NLA + 116 ± 3 113 ± 3   113 ± 4 114 ± 2 112 ± 2 110 ± 3 
 NLA+ EMD + 108 ± 4‡ 101 ± 3‡   100 ± 2†‡ 99 ± 2†‡ 100 ± 3†‡ 100 ± 3† 
10 Control - 20.3 ± 1.1 16.0 ± 1.1*   13.0 ± 0.6* 12.1 ± 0.5* 11.4 ± 0.5* 10.3 ± 0.4* 
 EMD - 16.1 ± 0.9† 13.1 ± 0.7*†   10.9 ± 0.5*† 10.5 ± 0.4*† 9.2 ± 0.3*† 8.6 ± 0.3*† 
6 Control + 21.9 ± 0.7 16.7 ± 1.0*   13.9 ± 0.8* 12.5 ± 0.5* 11.7 ± 0.4* 10.5 ± 0.4* 
 EMD + 17.7 ± 1.5† 12.0 ± 0.6*†   10.8 ± 0.4*† 10.2 ± 0.4*† 9.4 ± 0.2*† 8.6 ± 0.2*† 
7 NLA - 39.3 ± 2.3 27.0 ± 1.7*   22.6 ± 1.4* 20.9 ± 1.5* 18.7 ± 1.1* 15.9 ± 0.7* 
 NLA+ EMD - 30.7 ± 2.3† 21.7 ± 1.7*†   19.1 ± 1.4* 17.1 ± 1.0*† 15.0 ± 0.6*† 12.9 ± 0.5*† 
4 NLA + 38.2 ± 2.6 27.1 ± 1.1   23.9 ± 1.7 22.2 ± 0.7* 19.6 ± 1.0* 17.9 ± 0.7* 
 NLA+ EMD + 27.1 ± 0.3‡ 18.3 ± 0.8†‡   18.0 ± 0.3†‡ 15.6 ± 1.6‡ 15.3 ± 1.1‡ 14.0 ± 1.1*†‡ 
12 Control - 17 ± 1 18 ± 1   22 ± 1* 24 ± 1* 27 ± 1* 34 ± 1* 
 EMD - 15 ± 1† 14 ± 1†   17 ± 1*† 19 ± 1*† 23 ± 1*† 26 ± 1*† 
6 Control + 23 ± 2‡ 23 ± 3‡   28 ± 3*‡ 29 ± 2*‡ 33 ± 3*‡ 36 ± 2* 
 EMD + 19 ± 2†‡ 17 ± 2†   22 ± 2†‡ 23 ± 2*†‡ 26 ± 2*†‡ 29 ± 3*† 
10 NLA - 22 ± 2 25 ± 2   27 ± 2 28 ± 2 33 ± 2* 39 ± 3* 
 NLA+ EMD - 15 ± 2† 16 ± 2†   18 ± 2† 21 ± 2*† 23 ± 2*† 29 ± 2*† 
5 NLA + 27 ± 4 30 ± 4   38 ± 5 40 ± 5*‡ 44 ± 4*‡ 46 ± 3* 
 NLA+ EMD + 20 ± 3†‡ 20 ± 4†‡   22 ± 4†‡ 29 ± 4†‡ 30 ± 4†‡ 34 ± 3†‡ 
10 Control - 6 ± 1 5 ± 1*   6 ± 1 7 ± 1 9 ± 1* 11 ± 1* 
 EMD - 4 ± 1 3 ± 1   5 ± 1 6 ± 1* 9 ± 1* 11 ± 1* 
6 Control + 12 ± 2‡ 11 ± 2‡   14 ± 2‡ 15 ± 2‡ 17 ± 2*‡ 19 ± 2* 
 EMD + 11 ± 2‡ 9 ± 2*‡   13 ± 2†‡ 15 ± 2*‡ 17 ± 2*‡ 19 ± 2* 
9 NLA - 8 ± 1 6 ± 1   7 ± 1 8 ± 1 10 ± 1 10 ± 1 
 NLA+ EMD - 6 ± 1 6 ± 2   7 ± 1 8 ± 1* 9 ± 1* 10 ± 1* 
4 NLA + 13 ± 2‡ 13 ± 2‡   16 ± 2‡ 16 ± 1‡ 17 ± 2‡ 17 ± 1 
 NLA+ EMD + 10 ± 2‡ 10 ± 3‡   12 ± 3†‡ 16 ± 2*‡ 17 ± 2*‡ 19 ± 2*‡ 
HR
(bpm)
CO
(l/min)
Table 1: Hemodynamics of swine at rest and during exercise before and after administration of 
EMD360527 and NLA
HR: Heart Rate, CO: Cardiac Output, MAP: Mean Arterial Pressure, SVR: Systemic Vascular Resistance, 
PAP: Mean Pulmonary Arterial Pressure, LAP: Mean Left Atrial Pressure, Data are mean ± S.E.M.; 
*P≤0.05 vs rest (lying); †P≤0.05 vs corresponding control, ‡P≤0.05 vs corresponding normal swine
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NLA, caused an increase in cardiac output and a decrease in mean arterial pressure 
in normal and MI swine, resulting in a decreased systemic vascular resistance at 
rest (23±5% in normal and 27±6% in MI swine), which slightly waned during exercise 
(respectively to 17±3% and 22±4% at 4 km h-1) (table 1). 
Inhibition of PDE5 also caused vasodilation in the pulmonary vascular bed of 
normal and MI swine, demonstrated by a decrease in pulmonary vascular resistance 
at rest (32±12% in normal and 42±5% in MI swine), which increased slightly during 
exercise (respectively to 41±3% and 57±5% at 4 km h-1) (Fig.1). Surprisingly, the effect 
of PDE5 inhibition after inhibition of NO synthase is larger than the effect of PDE5 
inhibition alone, indicating that even though there is a loss of NO, the availability 
or sensitivity of cGMP is enlarged. The effect on the pulmonary vascular resistance 
of MI swine is also slightly larger than the effect on the pulmonary circulation of 
normal animals and increases with incremental exercise level (Fig.1).
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Figure 1: The effects of the PDE5 inhibitor EMD360527 alone and after prior administration of the 
NO synthase inhibitor NLA in normal swine (circles) and MI swine (squares) on pulmonary vascular 
resistance (PVR, upper panels) and pulmonary artery pressure (PAP, lower panels) plotted as a function 
of body O2 consumption. Control exercise trials are shown as open symbols, exercise trials in the 
presence of antagonists are shown as solid symbols. *P<0.05 effect of EMD360527 vs corresponding 
Control, † P<0.05 effect of EMD 360527 different after MI, ‡P<0.05 effect of EMD360527 after NLA vs 
effect of EMD360527 alone
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The main ﬁ ndings of the present study are that (i) PDE5-inhibition results in 
vasodilation in the pulmonary circulation of normal swine and MI swine both at rest 
and during exercise; (ii) after MI, PDE5-inhibition induced pulmonary vasodilation 
was slightly enhanced; (iii) in both normal and MI swine, the effect of PDE5 
inhibition at rest and during exercise was similarly enhanced after prior inhibition 
of NO synthase.
cGMP/PDE in pulmonary hypertension
In the present study we found that PDE5 inhibition in swine with secondary 
pulmonary hypertension after MI has a larger effect than in the normal swine 
under resting conditions, which indicates that there are increased cGMP-levels or 
an increased PDE5 activity. Increased levels of cGMP can be the result of increased 
NO synthase, which is found in early stages of pulmonary hypertension [6, 7] as is 
likely present in our model 2-3 weeks after MI. In our model we have previously 
shown that the vasodilator response of NO is maintained in pulmonary hypertension 
after myocardial infarction, but it is possible that increased NO synthase was 
accompanied by a similar increase in PDE5 activity. This is in accordance with 
studies that found that the NO-cGMP pathway is altered in pulmonary hypertension, 
demonstrated by different observations in animal models that cGMP activity and 
PDE5 activity are increased [21-24]. However, two studies showed that it leads to 
a net result of increased levels of cGMP [22, 23]. 
cGMP can also be produced through activation of particulate GC by ANP. ANP 
is stored within atrial secretory granules and is released in response of increased 
wall stress or pressure [25].  In pulmonary hypertension after myocardial infarction 
atrial pressures are increased and can thereby contribute to increased levels of 
ANP that is found in patients with pulmonary hypertension [26]. In accordance 
with these ﬁ nding, we have previously shown that ANP levels are in increased in 
our model of pulmonary hypertension [15, 16]. Since increased levels of ANP can 
lead to increased production of cGMP, the increased vasodilator effect on PDE5 
inhibition in MI swine could be the result of these increased levels of ANP. Future 
studies with an ANP receptor antagonist [27] are needed to further explore this 
hypothesis. However, inhibition of PDE5 after inhibition of NO, led to a decrease 
in pulmonary vascular resistance that was larger in swine with MI in comparison 
with normal swine. Thus, the increased response to PDE5 inhibition in pulmonary 
hypertension is preserved after inhibition of NO, indicating that this increased 
response was not NO-mediated.
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Conclusions and clinical relevance
Inhibition of PDE5 is often used to alleviate PAP and PVR in patients with 
pulmonary hypertension who suffer from endothelial dysfunction and therefore 
decreased availability of NO. Our study showed that patients with early pulmonary 
hypertension also beneﬁ t from the vasodilator capacity of PDE5 inhibition and 
that the effect is increased after MI in comparison with the healthy pulmonary 
circulation, probably as a result of increased cGMP availabilty or activity that 
was not NO-mediated. In addition, when patients develop endothelial dysfunction 
and decreased NO synthase as a result of aggravation of pulmonary hypertension, 
inhibition of PDE5 still results in pulmonary vasodilation and decreases PAP and 
PVR. 
Patients with pulmonary hypertension have a decreased exercise capacity 
because of the increased afterload of the right ventricle. Indeed, Franciosa et 
al found that it is the right ventricle and PAP that limit the exercise capacity 
in patients with left ventricular failure [28]. The present study showed that the 
decreases in PAP and PVR following inhibition of PDE5 are maintained during 
exercise, speculating that this therapy could increase exercise capacity in patients 
with pulmonary hypertension after myocardial infarction.
Regulation of pulmonary vascular tone in health and disease
192
1. Galie, N., et al., Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The 
Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European
Society of Cardiology. Eur Heart J, 2004. 25(24): p. 2243-78. 
2. Budhiraja, R., R.M. Tuder, and P.M. Hassoun, Endothelial dysfunction in pulmonary hypertension. 
Circulation, 2004. 109(2): p. 159-65. 
3. Moraes, D.L., W.S. Colucci, and M.M. Givertz, Secondary pulmonary hypertension in chronic heart 
failure: the role of the endothelium in pathophysiology and management. Circulation, 2000.
102(14): p. 1718-23. 
4. Tuder R, C.C., Geraci M, et al., Prostacyclin synthase expression is decreased in lungs from
patients with severe pulmonary hypertension. Am J Resp Crit Care Med, 1999. 159: p. 1925-32. 
5. Black, S.M., et al., Increased endothelial NOS in lambs with increased pulmonary blood flow and 
pulmonary hypertension. Am J Physiol Heart Circ Physiol, 1998. 275(5): p. H1643-1651. 
6. Archer, S. and S. Rich, Primary Pulmonary Hypertension : A Vascular Biology and Translational 
Research "Work in Progress". Circulation, 2000. 102(22): p. 2781-2791. 
7. Hampl, V. and J. Herget, Role of nitric oxide in the pathogenesis of chronic pulmonary 
hypertension. Physiol Rev, 2000. 80(4): p. 1337-72. 
8. Cooper CJ, J.F., Walsh T, et al, The influence of basal nitric oxide activity on pulmonary vascular 
resistance in patients with congestive heart failure. Am J Cardiol, 1998. 82: p. 609-614. 
9. Haitsma, D.B., et al., Nitric oxide production is maintained in exercising swine with chronic left 
ventricular dysfunction. Am J Physiol Heart Circ Physiol, 2002. 282(6): p. H2198-209. 
10. Houweling, B., et al., Role of endothelin receptor activation in secondary pulmonary hypertension 
in awake swine after myocardial infarction. J Physiol, 2006. 574(Pt 2): p. 615-26. 
11. Rybalkin, S.D., et al., Cyclic GMP phosphodiesterases and regulation of smooth muscle function. 
Circ Res, 2003. 93(4): p. 280-91. 
12. Levin, E.R., D.G. Gardner, and W.K. Samson, Natriuretic peptides. N Engl J Med, 1998. 339(5): p. 
321-8. 
13. Yap, L.B., et al., The natriuretic peptides and their role in disorders of right heart dysfunction 
and pulmonary hypertension. Clin Biochem, 2004. 37(10): p. 847-56. 
14. Silver, M.A., The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol 
Hypertens, 2006. 15(1): p. 14-21. 
15. van Kats, J.P., et al., Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor 
blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin 
II. Circulation, 2000. 102(13): p. 1556-63. 
16. Haitsma, D.B., et al., Minimal impairment of myocardial blood flow responses to exercise in the 
remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and 
neurohumoral alterations. Cardiovasc Res, 2001. 52(3): p. 417-28. 
17. Duncker, D.J., et al., Role of K(ATP)(+) channels in regulation of systemic, pulmonary, and 
coronary vasomotor tone in exercising swine. Am J Physiol Heart Circ Physiol, 2001. 280(1): p. 
H22-33. 
References
 18. Stubenitsky, R., P.D. Verdouw, and D.J. Duncker, Autonomic control of cardiovascular 
performance and whole body O2 delivery and utilization in swine during treadmill exercise. 
193
Chapter 8: Phosohodiesterase 5 inhibition in swine with pulmonary hypertension after MI 
Cardiovasc Res, 1998. 39(2): p. 459-74. 
19. van der Velden, J., et al., Alterations in myofilament function contribute to left ventricular 
dysfunction in pigs early after myocardial infarction. Circ Res, 2004. 95(11): p. e85-95. 
20. Duncker, D.J., et al., Nitric oxide contributes to the regulation of vasomotor tone but does not 
modulate O(2)-consumption in exercising swine. Cardiovasc Res, 2000. 47(4): p. 738-48. 
21. Hanson, K.A., et al., Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase 
activity. Am J Physiol Lung Cell Mol Physiol, 1998. 275(5): p. L931-941. 
22. Cohen, A.H., et al., Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase
selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest, 1996.
97(1): p. 172-9. 
23. Black, S.M., et al., sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and 
pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2001. 281(5): p. L1051-1057. 
24. Li, D., N. Zhou, and R.A. Johns, Soluble guanylate cyclase gene expression and localization in rat
lung after exposure to hypoxia. Am J Physiol, 1999. 277(4 Pt 1): p. L841-7. 
25. de Bold, A.J., et al., The physiological and pathophysiological modulation of the endocrine 
function of the heart. Can J Physiol Pharmacol, 2001. 79(8): p. 705-14. 
26. Nootens, M., et al., Neurohormonal activation in patients with right ventricular failure from 
pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll 
Cardiol, 1995. 26(7): p. 1581-5. 
27. Delporte, C., et al., Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors 
in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol, 1992. 224(2-3): p. 183-8. 
28. Franciosa, J.A., B.J. Baker, and L. Seth, Pulmonary versus systemic hemodynamics in determining 
exercise capacity of patients with chronic left ventricular failure. Am Heart J, 1985. 110(4): p. 
807-13. 

Chapter 9
General discussion and summary
Regulation of pulmonary vascular tone in health and disease
196
197
Chapter 9:  General discussion and summary
General discussion and summary
The studies presented in this thesis were carried out to obtain a better understanding 
of the regulation of pulmonary vascular tone in health and disease. Investigation 
of the pulmonary circulation is important, because there is increasing evidence 
that the regulation of vascular tone in the pulmonary and systemic circulation is 
different [1, 2]. Hence, rational pharmacotherapy of pulmonary vascular diseases 
needs to be tailored to the pulmonary vascular bed. In particular, the regulation 
of pulmonary vascular tone during physical exercise has received little attention. 
This is surprising, in view of reports that the pulmonary circulation and the right 
ventricle are the main determinants of exercise capacity [3, 4].
Pulmonary hypertension is a disease with different etiologies and a poor 
prognosis if left untreated. One of the etiologies is myocardial infarction (MI)-
induced left ventricular dysfunction. The incidence of post-MI pulmonary 
hypertension is increasing because of considerably improved survival after acute 
MI. The pulmonary vascular mechanisms that contribute to post-MI pulmonary 
hypertension and the optimal therapy for patients with pulmonary hypertension 
secondary to MI have received little attention. These therapies are important 
to prevent right ventricular failure due to the high pulmonary pressure. There 
are studies in patients with heart failure, for example to investigate endothelin 
receptor blockers, where they also looked at the pulmonary circulation but the 
main goal in these studies is to alleviate heart failure [5, 6]. More studies should 
be conducted to investigate speciﬁ cally the pulmonary vascular regulation in 
patients with heart failure. In addition, patients with pulmonary hypertension are 
particularly vulnerable to the exercise-induced additional elevations in pulmonary 
artery pressure and exercise capacity is often reduced [3, 4]. Therapy therefore 
should be aimed to increase exercise capacity. Indeed one of the endpoints often 
used in clinical trials is the six-minute-walk. However, there is little literature 
about the regulation of pulmonary vascular tone in pulmonary hypertension during 
exercise. 
In light of these considerations, we investigated the regulation of pulmonary 
vascular tone at rest and during exercise in our swine model. We used healthy 
swine and swine with MI-induced pulmonary hypertension. This thesis consists of 
two parts. Part one (Chapter 2-4), describes the regulation of pulmonary vascular 
tone under physiological conditions. Speciﬁ cally, we investigated the integrative 
control of pulmonary vascular resistance by endothelium dependent vasodilators 
and vasoconstrictors, at rest and at various levels of physical activity. Part two 
(Chapter 5-8), describes the alterations in the regulation of pulmonary vascular 
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tone in swine with pulmonary hypertension secondary to an MI.
Regulation of pulmonary vascular tone in swine under physiological 
conditions.
The endothelium plays a crucial role in the regulation of vascular tone by 
producing both vasodilating (nitric oxide (NO) and prostacyclin) and vasoconstricting 
(endothelin (ET)) substances. In a previous study reported by our group it has 
been shown that endogenous NO exerts a vasodilator inﬂ uence on the systemic 
and pulmonary vasculature of awake swine at rest, while the exercise-induced 
vasodilation was only slightly blunted after inhibition of NO production [7]. Hence, 
other vasodilators, such as prostacyclin, might be involved in exercise-induced 
vasodilation and act to compensate when NO synthase (NOS) activity is blunted. 
In Chapter 2 of this thesis the contribution of prostanoids to the regulation of 
systemic, as well as pulmonary vascular tone was investigated in chronically 
instrumented swine performing treadmill exercise. Furthermore we studied 
whether the contribution of prostanoids to the regulation of vascular tone is 
enhanced after inhibition of NOS in exercising swine. The results of Chapter 2 
demonstrate that prostanoids are involved in the regulation of vascular tone in 
the systemic circulation and that the contribution of prostanoids to vasodilation is 
increased when NOS activity is inhibited. In contrast, prostanoids do not contribute 
to the regulation of pulmonary vascular tone, even not when NO production is 
attenuated.
The endothelium produces not only vasodilating but also vasoconstricting 
substances, such as ET [8]. ET exerts its inﬂ uence on the vasculature via the ETA 
and ETB receptor. Both receptors are located on vascular smooth muscle cells 
where they induce vasoconstriction, while ETB receptors are also located on the 
endothelial cells where they induce vasodilation and regulate clearance of ET. 
The net effect of ET is the result of its action on binding to both receptors [9]. 
In Chapter 3 we investigated the role of ET and its receptors in regulation of 
systemic and pulmonary vascular tone of swine at rest and during exercise, using a 
selective ETA as well as a mixed ETA/ETB receptor antagonist. The most important 
ﬁ ndings are that ET contributes to basal resting tone in the systemic, but not in the 
pulmonary circulation. During treadmill exercise, the ETA-mediated constriction of 
the systemic vascular bed wanes, thereby facilitating vasodilation. In contrast, an 
ET-mediated constriction becomes apparent in the pulmonary bed during exercise, 
which appears to be ETB-mediated.
Since ET can increase the production of NO and prostanoids, which in turn 
can blunt the release of ET and/or modify the responsiveness of its receptors, 
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we investigated the integrated vasomotor control of systemic and pulmonary 
vascular resistance by NO, prostanoids and ET in Chapter 4. The results show that 
prostanoids blunt the vasoconstrictor inﬂ uence of ET in the systemic but not in the 
pulmonary circulation while NO blunts the vasoconstrictor inﬂ uence of ET in both 
the systemic and pulmonary circulation, particularly during exercise. Prostanoids 
and NO blunt the vasoconstrictor inﬂ uence of ET on the systemic vascular bed by an 
additive manner, but loss of NO does not unmask a role of prostanoids in blunting 
the vasoconstrictor inﬂ uence of ET in the pulmonary circulation. Thus, under 
conditions of endothelial dysfunction, in particular reduced NO bioavailability, 
the exercise-induced pulmonary vasodilation is impaired, due to “unopposed” ET-
mediated pulmonary vasoconstriction. 
Regulation of pulmonary vascular tone in healthy swine at rest and during 
exercise as studied in this thesis is schematically presented in ﬁ gure 1.
Regulation of pulmonary vascular tone in swine with pulmonary hypertension 
after myocardial infarction.
Congestive heart failure is the only major cardiovascular disorder of which 
the incidence has increased over the past decade, which is principally related to a 
reduction in mortality associated with acute MI [10]. The loss of viable myocardial 
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Figure 1: Regulation of pulmonary vascular tone at rest and during exercise in healthy swine. ETA: 
Endothelin A receptor; ETB: ET B receptor; cGMP: cyclic guanosine monophosphate; cAMP: cyclic 
adenosine monophospate; PDE5: phosphodiesterase 5
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tissue after MI causes left ventricular dysfunction. This leads to an increase in 
left ventricular ﬁ lling pressure and neurohumoral activation particularly during 
exercise [11-13]. The increase in left ventricular ﬁ lling pressure is transmitted 
backwards into the pulmonary circulation, resulting in pulmonary congestion and an 
increase in pulmonary arterial blood pressure, thereby elevating right ventricular 
afterload [11, 14]. The resultant right ventricular hypertrophy is a risk factor 
for the development of right-sided heart failure [15]. Pulmonary hypertension is 
often accompanied by endothelial dysfunction resulting in impaired vasodilation 
and exaggerated vasoconstriction [16-18], which can be the result of activation 
of the ET system. Elevated plasma ET-1 levels found in patients with pulmonary 
hypertension correlate with their New York Heart Association (NYHA) functional 
class [19] suggesting a role for ET-1 in pulmonary hypertension.
In Chapter 5 we investigated whether increased ET vasoconstrictor tone in 
the pulmonary circulation contributes to secondary pulmonary hypertension in 
swine with a recent MI and assessed the role of ETA and ETB receptor subtypes in 
this process. Since in healthy swine a pulmonary ET –dependent vasoconstriction 
emerges during exercise, but is negligible under resting conditions (Chapter 3), 
the vasoconstrictor inﬂ uence of endogenous ET in MI swine was studied both at 
rest and during treadmill exercise. The results show that plasma ET levels as well 
as the pulmonary vascular responsiveness to exogenous ET-1 are increased after MI 
and that this increase is principally mediated by the ETA receptor. The pulmonary 
vasoconstriction of ET mediated by the ETB receptor is not altered as compared to 
healthy swine. Thus, although the ETA receptor does not contribute to the regulation 
of pulmonary vasomotor tone in healthy swine at rest or during exercise, an ETA-
mediated vasoconstriction emerged after pulmonary hypertension secondary to an 
MI. The enhanced vasodilator effect of combined ETA/ETB receptor blockade after 
MI was conﬁ rmed recently in a mouse model of MI [20]. It has been proposed that 
for treatment of pulmonary hypertension ETA receptor blockade is more favourable 
than combined ETA/ETB receptor blockade because single blockade of ETA receptor 
leaves both the ETB-receptor-mediated clearance of ET and the endothelium ETB-
receptor-mediated pulmonary vasodilation unaffected [21]. However, our results 
suggest that patients with pulmonary hypertension secondary to an MI may beneﬁ t 
more from combined ETA/ETB than from selective ETA receptor blockade. To date, 
only one clinical trial compared the treatment of pulmonary hypertension with 
a combined ETA/ETB blocker and with a selective ETA receptor blocker [22]. This 
trial reported a signiﬁ cant improvement in exercise capacity and World Health 
Organisation Functional Class (WHO FC) following ETA/ETB blockade, whereas the 
effects of selective ETA receptor blockade reached statistical signiﬁ cance only at 
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the highest dose [22].  
The increased ET-dependent vasoconstriction in swine with a recent MI can be 
the result of decreased vasodilation by NO and/or prostanoids since they are both 
capable of limiting the ET-production or receptor sensitivity to ET [23-25]. Based on 
the observations in Chapter 4, we hypothesized that the increased ET-dependent 
vasoconstriction was the result of a decreased NO- (but not prostanoid-) mediated 
inhibition on ET-vasoconstriction. Therefore, we investigated the alterations in 
integrated endothelium dependent control of pulmonary vascular tone in swine with 
pulmonary hypertension following an MI in Chapter 6. In contrast to our hypothesis, 
we found that the pulmonary vasodilator inﬂ uence of NO was well maintained 
after MI and that the inhibition of the ET-mediated vasoconstrictor inﬂ uence by 
NO was unmitigated. In contrast, an increased production of prostanoids after 
MI appeared to limit the ET-induced pulmonary vasoconstriction and contributed 
to lower pulmonary vascular resistance under resting conditions. Taken together 
these ﬁ ndings indicate that the increased ET-dependent vasoconstriction in the 
pulmonary circulation after an MI is not explained by a loss of vasodilator inﬂ uence 
of NO or prostanoids. 
Regulation of pulmonary vascular tone in swine with post-MI pulmonary 
hypertension at rest and during exercise as studied in this thesis is schematically 
presented in ﬁ gure 2.
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Figure 2: Regulation of pulmonary vascular tone at rest and during exercise in  swine with pulmonary 
hypertension after myocardial infarction. ETA: Endothelin A receptor; ETB: ET B receptor; cGMP: cyclic 
guanosine monophosphate; cAMP: cyclic adenosine monophospate; PDE5: phosphodiesterase 5
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Vasodilator therapy of pulmonary hypertension
Vasodilator therapy for patients with pulmonary hypertension is aimed at 
reducing pulmonary artery pressure both at rest and during exercise. Currently 
available therapies include inhalation of NO and administration of Ca2+-channel 
blockers, exogenous prostacyclin or combined ET-receptor blockers. However, these 
therapies have short-duration, limited efﬁ cacy, are expensive and/or are associated 
with signiﬁ cant side effects. Thus there is room for improvement of vasodilator 
therapie in pulmonary hypertension [26]. In recent years, phosphodiesterase (PDE) 
5 inhibition has emerged as a promising novel vasodilator therapy [26-28]. In 
Chapters 7 and 8, we assessed the vasodilator proﬁ les of the novel PDE5 inhibitor 
EMD360527 [29] in healthy swine (Chapter 7) and swine with a recent MI (Chapter 
8).
In Chapter 7, we investigated the selectivity of EMD360527 for the pulmonary 
vascular bed as compared to the systemic vascular bed. Furthermore, since NO is 
considered as one of the major sources of cGMP [30] and pulmonary hypertension 
has shown to be associated with endothelial dysfunction, and reduced endothelial 
NOS (eNOS) activity [31], we determined to what extent the action of the PDE5 
inhibitor EMD360527 depends on the activity of endothelial NOS. Our results show 
that administration of EMD360527 results in a dose-dependent vasodilation of the 
pulmonary and systemic circulation under resting conditions. The vasodilation is 
slightly higher in the pulmonary than in the systemic circulation. During exercise, 
the vasodilator effects of EMD360527 in the pulmonary circulation were well 
maintained, but decreased slightly in the systemic circulation. Unexpectedly, 
inhibition of eNOS increased the vasodilator effect of EMD360527 as well as of 
nitroprusside in both the pulmonary and systemic circulation (Fig. 1). Several 
reasons might explain the unperturbed vasodilator response to EMD360527 in the 
absence of NO, for example, increased activity of other vasoactive mediators that 
stimulate the production of cGMP or supersensitization of the NO/cGMP pathway 
[32-34]. The observation that the vasodilator effect of inhibition of PDE5 was 
enhanced following eNOS inhibition, and that it correlated well with the basal 
level of pulmonary vasoconstrictor tone, suggests that PDE5 inhibition will be most 
effective in patients with the most severe degree of pulmonary hypertension.
In post-MI pulmonary hypertension, one of the other main stimulators of cGMP, 
atrial natriuretic peptide (ANP), has shown to be increased in patients with heart 
failure and pulmonary hypertension [35, 36] and in our swine model [11, 14]. This 
possibly result in an increased availability of cGMP in post MI pulmonary hypertension 
and consequently an enhanced vasodilator effect of EMD360527. The increased 
203
Chapter 9:  General discussion and summary
ANP levels after MI, in combination with the unaltered NO-induced vasodilation 
(Chapter 6), led us to hypothesize that the vasodilator effect of inhibition of PDE5 
in the pulmonary circulation would be increased after MI. In Chapter 8 we found 
that pulmonary vasodilation after PDE5-inhibition was slightly enhanced in swine 
with MI-induced pulmonary hypertension (Fig. 2). To test the hypothesis that an 
increased vasodilator response was not the result of altered NO bioavailability, we 
also studied the vasodilator effects of EMD360527 following inhibition of eNOS. 
The results demonstrated that in both healthy and in MI swine, the effect of PDE5 
inhibition at rest and during exercise was similarly enhanced after prior inhibition 
of eNOS. These ﬁ ndings indicate that the enhanced vasodilator effect of PDE5 
inhibition after MI is not the result of altered NO-bioavailabilty. 
Future perspectives
In our studies, the underlying mechanism of two important, currently used 
and investigated, vasodilator therapies for pulmonary hypertension were studied: 
ET receptor blockade and PDE5 inhibition. The ﬁ ndings demonstrate that both 
pulmonary vasodilation after PDE5 inhibition and vasoconstriction by endogenous 
ET are increased in post-MI pulmonary hypertension. Since both vasodilator and 
vasoconstrictor effects are enhanced, it can be hypothesized that these two 
effects balance each other and that combination therapy  results in an improved 
vasodilator effect. This hypothesis can be tested by using a combination of 
an ET receptor blocker and PDE5 inhibitor in our swine model with pulmonary 
hypertension. At the moment, some clinical studies have already combined both 
therapies [37-39]. This combination therapy is initiated when monotherapy with 
one vasodilator is not effective. The combination therapy appears to be safe and 
on average is associated with an imrovement in 6 min walk distance, pulmonary 
artery pressure and oxygen uptake [37-39].
From a clinical point of view, long-term studies to investigate vasodilator 
therapies are more relevant than the single dose studies employed in the described 
studies of this thesis. Our animal model of post-MI pulmonary hypertension is well 
suited to study long-term effect of various vasodilator therapies on the systemic 
and pulmonary circulation both at rest and during exercise. With this approach 
pulmonary arterial pressure and pulmonary vascular resistance can be monitored 
continuously and the effects of  therapy can be followed for prolonged periods. 
This approach makes it also possible to evaluate the effect of different therapies 
on vascular remodelling in ex-vivo experiments using isolated pulmonary blood 
vessels. In addition, histology might be used to investigate the remodelling of 
Regulation of pulmonary vascular tone in health and disease
204
small pulmonary vessels [40]. Histological images of small pulmonary arteries of 
our animal model are presented in ﬁ gure 3.
 The animal model used in our studies is a model of pulmonary hypertension 
after a MI. Pulmonary hypertension has many different etiologies. Unfortunately, 
little epidemiologic information is available on the prevalence of post-MI pulmonary 
hypertension in patients. Moreover pulmonary hypertension in association with left-
sided heart failure is usually either mild or moderate, though it can be severe in up 
to a third of patients. The speculation is that signiﬁ cant pulmonary hypertension 
may be present in up to 250,000 heart failure patients in the United States, which 
is far greater than the reported prevalence of pulmonary hypertension associated 
with other condition [41]. Yet, for a better understanding of pathophysiology of 
pulmonary hypertension of other etiologies and response to therapy other animal 
models of pulmonary hypertension have to be developed. There are genetically 
modiﬁ ed small animals like mice and rats that develop pulmonary hypertension. 
However, the advantage of a large animal model is that its (patho)physiology usually 
more closely resembles human (patho)physiology and that more parameters can be 
monitored for prolonged periods of time. In our swine model pulmonary hypertension 
can be induced by injecting microparticles into the pulmonary circulation to cause 
small pulmonary embolies. In addition monocrotaline injections and hypoxia may 
be other possibilities to induce pulmonary hypertension.
 
 
Internal E.L
Media
External E.L.
A. Control Swine
Media
Internal E.L.
External E.L.
B. Swine with MI
Figure 3: Small pulmonary arteries in Control Swine (A) and Swine with MI (B). E.L.: Elastica Lamina. 
Elastin stain (Resorcin/fuchsin).
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Algemene discussie en samenvatting
De studies in dit proefschrift zijn uitgevoerd om beter begrip te krijgen over 
hoe de pulmonale vaattonus gereguleerd wordt onder gezonde omstandigheden 
en tijdens ziekte. Het is belangrijk om de pulmonale circulatie te bestuderen 
omdat het steeds duidelijker wordt dat de pulmonale circulatie verschillend 
is van bijvoorbeeld de systemische circulatie [1, 2]. Dit betekent ook dat 
geneesmiddelentherapieën voor ziektes van de pulmonale circulatie aangepast 
moeten worden aan deze speciﬁ eke circulatie. Er is vooral weinig bekend over de 
pulmonale circulatie tijdens fysieke inspanning, terwijl uit verschillende studies 
is gebleken dat de pulmonale circulatie en de rechter ventrikel de belangrijkste 
determinanten zijn van inspanningscapaciteit [3, 4].
Pulmonale hypertensie is een ziekte met veel mogelijke oorzaken en deze 
ziekte heeft een slechte prognose wanneer de patient niet behandeld wordt. Eén 
van de oorzaken van pulmonale hypertensie is linkerventrikel falen, bijvoorbeeld 
als gevolg van een myocard infarct (MI). Pulmonale hypertensie na een MI komt 
steeds vaker voor aangezien er steeds meer patiënten een MI overleven. Deze 
hebben allen kans om pulmonale hypertensie te ontwikkelen. Tot nu toe is er weinig 
bekend over de vasculaire mechanismen van de pulmonale circulatie die bijdragen 
aan deze vorm van pulmonale hypertensie en er ook is er weinig bekend over 
therapieën voor patiënten met pulmonale hypertensie als gevolg van een MI. Deze 
therapieën zijn wel belangrijk om rechterventrikelfalen en daarmee verslechteren 
van de toestand van de patiënt te voorkomen. Er zijn wel studies in patiënten 
met hartfalen, bijvoorbeeld endotheline receptor blokkers te bestuderen, waarbij 
ook naar de pulmonale circulatie is gekeken, maar het doel van deze studies was 
altijd om het hartfalen te verminderen. [5, 6]. Er moeten dus meer studies gedaan 
worden die speciﬁ ek onderzoek doen naar de pulmonale vaattonus regulatie in 
patiënten met hartfalen.. Aangezien patiënten met pulmonale hypertensie al een 
verlaagde inspanningscapaciteit hebben [3, 4]. is het belangrijk dat therapieën 
ook tijdens inspanning werken. Daarom is het van belang dat ook naar de vaattonus 
regulatie tijdens inspanning onderzoek gedaan wordt. 
Dit alles heeft geleid tot dit proefschrift, welke bestaat uit twee delen. In 
het eerste deel (Hoofstuk 2-4) is de regulatie van pulmonale vaattonus onder 
normale fysiologische omstandigheden bestudeerd. In het bijzonder is de rol van 
verschillende vaatverwijders (stikstofoxide (NO) en prostacyline) en vaatvernauwers 
(endotheline) bestudeerd. Deze onderzoeken zijn gedaan in varkens, tijdens 
rust en tijdens verschillende nivo’s van fysieke inspanning. In deel twee van 
dit proefschrift (Hoofdstuk 5-8) zijn de veranderingen in pulmonale vaattonus 
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regulatie die optreden bij pulmonale hypertensie als gevolg van MI bestudeerd. 
Deze onderzoeken zijn ook gedaan in varkens tijdens rust en verschillende nivo’s 
van inspanning.
Regulatie van de pulmonale vaattonus in varkens onder gezonde condities
Het endotheel speelt een belangrijke rol in de vaattonus regulatie door het 
produceren van verschillende vaatverwijders zoals NO en prostacycline. Het 
endotheel produceerd ook vaatvernauwers zoals bijvoorbeeld endotheline. Een 
eerdere studie in ons laboratorium heeft laten zien dat lichaamseigen NO een 
vaatverwijdende invloed heeft in de lichaams- (systemische) en de pulmonale 
circulatie van wakkere varkens. Tijdens inspanning bleef het effect van NO 
nagenoeg gelijk want het blokkeren van NO resulteerde slechts in een kleine daling 
van de vaatverwijding die door inspanning ontstaat [7]. Dit betekent dus dat de 
vaatverwijding die door inspanning ontstaat niet het gevolg is van een grotere invloed 
van NO maar dat dit door andere vaatverwijders, zoals misschien prostacycline 
ontstaat. Of, dat het blokkeren van de invloed van NO ervoor zorgt dat andere 
vaatverwijders het overnemen. Om dit te onderzoeken hebben we in Hoofdstuk 2 
van dit proefschrift gekeken naar de bijdrage van prostacycline aan de systemische 
en pulmonale vaattonus regulatie in chronische geïnstrumenteerde varkens in rust 
en tijdens inspanning op een loopband. Tevens hebben we bestudeerd of de rol van 
prostacycline verhoogd is na het blokkeren van NO. Uit de resultaten van Hoofstuk 
2 blijkt dat prostacycline betrokken is bij de regulatie van het systemische vaatbed 
en dat de vaatverwijdende invloed verhoogd is wanneer NO geblokkeerd is. In het 
pulmonale vaatbad daarentegen heeft prostacycline geen rol in het reguleren van 
de vaattonus, zelfs niet wanneer een andere belangrijke vaatverwijder (NO) is 
uitgeschakeld.
Het endotheel produceerd niet alleen de vaatverwijders zoals NO en 
prostacycline, maar ook vaatvernauwers zoals endotheline [8]. Endotheline werkt 
via twee receptor subtypes, de ETA en de ETB receptor.  Beide receptoren bevinden 
zich op de gladde spiercellen van de bloedvaten en wanneer endotheline aan een 
van deze receptoren bindt zorgt dit voor vaatvernauwing. Er bevinden zich echter 
ook ETB receptoren op de endotheelcellen van de vaatwand en wanneer endotheline 
aan deze receptoren bindt zorgt dit voor vaatverwijding. De ETB receptoren op de 
endotheelcellen zijn ook verantwoordelijk voor de klaring van endotheline. Het 
netto effect van endotheline op de vaatwand is dus afhankelijk van de mate van 
binding aan alle receptoren. [9]. In Hoofdstuk 3 hebben we de rol van endotheline 
en de receptoren bestudeerd in zowel de systemische als de pulmonale circulatie. 
We hebben daarvoor gebruik gemaakt van een selectieve ETA antagonist en een 
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gecombineerde ETA/ETB antagonist. De belangrijkste bevindingen uit deze studie is 
dat endotheline bijdraagt aan de basale vaattonus van de systemische circulatie. 
Tijdens inspanning verdwijnt de ETA gemedieerde constrictie van het systemsiche 
vaatbed, wat bijdraagt aan de inspannings geinduceerde vaatverwijding. Deze 
bevindingen staan in tegenstelling tot de bevindingen in het pulmonale vaatbed, 
waar endotheline niet bijdraagt aan de basale vaattonus, maar tijdens inspanning 
een vaatvernauwende rol heeft . Deze vaatvernauwende rol tijdens inspanning is 
gemedieerd door de ETB receptoren.
Endotheline kan de productie van NO en prostacycline verhogen en deze 
kunnen op hun beurt het vrijkomen van endotheline of de gevoeligheid van de 
endotheline receptoren verlagen.  Om deze redenen hebben wij de rol van NO, 
prostacycline en endotheline samen onderzocht in zowel de systemische als de 
pulmonale circulatie in Hoofstuk 4. Uit deze resulaten blijkt dat prostacycline het 
vaatvernauwende effect van endotheline verlaagd in het systemische vaatbed, 
maar niet in het pulmonale vaatbed. NO verlaagd ook het vaatvernauwende effect 
van endotheline in het systemische vaatbed, maar doet dit ook in het pulmonale 
vaatbed. Beide met name tijdens inspanning. Na het blokkeren van NO wordt 
de rol van prostacycline groter in het systemische vaatbed wat betekent dat 
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Figuur 1: Regulatie van de pulmonale vaattonus in rust en tijdens inspanning in gezonde varkens. 
ETA: Endothelin A receptor; ETB: ET B receptor; cGMP: cyclic guanosine monophosphate; cAMP: cyclic 
adenosine monophospate; PDE5: phosphodiesterase 5
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NO en prostacycline elkaar aanvullen en over kunnen nemen. In het pulmonale 
vaatbed daarentegen speelt prostacycline ook geen vaatverwijdende rol wanneer 
NO geblokkeerd is. Dus, uit dit hoofdstuk blijkt dat onder omstandigheden van 
endotheeldysfunctie, met name wanneer de beschikbaarheid van NO verlaagd is, 
dat de pulmonale vaatverwijding tijdens inspannings verdwijnt als gevolg van een 
verhoogde endotheline invloed doordat de NO deze niet afremt. 
De regulatie van het pulmonale vaatbed in gezonde varkens tijdens rust en 
inspanning is weergegeven in ﬁ guur 1.
Regulatie van pulmonale vaattonus in varkens met pulmonale hypertensie na 
een hartinfarct.
Hartfalen is de enige grote cardiovasculaire aandoening waarvan het aantal 
patiënten verhoogd is in de afgelopen jaren. Deze verhoging is grotendeels 
veroorzaakt door een afname in het aantal patiënten dat een hartinfarct overleefd. 
[10]. Bij deze patiënten is na het hartinfarct echter wel een deel van het hartweefsel 
afgestorven waardoor het voor het resterende levende weefsel lastiger is om de 
juiste hoeveelheid bloed rond te pompen. Patiënten krijgen linkerventrikel falen 
wat leidt tot een hogere druk in de linkerventrikel en een veranderde neurohumorale 
activatie met name tijdens inspanning [11-13]. De verhoogde linkerventrikeldruk 
wordt overgedragen naar de pulmonale circulatie waardoor er longoedeem en een 
hoge bloeddruk in het longvaatbed kan onstaan wat leid tot een verhoogde druk 
in de rechterventrikel [11, 14]. Deze verhoogde druk in de rechterventrikel is 
een risicofactor voor het intwikkelen van rechterventrikel falen [15]. Pulmonale 
hypertensie gaat vaak gepaard met endotheeldysfunctie wat leid tot verslechterde 
vaatverwijding en een verhoogde vaatvernauwing [16-18], wat het resultaat van 
activatie van het endotheline systeem zou kunnen zijn. In een patiëntenonderzoek 
met patiënten met pulmonale hypertensie was de mate van pulmonale hypertensie 
gecorreleerd aan de hoogte van hun (verhoogde) endotheline-1 plasmaspiegels [19] 
wat aangeeft dat endotheline een rol speelt bij pulmonale hypertensie.
In Hoofdstuk 5 hebben we de onderzocht of deze verhoogde vasoconstrictie 
door endotheline bijdraagt aan secundaire pulmonale hypertensie in de pulmonale 
circulatie in varkens met een recent MI. Ook hebben we de rol van ETA en de 
ETB receptor subtypes in dit proces onderzocht. Aangezien in gezonde varkens de 
rol van endotheline toeneemt tijdens inspanning, maar verwaarloosbaar is onder 
rust condities (Hoofstuk 3) hebben we de vasoconstrictor invloed van endogeen 
endotheline in MI varkens bestudeerd, in rust en tijdens inspanning. De resultaten 
van dit hoofstuk laten zien dat zowel de circulerende endotheline-levels als de 
gevoeligheid ten opzichte van exogeen endotheline verhoogd zijn na een MI en 
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dat deze verhoogde vasoconstrictieve invloed door de ETA receptor geregeld is. De 
vaatvernauwende invloed van endotheline die door de ETB receptor geregeld wordt, 
is niet veranderd ten opzichte van gezonde varkens. Dus, de ETA receptor draagt 
niet bij aan de regulatie van pulmonale vaattonus in gezonde varkens, maar wel bij 
MI varkens. Het verhoogde vaatverwijdende effect van een gecombineerde ETA/ETB 
receptor blokkade na een MI is onlangs bevestigd in een studie met een muismodel 
met MI [20]. Een belangrijke gedachte in de behandeling van pulmonale hypertensie 
is dat ETA blokkade beter zou zijn dan een gecombineerde ETA/ETB blokkade, omdat 
je dan de ETB geregelde vaatverwijding en de klaring van endotheline ongemoeid 
laat [21]. De resultaten van Hoofdstuk 5 suggereren echter dat patiënten met 
pulmonale hypertensie na een MI meer gebaat zouden zijn met een gecombineerde 
ETA/ETB therapie. Tot nu toe is er slechts één klinische trial die de effecten van 
gecombineerde ETA/ETB blokkade vergelijkt met ETA blokkade in patiënten met 
pulmonale hypertensie [22]. In deze trial is een signiﬁ cante verbetering in de mate 
van pulmonale hypertensie en in de inspanningscapaciteit na de gecombineerde 
therapie terwijl slechts de hoogste dosering van de ETA blokkade signiﬁ cante 
verbeteringen gaf. [22].  
De verhoogde vasoconstrictie in varkens met een MI kan voortkomen uit een 
verlaagde vaatverwijdende invloed van NO en/of prostanoiden, aangezien beide 
verantwoordelijk kunnen zijn voor het verlagen van de productie en/of verlagen 
van de gevoeligheid van de receptoren van endotheline [23-25]. Gebaseerd op de 
observaties in Hoofdstuk 4 hebben we de hypothese gevormd dat de verhoogde 
vaatvernauwende invloed van endotheline het gevolg is van een verlaagde NO- 
(maar niet prostanoid-) gemedieerde remming van endotheline. Daarom hebben 
we de veranderingen in de gezamenlijke rol van deze endotheliale stoffen, in 
de vaattonus regulatie van het pulmonale vaatbed onderzocht in Hoofstuk 6. In 
tegenstelling tot de hypothese vonden we dat de NO gemedieerde vaatverwijding 
in het pulmonale vaatbed na een MI gehandhaafd blijft en dat de remmende 
invloed van NO op endotheline ook onveranderd is. Onverwacht bleek er een 
verhoogde productie van prostanoiden na een MI te zijn, welke bijdraagt aan een 
lagere weerstand tijdens rust. Alles bij elkaar betekenen deze bevindingen dat de 
verhoogde vaatvernauwende invloed na een MI niet het gevolg is van een verlaagde 
remmende werking van NO en/of prostanoiden.
De regulatie van het pulmonale vaatbed tijdens rust en inspanning in varkens 
met pulmonale hypertensie na een MI is weergegeven in ﬁ guur 2.
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Vaatverwijdende therapie voor pulmonale hypertensie
Vaatverwijdende therapie voor patiënten met pulmonale hypertensie is 
voornamelijk gericht op het verlagen van de pulmonale druk en de vaatweerstand. 
Momenteel beschikbare therapieën omvatten onder andere de inhalatie van NO 
en het toedienen van  Ca2+ kanaal blokkers, exogene prostacycline en endotheline 
receptor blokkers. Maar deze therapieën hebben een korte werkingsduur, hebben 
een beperkt effect, zijn duur en/of hebben ernstige bijwerkingen. Dit geeft al 
aan dat er ruimte is voor verbetering van deze therapieën of het ontwikkelen van 
nieuwe therapieën [26]. De afgelopen jaren is het remmen van phosphodiesterase 
(PDE) 5 als een belangrijke nieuwe vaatverwijdende therapie naar voren gekomen 
[26-28]. In Hoofstukken 7 & 8 hebben we het vaatverwijdende proﬁ el van PDE5 
remmer EMD 360527 onderzocht in zowel gezonde (Hoofstuk 7) als in varkens met 
een MI (Hoofstuk 8).
In Hoofdstuk 7 hebben we de selectiviteit van EMD 360527 voor het pulmonale 
versus het systemische vaatbed onderzocht. Verder hebben we onderzocht in welke 
mate de effectiviteit van PDE5 remmer EMD360527 afhankelijk is van de activiteit 
van endotheliale NO synthase (eNOS), aangezien NO beschouwd wordt als de 
belangrijkste bron voor cGMP [30] en pulmonale hypertensie geassociëerd is met 
endotheel disfunctie en daarmee verlaagde endotheliale eNOS [31]. De resultaten 
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Figuur 2: Regulatie van de pulmonale vaattonus in rust en tijdens inspanning in varkens met pulmonale 
hypertensie na een myocard infarct.  ETA: Endothelin A receptor; ETB: ET B receptor; cGMP: cyclic 
guanosine monophosphate; cAMP: cyclic adenosine monophospate; PDE5: phosphodiesterase 5
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laten zien dat EMD 360527 een dosis-afhankelijke vaatverwijding in zowel het 
pulmonale als het systemische vaatbed geeft onder rust omstandigheden, met 
een iets hogere gevoeligheid voor het pulmonale vaatbed. De vaatverwijdende 
effecten bleven in het pulmonale vaatbed bestaan tijdens inspanning terwijl deze 
in het systemische vaatbed afnam. Daarbij namen de vaatverwijdende effecten 
van zowel EMD 360527 als nitroprusside (NO donor) toe in beide circulaties na 
het blokkeren van NO (Fig. 1). Verschillende redenen kunnen hiervan de oorzaak 
zijn, bijvoorbeeld een verhoogde activiteit van een andere bron van cGMP of een 
verhoogde gevoeligheid van de NO-cGMP pathway [32-34]. De observatie dat PDE5 
inhibitie het beste werkt wanneer NO geblokkeerd is en dat het gecorreleerd is aan 
de basale pulmonale vaatweerstand suggereerd dat PDE5 remming het beste werkt 
in patiënten met ernstige pulmonale hypertensie.
Bij patiënten met pulmonale hypertensie na een MI was een andere bron van 
cGMP, atrial natriuretic peptide (ANP) verhoogd [35, 36] en dit was ook het geval in 
ons varkensmodel [11, 14]. Dit suggereert dat er meer cGMP aanwezig zou zijn en 
dat het effect van EMD 360527 na een MI verhoogd zou kunnen zijn. De verhoogde 
ANP spiegels in combinatie met de onveranderde rol van NO (Hoofstuk 6) leidde 
tot onze hypothese dat het effect van EMD 360527 verhoogd zou zijn bij pulmonale 
hypertensie na een MI. In Hoofstuk 8 vonden we dat de pulmonale vaatverwijding 
na blokkade van PDE5 licht verhoogd  was in varkens met pulmonale hypertensie 
na een MI (Fig. 2). Omwille van de hypothese dat de verhoogde vaatverwijding niet 
het resultaat was van een veranderde invloed van NO, hebben we ook de effecten 
van EMD 360527 onderzocht na blokkade van NO. De resultaten lieten zien dat in 
zowel in gezonde als in MI varkens het effect van PDE5 inhibitie gelijk verhoogd 
was na blokkade van NO en dat de vehoogde vaatverwijding na een MI dus niet het 
gevolg was van een verandering in de beschikbaarheid van NO.
Toekomst perspectieven
In onze studies zijn de mechanismen van twee belangrijke vaatverwijder 
therapieën onderzocht, namelijk endotheline receptor blokkade en PDE5 remming. 
Onze bevindingen laten zien dat zowel de vaatverwijding door PDE5 remming als 
vaatvernauwing door endogeen endotheline verhoogd zijn in varkens met pulmonale 
hypertensie na een MI. Aangezien dus een vaatverwijdend en een vaatvernauwend 
effect verhoogd is, kan het zo zijn dat deze twee effecten elkaar in evenwicht 
houden en dat een combinatie van beide therapieën een betere vaatverwijding 
zal geven.  Deze hypothese kan getest worden door een endotheline receptor 
blokker te gebruiken in combinatie met een PDE5 remmer in ons varkensmodel 
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met pulmonale hypertensie. Op dit moment wordt deze combinatie therapie al bij 
enkele patiënten studies gebruikt [37-39]. Deze combinatie therapie wordt gestart 
wanneer therapie met een enkele vaatverwijder niet effectief is. De combinatie 
therapie lijkt veilig en is gemiddeld geassocieerd met een verbetering in de 
pulmonale vaatweerstand en de zuurstofopnamen. Ook is de afstand welke binnen 
6 minuten door de patient afgelegd kan worden verbeterd [37-39]. 
Vanuit een klinisch oogpunt zijn langdurige studies om een vaatberwijder te 
bestuderen meer relevant dan het eenmalig toedienen zoals beschreven in dit 
proefschrift. Ons diermodel met pulmonale hypertensie na een MI is erg geschikt 
om de effecten van langdurende toediening van vaatverwijdende therapieën te 
onderzoeken in de systemische en pulmonale circulatie, in rust en tijdens inspanning. 
Op deze manier kunnen pulmonale arteriële druk en pulmonale vaatweerstand 
continu gemeten worden en kunnen de effecten van de therapie gedurende langere 
tijd bestudeerd worden. Op deze manier kan ook gekeken worden naar effecten 
van langdurig gebruik van deze therapieën op vaatremodellering in geisoleerde 
pulmonale vaatjes. Ten slotte kan histologie gebruikt worden om remodellering 
van kleine pulmonale vaatjes te bestuderen [40]. In ﬁ guur 3 zijn histologische 
afbeeldingen van kleine pulmonale arteriën in ons diermodel weergegeven.
Het diermodel dat wij in onze studies gebruikt hebben is een model voor 
Internal E.L
Media
External E.L.
A. Controle varken
Media
Internal E.L.
External E.L.
B. Varken met MI
Figuur 3: Kleine pulmonale arteriën in een controle varken (A) en in een varken met pulmonale 
hypertensie na een MI (B). E.L.: Elastica Lamina. Elastine kleuring (Resorcine/fuchsine).
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Dankwoord
Als je aan het dankwoord voor je proefschrift kan gaan beginnen betekent dat 
over het algemeen dat het proefschrift zo goed als af is. Wat een ﬁ jn gevoel! Wat 
ook erg ﬁ jn is aan het dankwoord, is dat je niet afhankelijk bent van resultaten, 
ﬁ guren, statistiek en is het wel of niet signiﬁ cant. Het gaat over het behalen van 
dit ene resultaat, dit proefschrift! En over de mensen die geholpen hebben om dat 
te bereiken.
In de eerste plaats wil ik mijn promotor Prof. Dr. D.J. Duncker bedanken. Beste 
Dirk, toen ik op de afdeling Experimentele Cardiologie stage kwam lopen had ik 
al gauw door dat ik onderzoek wilde doen. Jouw enthousiasme voor dit vak heeft 
daar zeker aan bijgedragen. Ik wil je ontzettend bedanken voor het vertrouwen 
dat ik heb gekregen om als analist het promotietraject in te gaan. Deze hele 
promotietijd kon ik altijd met vragen bij je terecht en had je (bijna) altijd een 
gaatje in je drukke agenda. Het afgelopen jaar heb ik ook gemerkt hoe ﬁ jn het is 
om een baas te hebben die met je meevoelt en die wil dat het goed met je gaat. 
Kortom, heel erg bedankt voor alles.
Mijn co-promotor Dr. D. Merkus. Beste Daphne, bedankt voor al je hulp en steun 
de afgelopen jaren. Het was vaak hard werken op het lab met alle DJ’s, MI’s, ED’s, 
EX’s en SED’s, maar het was altijd heel erg gezellig. Het was vaak wij samen tegen 
de rest (meestal mannelijke collega’s en studenten) en ik heb toch het gevoel dat 
wij het altijd beter deden! Maar zonder gekheid: ik heb ontzettend veel aan je te 
danken, je was er altijd als ik je nodig had, of als ik iets niet snapte. Of als ik hulp 
nodig had bij statistiek, of als ik gewoon even tegen iemand aan wilde zeuren. En 
ook al zeggen we het vaak om te plagen, je bent echt al een ‘Dirk’. 
Prof.dr. Lamers, Prof.dr. Danser, Dr. van den Meiracker: hartelijk dank voor het 
lezen en beoordelen van mijn proefschrift en voor de nuttige suggesties.
Prof.dr. van der Giessen, Prof.dr. Verdouw, Prof.dr. van Bavel en Dr. Vonk 
Noordegraaf: hartelijk dank voor uw bereidheid plaats te nemen in de commissie.
Mijn paranimfen Elza en Esmé: ﬁ jn dat jullie naast me willen staan op het moment 
dat ik dit proefschrift moet verdedigen.
Elza: ik ben heel blij dat ik jou altijd had om tegen te zeuren, of het nou over het 
werk ging of niet. Je was ook altijd bereid om in te springen en te helpen waar 
nodig, hopelijk heb ik daar tijdens de verdediging ook wat aan. Ik heb in elk geval 
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in het Hilton wel gezien dat je best onderzoek naar pulmonale hypertensie had 
kunnen doen! (en ik vond het erg leuk om bij je te logeren in Minneapolis)
Esmé: ik vind het erg leuk dat we nog steeds bevriend zijn, zeker als je bedenkt 
dat we eigenlijk maar 1 jaar bij elkaar in de klas hebben gezeten. Ik vind het erg 
gezellig om af en toe te gaan lunchen en te klagen hoe zwaar wij aio’s het eigenlijk 
hebben. Nog even doorzetten en je kan ook aan je dankwoord!
Al mijn collega’s van Experimentele Cardiologie alsmede alle studenten en 
stagiaires waar ik de afgelopen jaren mee heb samengewerkt wil ik bedanken. Er 
was altijd wel iemand beschikbaar als we een varkenscoach nodig hadden, of als ik 
vragen had over een speciﬁ ek vakgebied. Iedereen bedankt! Maar, toch wil ik nog 
even in het bijzonder Reier, Oana en Vincent bedanken. Met jullie heb ik heeeeeel 
wat uurtjes op het lab doorgemaakt en dat schept toch een (loop)band. Ik hoop 
dat jullie er ook met plezier aan terug denken en ik wens jullie veel succes in jullie 
verdere carrière (en voor Reier rustig aan in de tuinen werken).
Carla: heel erg bedankt voor de hulp alle jaren en bij alle rompslomp rondom het 
promoveren. Je bent een kanjer!
Tot slot wil ik mijn familie, schoonfamilie en vrienden bedanken. De afgelopen 
jaren heb ik het vaak heel druk gehad met mijn werk, maar die tijd haal ik nu een 
beetje in! Dankzij jullie steun heb ik het zover gebracht dat mijn eigen proefschrift 
er is!
Lieve Paul, je hebt me altijd heel erg gesteund en geholpen en ik ben ontzettend 
blij met jou! Ik ben er trots op om met je getrouwd te zijn en ik blijf voor altijd 
je meissie.
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